Download:
pdf |
pdfNational HIV Surveillance System (NHSS)
Attachment 5.
HIV Surveillance Report
Volume 29
Diagnoses of HIV Infection in the
United States and Dependent Areas, 2017
The HIV Surveillance Report is published annually by the Division of HIV/AIDS Prevention, National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and
Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.
Data are presented for diagnoses of HIV infection reported to CDC through June 2018.
The HIV Surveillance Report is not copyrighted and may be used and reproduced without permission.
Citation of the source is, however, appreciated.
Suggested citation
Centers for Disease Control and Prevention. HIV Surveillance Report, 2017; vol. 29.
http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published November 2018. Accessed [date].
On the Web: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
Confidential information, referrals, and educational material on HIV infection
CDC-INFO
1-800-232-4636 (in English, en Español)
1-888-232-6348 (TTY)
http://wwwn.cdc.gov/dcs/ContactUs/Form
Acknowledgments
Publication of this report would not have been possible without the contributions of the state and territorial
health departments and the HIV surveillance programs that provided surveillance data to CDC.
This report was prepared by the following CDC staff and contractors: Kristen Hess, Shacara Johnson,
Xiaohong Hu, Jianmin Li, Baohua Wu, Chenchen Yu, Hong Zhu, Chan Jin, Mi Chen, John Gerstle, Marie
Morgan, Michael Friend, Anna Satcher Johnson, Azfar Siddiqi, Angela Hernandez, the HIV Incidence and
Case Surveillance Branch, and the Data Management Team of the Quantitative Sciences and Data
Management Branch.
HIV Surveillance Report
2
Vol. 29
Contents
Contents
Commentary
Technical Notes
Tables
Section 1 Diagnoses of HIV Infection and Diagnoses of Infection Classified as Stage 3 (AIDS)
1a Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States
1b Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States and
6 dependent areas
2a Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States
2b Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States and 6
dependent areas
3a Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States
3b Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas
4a Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States
4b Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas
5a Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics,
2012–2017—United States
5b Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics,
2012–2017—United States and 6 dependent areas
6a Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—
United States
6b Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—
United States and 6 dependent areas
7a Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection
drug use, by selected characteristics, 2012–2017—United States
7b Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection
drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas
8a Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States
8b Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and
6 dependent areas
9a Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States
9b Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States
and 6 dependent areas
10a Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States
10b Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States and 6 dependent areas
11a Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States
11b Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6
dependent areas
12a Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States
12b Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6
dependent areas
13a Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States
13b Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States and
6 dependent areas
14a Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States
14b Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States and
6 dependent areas
HIV Surveillance Report
3
5
11
17
18
19
20
21
22
23
24
25
26
27
28
29
33
37
41
45
49
53
57
61
65
69
73
77
77
78
78
Vol. 29
15
16
17
Stage 3 (AIDS) among children aged <13 years, by year of diagnosis, 1992–2017—United States and
6 dependent areas
Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of
birth, 2017—United States and 6 dependent areas
Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2017—
United States and 6 dependent areas
79
80
81
Section 2 Deaths after a Diagnosis of HIV Infection or Stage 3 (AIDS) Classification
18a Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—
United States
18b Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—
United States and 6 dependent areas
19a Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected
characteristics, 2012–2016 and cumulative—United States
19b Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected
characteristics, 2012–2016 and cumulative—United States and 6 dependent areas
20a Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States
20b Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States
and 6 dependent areas
21a Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected
characteristics, 2016—United States
21b Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected
characteristics, 2016—United States and 6 dependent areas
22a
22b
23a
23b
24a
24b
25a
25b
26
27
28
29
30
31
Section 3 Persons Living with Diagnosed HIV Infection or with Infection Ever Classified as
Stage 3 (AIDS) (Prevalence)
Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States
Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States and
6 dependent areas
Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics,
2012–2016—United States
Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics,
2012–2016—United States and 6 dependent areas
Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—
United States
Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—
United States and 6 dependent areas
Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected
characteristics, year-end 2016—United States
Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected
characteristics, year-end 2016—United States and 6 dependent areas
HIV Surveillance Report
4
84
86
88
90
92
94
96
98
100
102
104
106
108
110
112
Section 4 Data by Area of Residence
Diagnoses of HIV infection, by area of residence, 2016 and 2017—United States and 6 dependent areas
Stage 3 (AIDS), by area of residence, 2016, 2017, and cumulative—United States and 6 dependent areas
Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2016—
United States and 6 dependent areas
Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and
area of residence, year-end 2016—United States and 6 dependent areas
Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), year-end 2016, by
metropolitan statistical area of residence—United States and Puerto Rico
Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3
(AIDS) (prevalence), year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico
Web Addresses for Reports of State and Local HIV Surveillance
82
114
115
117
119
121
124
129
Vol. 29
Commentary
DEFINITIONS AND DATA SPECIFICATIONS
The Centers for Disease Control and Prevention
(CDC) collects, analyzes, and disseminates surveillance data on HIV infection; these data are one of the
nation’s primary sources of information on HIV in the
United States. The annual surveillance report, published by the Division of HIV/AIDS Prevention, summarizes information about diagnosed HIV infection
in the United States and dependent areas. HIV surveillance data are used by CDC’s public health partners in other federal agencies, health departments,
nonprofit organizations, academic institutions, and
the general public to help focus prevention efforts;
plan services; allocate resources; develop policy;
detect, monitor, and intervene in HIV clusters; and
monitor trends in HIV infection.
Numbers and rates of diagnoses of HIV infection
during 2012–2016 and preliminary numbers for
2017 are based on data from all 50 states, the District
of Columbia, and 6 U.S. dependent areas (American
Samoa, Guam, the Northern Mariana Islands,
Puerto Rico, the Republic of Palau, and the U.S.
Virgin Islands).
During 2012–2016, the annual rate of diagnoses of
HIV infection in the United States decreased; the
annual number of diagnoses remained stable. Numbers
and rates of diagnoses of HIV infection increased in
some subgroups and decreased in others. Variations in
trends among groups are expected and may be due to
differences in testing behaviors, targeted HIV testing
initiatives, or changes in the numbers of new HIV
infections (incidence) in some subgroups. (For slide
sets of trends among selected populations [2010–
2016], see Additional Resources.)
The term diagnosis of HIV infection is defined as a
diagnosis of HIV infection regardless of the stage of
disease (stage 0, 1, 2, 3 [AIDS], or unknown) and
refers to all persons with a diagnosis of HIV infection.
The term HIV infection, stage 3 (AIDS) and its condensed version—stage 3 (AIDS)—refer specifically to
persons with diagnosed HIV whose infection was
classified as stage 3 (AIDS) during a given year (for
diagnoses) or whose infection has ever been classified
as stage 3 (AIDS) (for prevalence and deaths). The
2008 surveillance case definition for HIV infection
was used to classify cases diagnosed through 2013.
The 2014 revised surveillance case definition was
used to classify cases diagnosed after 2013. For more
information on HIV surveillance case definitions and
the stages of HIV infection, please review the Technical Notes.
The data on diagnoses of HIV infection reflect the
date of diagnosis (diagnosed by December 31, 2017;
reported to CDC as of June 30, 2018), not the date of
report to CDC. Similarly, the data specific to stage 3
(AIDS) reflect the first date the criteria for stage 3
(AIDS) were met. HIV diagnoses do not necessarily
reflect when a person became infected. HIV surveillance data may not be representative of all persons
infected with HIV because not all infected persons
have been (1) tested or (2) tested at a time when their
infection could be detected and diagnosed. Because of
reporting delays, the number of cases diagnosed in a
given year may be lower than the numbers presented in
later reports; however, fluctuations in the number of
diagnoses for a calendar year typically subside after 2
to 3 years of reporting.
REPORT CHANGES
In response to our partners’ requests for expanded
data, the 2017 report includes tables that provide data
on diagnoses and stage 3 (AIDS) classifications
among adults and adolescents, by year (2012–2017),
sex, and selected characteristics.
• For diagnosis data (United States/United States
and dependent areas), see Tables 5a/b.
• For stage 3 (AIDS) classification data (United
States/United States and dependent areas), see
Tables 6a/b.
HIV Surveillance Report
HIGHLIGHTS OF ANALYSES
All rates are per 100,000 population. The standard
used for reporting trends in numbers and rates is an
increase or a decrease of 5% or more during the specified time frame (e.g., when comparing 2012 and
2016). Exceptions to this standard were made where
numbers were small or rates were based on small
numbers. The HIV diagnosis and stage 3 (AIDS) classification data for the year 2017 are considered pre-
5
Vol. 29
liminary because they are based on only a 6-month
reporting delay and therefore should not be included
when assessing trends.
Please read all table titles and footnotes carefully to
ensure a complete understanding of the displayed data.
tions attributed to male-to-male sexual contact
remained stable. Among female adults and adolescents, the number of infections attributed to
injection drug use or to heterosexual contact
decreased. In 2017, among all adults and adolescents, the diagnosed infections attributed to maleto-male sexual contact (70%, including 3% maleto-male sexual contact and injection drug use) and
those attributed to heterosexual contact (24%)
accounted for approximately 94% of diagnosed
HIV infections in the United States.
• Region: From 2012 through 2016, the rates of
diagnoses of HIV infection in the Northeast and
the Midwest decreased. The rates in the South and
the West remained stable. In 2017, rates were 16.1
in the South, 10.6 in the Northeast, 9.4 in the
West, and 7.4 in the Midwest.
Diagnoses of HIV Infection and Diagnoses of
Infection Classified as Stage 3 (AIDS)
Diagnoses of HIV infection
From 2012 through 2016, the rate of diagnoses of
HIV infection in the United States decreased; the
annual number of diagnoses remained stable (Table
1a). In 2017, the rate was 11.8.
• Age group: From 2012 through 2016, the rate
for persons aged 25–29 years increased. The
rates for children (aged less than 13 years) and
persons aged 13–14, 15–19, 40–44, 45–49, 50–
54, 55–59, 60–64 years, and 65 years and older
decreased. The rates for persons aged 20–24,
30–34, and 35–39 years remained stable. In
2017, the highest rate (32.9) was for persons
aged 25–29 years, followed by the rate (28.7) for
persons aged 20–24 years.
• Race/ethnicity: From 2012 through 2016, the
rates for American Indians/Alaska Natives and
Asians increased. The rates for blacks/African
Americans, Native Hawaiians/other Pacific
Islanders, whites, and persons of multiple races
decreased. The rates for Hispanics/Latinos
remained stable. In 2017, the highest rate was 41.1
for blacks/African Americans, followed by 16.1
for Hispanics/Latinos, 12.6 for persons of multiple
races, 9.9 for Native Hawaiians/other Pacific
Islanders, 8.8 for American Indians/Alaska
Natives, and 5.1 for both Asians and whites.
• Sex: From 2012 through 2016, the rates for male
and female adults and adolescents decreased. In
2017, males accounted for 81% of all diagnoses of
HIV infection among adults and adolescents. The
2017 rate for male adults and adolescents was
23.1; the 2017 rate for females was 5.2.
• Transmission category: From 2012 through
2016, among male adults and adolescents, the
annual number of diagnosed HIV infections
attributed to injection drug use, to male-to-male
sexual contact and injection drug use, or to heterosexual contact decreased. The number of infec
HIV Surveillance Report
Stage 3 (AIDS)
From 2012 through 2016, the annual number and the
rate of infections classified as stage 3 (AIDS) in the
United States decreased (Table 2a). In 2017, the rate
of infections classified as stage 3 (AIDS) was 5.4.
• Age group: Because of the change in case definition in 2014, the trend among children (aged less
than 13 years) was not assessed. From 2012
through 2016, the rates for all other age groups
decreased. In 2017, the highest rate (11.1) was for
persons aged 30–34 years, followed by the rate
(10.4) for persons aged 35–39 years. Please use
caution when interpreting data for children (aged
less than 13 years) and persons aged 13–14 years:
the numbers are small.
• Race/ethnicity: From 2012 through 2016, the rate
for American Indians/Alaska Natives increased.
The rates for all other race/ethnicity groups
decreased. In 2017, the highest rate was 20.5 for
blacks/African Americans, followed by 9.3 for
persons of multiple races, 6.6 for Hispanics/
Latinos, 4.7 for Native Hawaiians/other Pacific
Islanders, 3.0 for American Indians/Alaska
Natives, 2.2 for whites, and 1.8 for Asians.
• Sex: From 2012 through 2016, the rates for male
and female adults and adolescents decreased. In
2017, males accounted for 76% of all infections
classified as stage 3 (AIDS) among adults and
adolescents. The 2017 rate for males was 10.0; the
2017 rate for females was 3.0.
6
Vol. 29
• Transmission category: From 2012 through
2016, the annual number of infections classified
as stage 3 (AIDS) among male adults and adolescents with HIV infection attributed to male-tomale sexual contact, to injection drug use, to
male-to-male sexual contact and injection drug
use, or to heterosexual contact decreased. The
number of infections classified as stage 3 (AIDS)
among female adults and adolescents with HIV
infection attributed to injection drug use or to
heterosexual contact decreased. Please use caution when interpreting data for children with
infection attributed to perinatal transmission: the
numbers are small.
• Region: From 2012 through 2016, the rates of
infections classified as stage 3 (AIDS) in the 4
regions of the United States decreased. In 2017,
rates were 7.6 in the South, 5.3 in the Northeast,
3.9 in the West, and 3.3 in the Midwest.
Please use caution when interpreting data for
Native Hawaiians/other Pacific Islanders: the
numbers are small.
• Sex and transmission category: From 2012
through 2016, the rates of deaths for male and
female adults and adolescents decreased. The
number of deaths among males with diagnosed
HIV infection attributed to injection drug use or to
perinatal transmission decreased. The numbers of
deaths among males attributed to male-to-male
sexual contact, male-to-male sexual contact and
injection drug use, or heterosexual contact
remained stable. The number of deaths among
female adults and adolescents with infection
attributed to perinatal transmission increased. The
number of deaths among females with infection
attributed to injection drug use or to heterosexual
contact decreased. Please use caution when interpreting data for children with infection attributed
to perinatal transmission: the numbers are small.
• Region: From 2012 through 2016, the rates of
deaths in the Northeast, the Midwest, and the
South decreased. The rates of deaths in the West
remained stable. In 2016, rates were 6.4 in the
Northeast, 6.1 in the South, 3.4 in the West, and
2.5 in the Midwest.
Deaths
Deaths of persons with diagnosed
HIV infection
From 2012 through 2016 in the United States, the
rate of deaths of persons with diagnosed HIV infection decreased; the number of deaths remained stable (Table 18a). In 2016, the rate of deaths of
persons with diagnosed HIV infection was 4.8.
Deaths of persons with diagnosed HIV infection
may be due to any cause (i.e., may or may not be
related to HIV infection).
• Age group: From 2012 through 2016, the rates of
deaths for persons aged 60–64 and 65 years and
older increased. The rates of deaths for persons
aged 20–24, 30–34, 35–39, 40–44, 45–49, and 50–
54 years decreased. The rates for persons aged 25–
29 and 55–59 years remained stable. Please use
caution when interpreting data for children (aged
less than 13 years at death) and persons aged 13–
14 and 15–19 years: the numbers are small.
• Race/ethnicity: From 2012 through 2016, the
rates of deaths for American Indians/Alaska
Natives, blacks/African Americans, and
Hispanics/Latinos decreased. The rates for
Asians, whites, and persons of multiple races
remained stable. In 2016, the highest rate of
deaths was for blacks/African Americans: 16.9.
HIV Surveillance Report
Deaths of persons with infection ever
classified as stage 3 (AIDS)
From 2012 through 2016 in the United States, the
annual number and rate of deaths of persons with
infection ever classified as stage 3 (AIDS) decreased
(Table 19a). In 2016, the rate of deaths of persons
with stage 3 (AIDS) was 3.8. Deaths of persons with
stage 3 (AIDS) may be due to any cause.
• Age group: From 2012 through 2016, the rates of
deaths among persons aged 60–64 and 65 years
and older increased. Rates of deaths among persons aged 20–24, 25–29, 30–34, 35–39, 40–44,
45–49, and 50–54 years decreased. Rates among
persons aged 55–59 years remained stable. Please
use caution when interpreting data for children
(aged less than 13 years) and persons aged 13–14
and 15–19 years: the numbers are small.
• Race/ethnicity: From 2012 through 2016, the
rates of deaths for American Indians/Alaska
Natives, blacks/African Americans, and
Hispanics/Latinos decreased. The rates of deaths
7
Vol. 29
for Asians, whites, and persons of multiple races
remained stable. In 2016, the highest death rate
was for blacks/African Americans: 13.4. Please
use caution when interpreting data for Native
Hawaiians/other Pacific Islanders: the numbers
are small.
• Sex and transmission category: From 2012
through 2016, the rates of deaths for male and
female adults and adolescents decreased. The
numbers of deaths among males with infection
attributed to injection drug use or to perinatal
transmission decreased. The numbers of deaths
among males with infection attributed to male-tomale sexual contact, male-to-male sexual contact
and injection drug use, or heterosexual contact
remained stable. The number of deaths among
female adults and adolescents with infection
attributed to perinatal transmission increased.
Among female adults and adolescents with infection attributed to injection drug use or to heterosexual contact, the number of deaths decreased.
Please use caution when interpreting data for children with infection attributed to perinatal transmission: the numbers are small.
• Region: From 2012 through 2016, the rates of
deaths in the Northeast, the Midwest, and the
South decreased; the rate in the West remained
stable. In 2016, rates were 5.1 in the Northeast,
4.9 in the South, 2.8 in the West, and 2.0 in
the Midwest.
largest percentage increase in rates (56%) was
among persons aged 65 years and older (from
104.4 in 2012 to 162.6 in 2016).
• Race/ethnicity: At year-end 2016, the highest
rate (1,026.6) and the largest percentage (42%)
were those for blacks/African Americans. Among
the remaining race/ethnicity groups, the rates
were 628.4 for persons of multiple races, 372.1
for Hispanics/Latinos, 152.8 for whites, 150.4 for
Native Hawaiians/other Pacific Islanders, 124.0
for American Indians/Alaska Natives, and 76.3
for Asians.
• Sex and transmission category: At year-end
2016, the rates were 570.1 for male adults and
adolescents, 169.9 for female adults and adolescents, and 4.2 for children (aged less than 13 years
at year-end 2016). Among a total of 754,218
males (aged 13 years and older at year-end 2016),
72% of infections were attributed to male-to-male
sexual contact, 10% to heterosexual contact, 10%
to injection drug use, 7% to male-to-male sexual
contact and injection drug use, and 1% to perinatal transmission. Among a total of 235,004
females (aged 13 years and older at year-end
2016), 76% of infections were attributed to heterosexual contact, 21% to injection drug use, and
2% to perinatal transmission. Among a total of
2,225 children aged less than 13 years at year-end
2016, 81% of infections were attributed to perinatal transmission.
• Region: At year-end 2016, the rate was highest
in the Northeast at 418.8, followed by 361.3
in the South, 253.7 in the West, and 174.5 in
the Midwest.
Prevalence: Persons Living with Diagnosed
HIV Infection and Persons Living with
Infection Ever Classified as Stage 3 (AIDS)
Prevalence of diagnosed HIV infection
From 2012 through 2016, the number and rate of persons in the United States living with diagnosed HIV
infection increased (Table 22a). At year-end 2016,
991,447 persons in the United States were living with
diagnosed HIV infection. The prevalence of diagnosed HIV infection was 306.6.
• Age group: At year-end 2016, persons aged 50–
54 years made up the largest percentage (17%) of
persons living with diagnosed HIV. The highest
rate (777.6) was among persons aged 50–54 years,
followed by those aged 45–49 (661.6) and those
aged 55–59 (630.1). From 2012 through 2016, the
HIV Surveillance Report
Prevalence of stage 3 (AIDS)
From 2012 through 2016, the number of persons living with infection ever classified as stage 3 (AIDS)
increased; the rate remained stable (Table 23a). At
year-end 2016, 525,374 persons in the United States
were living with infection ever classified as stage 3
(AIDS). The prevalence of infections classified as
stage 3 (AIDS) was 162.5.
• Age group: At year-end 2016, the highest rate
(480.2) and the largest percentage (20%) were
those for persons aged 50–54 years, followed by
persons aged 55–59 (405.2 and 17%, respectively). From 2012 through 2016, the largest per-
8
Vol. 29
• NCHHSTP AtlasPlus [interactive tool for accessing HIV/AIDS, STD, TB, and hepatitis data]:
http://www.cdc.gov/nchhstp/atlas/
centage increase in rates (54%) was among
persons aged 65 years and older (from 70.0 in
2012 to 107.6 in 2016).
• Race/ethnicity: At year-end 2016, the highest
rate (538.8) and the largest percentage (41%)
were those for blacks/African Americans.
Among the remaining race/ethnicity groups,
the rates were 366.8 for persons of multiple
races, 206.0 for Hispanics/Latinos, 79.0 for
whites, 73.7 for Native Hawaiians/other Pacific
Islanders, 62.3 for American Indians/Alaska
Natives, and 35.5 for Asians.
• Sex and transmission category: At year-end
2016, the rates were 303.0 for male adults and
adolescents, 89.8 for female adults and adolescents, and 0.5 for children (aged less than 13
years at year-end 2016). Among a total of
400,859 males (aged 13 years and older at yearend 2016), 67% of infections were attributed to
male-to-male sexual contact, 12% to injection
drug use, 12% to heterosexual contact, 8% to
male-to-male sexual contact and injection drug
use, and 1% to perinatal transmission. Among a
total of 124,228 females (aged 13 years and older
at year-end 2016), 72% of infections were
attributed to heterosexual contact, 24% to injection drug use, and 2% to perinatal transmission.
Among a total of 287 children aged less than 13
years at year-end 2016, 86% of infections were
attributed to perinatal transmission.
• Region: At year-end 2016, the rate was highest in
the Northeast at 237.0, followed by 185.7 in the
South, 137.1 in the West, and 87.4 in the Midwest.
SUGGESTED READINGS
CDC. Establishing a holistic framework to reduce
inequities in HIV, viral hepatitis, STDs, and tuberculosis in the United States. http://stacks.cdc.gov/
view/cdc/11585. Published October 2010. Accessed
September 26, 2018.
CDC. Estimated HIV incidence and prevalence in the
United States, 2010–2015. HIV Surveillance Supplemental Report 2018;23(No. 1). http://www.cdc.gov/
hiv/library/reports/hiv-surveillance.html. Published
March 2018. Accessed September 26, 2018.
CDC. Monitoring selected national HIV prevention
and care objectives by using HIV surveillance
data—United States and 6 dependent areas, 2016.
HIV Surveillance Supplemental Report 2018;
23(No. 4). http://www.cdc.gov/hiv/library/reports/
hiv-surveillance.html. Published June 2018.
Accessed September 26, 2018.
CDC [Selik RM, Mokotoff ED, Branson B, Owen SM,
Whitmore S, Hall HI]. Revised surveillance case
definition for HIV infection—United States, 2014.
MMWR 2014;63(RR-03):1–10. http://www.cdc
.gov/mmwr/indrr_2014.html. Accessed September
26, 2018.
CDC. Revised surveillance case definitions for HIV
infection among adults, adolescents, and children
aged <18 months and for HIV infection and AIDS
among children aged 18 months to <13 years—
United States, 2008. MMWR 2008;57(RR-10):1–12.
http://www.cdc.gov/mmwr/indrr_2008.html.
Accessed September 26, 2018.
ADDITIONAL RESOURCES
The following were prepared by using HIV surveillance data:
CDC [Smith DK, Van Handel M, Wolitski RJ, et al].
Vital Signs: Estimated percentages and numbers
of adults with indications for preexposure
prophylaxis to prevent HIV acquisition—United
States, 2015. MMWR 2015;64(46):1291–1295.
http://www.cdc.gov/mmwr/index2015.html.
Accessed September 26, 2018.
• MMWR articles (selected): http://www.cdc.gov/
hiv/library/reports/mmwr.html
• Other surveillance reports: http://www.cdc.gov/
hiv/library/reports/hiv-surveillance.html
• Public-use slides updated annually: http://www
.cdc.gov/hiv/library/slidesets/
HIV Surveillance Report
9
Vol. 29
CDC [Dailey AF, Hoots BE, Hall HI, et al]. Vital
Signs: Human immunodeficiency virus testing and
diagnosis delays—United States. MMWR
2017;66(47):1300–1306. http://www.cdc
.gov/mmwr/volumes/66/wr/mm6647e1.htm.
Accessed September 26, 2018.
Cohen SM, Gray KM, Ocfemia MC, Johnson AS,
Hall HI. The status of the National HIV Surveillance System, United States, 2013. Public Health
Rep 2014;129(4):335–341. doi:10.1177/
003335491412900408.
Frieden TR, Foti KE, Mermin J. Applying public
health principles to the HIV epidemic—how are
we doing? N Engl J Med 2015;373:2281–2287.
doi:10.1056/NEJMms1513641.
Hall HI, Song R, Tang T, et al. HIV trends in the
United States: diagnoses and estimated incidence.
JMIR Public Health Surveill 2017;3(1):e8.
doi.10.2196/publichealth.7051.
HIV Surveillance Report
10
Vol. 29
Technical Notes
SURVEILLANCE OF HIV INFECTION
STAGES OF HIV INFECTION
This report includes case report data from 50 states,
the District of Columbia, and 6 U.S. dependent areas
(American Samoa, Guam, the Northern Mariana
Islands, Puerto Rico, the Republic of Palau, and the
U.S. Virgin Islands) in which laws or regulations
require confidential reporting to the jurisdiction (not
to CDC), by name, for adults, adolescents, and children with confirmed diagnoses of HIV infection.
After the removal of personally identifiable information, data from these reports were submitted to CDC.
Although AIDS cases have been reported to CDC
since 1981, the date of implementation of HIV infection reporting has differed from jurisdiction to jurisdiction. All states, the District of Columbia, and 6
U.S. dependent areas had fully implemented namebased HIV infection reporting by April 2008.
Please use caution when interpreting data on diagnoses of HIV infection. HIV surveillance reports may not
be representative of all persons with HIV because not
all infected persons have been (1) tested or (2) tested at
a time when the infection could be detected and diagnosed. Also, some states offer anonymous HIV testing;
the results of anonymous tests are not reported to the
confidential name-based HIV registries of state and
local health departments. Therefore, reports of confidential test results may not represent all persons who
tested positive for HIV infection. In addition, testing
patterns are influenced by many factors, including the
extent to which testing is routinely offered to specific
groups and the availability of, and access to, medical
care and testing services. The data presented in this
report provide minimum counts of persons for whom
HIV infection has been diagnosed and reported to the
surveillance system. Finally, although all jurisdictions
use a uniform case report form, surveillance practices
in data collection and updating of case records may differ among jurisdictions.
Based on annual standard evaluation results, the
completeness of reporting of HIV infection, as of
December 2017, is estimated to be at least 85% in all
but 1 jurisdiction [1].
Both the 2008 and 2014 HIV case definitions were
used to classify HIV infection among adults and adolescents and among children [2, 3]. In the following
lists, some bulleted items are paraphrases, not quotations from the published surveillance case definitions.
The intention is to emphasize the differences between
the 2008 and 2014 case definitions.
The 2008 case definition was used to classify
cases diagnosed through 2013. For adults and adolescents, this definition incorporates an HIV infection
staging system that includes AIDS (HIV infection,
stage 3). The 2008 stages of HIV infection are defined
as follows:
HIV Surveillance Report
• HIV infection, stage 1: No AIDS-defining opportunistic illness (OI) and either CD4+ Tlymphocyte (CD4 lymphocyte) count of ≥500
cells/L or CD4 percentage of total lymphocytes
of ≥29.
• HIV infection, stage 2: No AIDS-defining OI
and either CD4 lymphocyte count of 200–499
cells/L or CD4 percentage of total lymphocytes
of 14–28.
• HIV infection, stage 3 (AIDS): Documentation
of an AIDS-defining OI or either a CD4 lymphocyte count of <200 cells/L or CD4 percentage of
total lymphocytes of <14. Documentation of an
AIDS-defining OI supersedes a CD4 lymphocyte
count or percentage that would not, by itself, be
the basis for a stage 3 (AIDS) classification.
• HIV infection, stage unknown: No reported
information on AIDS-defining OIs and no information available on CD4 lymphocyte count
or percentage.
The 2014 case definition was used to classify cases
diagnosed after 2013. It is similar to the 2008 case
definition except for the following: (1) inclusion of
criteria for stage 0, (2) the inclusion of CD4 lymphocyte testing criteria for stage 3 in children, and
(3) changes in the cutoffs for CD4 percentage of total
lymphocytes used for classification of stages 1 and 2 in
persons aged 6 years and older [3]. The stages of HIV
infection in the 2014 case definition are based on age-
11
Vol. 29
TABULATION AND PRESENTATION OF DATA
specific CD4 lymphocyte counts or percentages of
total lymphocytes and are defined as follows:
• HIV infection, stage 0: Negative (nonreactive) or
indeterminate HIV-1 test result within 6 months
before the first positive (reactive) HIV-1 test
result, or a negative or an indeterminate HIV-1
antibody test result within 6 months before or
after the first positive HIV-1 nucleic acid test
result (if the latter was not the first positive HIV
test). The stage remains stage 0 during the 6
months after the first positive test result; after 6
months, the stage is reclassified, depending upon
CD4 lymphocyte test results (stage 1, 2, or 3), the
diagnosis of an AIDS-defining OI (stage 3), or
the absence of reported CD4 or OI information
(stage unknown).
• HIV infection, stages 1, 2, and 3: Documentation
of an AIDS-defining OI (excluding stage 0 as
described above) is stage 3. Otherwise, the stage
is determined by the lowest CD4 lymphocyte test
result [3, p 7].
• HIV infection, stage unknown: No reported
information on AIDS-defining OIs and no information available on CD4 lymphocyte count or
percentage.
The transition to CD4 lymphocyte-based criteria for
stage 3 (AIDS) among children has resulted in an
increase in the number of annual stage 3 (AIDS) classifications among pediatric cases diagnosed after
2013. Before implementation of the 2014 revised case
definition, an OI diagnosis was required for a pediatric
case to meet the criteria for stage 3 classification.
In this report, the term diagnosis of HIV infection
is defined as a diagnosis of HIV infection regardless
of the stage of disease (stage 0, 1, 2, 3 [AIDS], or
unknown) and refers to all persons with a diagnosis of
HIV infection. The term HIV infection, stage 3 (AIDS)
and its condensed version—stage 3 (AIDS)—refer
specifically to persons with diagnosed HIV whose
infection was classified as stage 3 (AIDS) during a
given year (for diagnoses) or whose infection has
ever been classified as stage 3 (AIDS) (for prevalence
and deaths).
HIV Surveillance Report
The data in this report include information received
by CDC through June 30, 2018. The data are organized into 4 sections.
• Section 1 (Tables 1a/b–17): numbers and rates of
diagnoses of HIV infection (any stage) and diagnoses of infection classified as stage 3 (AIDS)
• Section 2 (Tables 18a/b–21a/b): numbers and
rates of deaths among persons with diagnosed
HIV infection (any stage) and persons with infection ever classified as stage 3 (AIDS)
• Section 3 (Tables 22a/b–25a/b): numbers and
rates of persons living with diagnosed HIV infection (any stage) and persons living with infection
ever classified as stage 3 (AIDS) (i.e., prevalence)
• Section 4 (Tables 26–31): numbers and rates of
diagnoses and prevalence of HIV infection (any
stage) and diagnoses and prevalence of infection
classified as stage 3 (AIDS), presented by state
and metropolitan statistical area (MSA)
Many tables in the 2017 report present data in 2 formats. Tables in the first format—labeled “a”—exclude
data from the dependent areas (American Samoa,
Guam, the Northern Mariana Islands, Puerto Rico, the
Republic of Palau, and the U.S. Virgin Islands). Tables
in the second format—labeled “b”—include data from
the dependent areas.
Please use caution when interpreting numbers less
than 12, and rates and trends based on these numbers.
Numbers of diagnoses for the most recent year
(2017) are considered preliminary. Please use caution
when interpreting these numbers, and do not include
them when assessing trends.
Diagnoses of HIV Infection and
Stage 3 (AIDS) Classifications
This report is based on diagnoses of HIV infection
that the 50 states, the District of Columbia, and 6 U.S.
dependent areas reported to CDC as of June 30, 2018.
Data from all areas are included in tables displaying
numbers and rates of diagnoses of HIV infection and
of stage 3 (AIDS) classifications, by selected characteristics, area of residence, and MSA (Tables 1a/b–17,
26, 27, 30, and 31). For tables presenting diagnosis
data, region or area of residence reflects the address at
12
Vol. 29
the time of HIV diagnosis or at the time of stage 3
(AIDS) classification.
specified year. For presentations of data on deaths of
persons with diagnosed HIV infection (Tables 18a/b
and 20a/b) and deaths of persons with infection classified as stage 3 (AIDS) (Tables 19a/b and 21a/b), agegroup assignment is determined by the person’s age at
the time of death. For all other tables, the age designation or the specific age-group assignment is based on
the person’s age at the time of HIV diagnosis or at the
time of stage 3 (AIDS) classification.
Age-group designations for transmission categories
in tables displaying data on prevalence and on deaths
are based on a person’s age at the end of the specified
year or age at death, respectively. The transmission
categories among “adults and adolescents” in these
tables include persons who were children at the time of
diagnosis but who were aged 13 years and older during
the specified year or at death.
Deaths
Persons reported to the National HIV Surveillance
System are assumed alive unless their deaths have
been reported to CDC. Death data include deaths of
persons with diagnosed HIV infection (Tables 18a/b
and 20a/b) or with infection ever classified as stage 3
(AIDS) (Tables 19a/b and 21a/b) regardless of the
cause of death. Because of delays in the reporting of
deaths, only 5 years (2012–2016) of death data are displayed. The exclusion of data from the most recent
year allowed at least 18 months for deaths to be
reported to CDC. For the death tables, region or area
of residence is based on residence at death. When
information on residence at death is not available, the
state where a person’s death occurred is used.
Sex
Sex designations in this report are based on a person’s sex at birth. Transgender is an umbrella term
that is used to identify persons whose sex assigned at
birth does not match current gender identity or
expression. Data for transgender persons are not presented in this report because information on gender
identity (a person’s internal understanding of his or
her gender or the gender with which a person identifies) is not consistently collected or documented in
the data sources used by HIV reporting jurisdictions.
HIV surveillance personnel collect data on gender
identity, when available, from sources such as case
report forms submitted by health care or HIV testing
providers and medical records, or by matching with
other health department databases (e.g., Ryan White
program data). In May 2012, CDC issued guidance to
state and local programs on methods for collecting
data on transgender persons and working with
transgender-specific data. However, characterization
of HIV infection among transgender persons may
require supplemental data from special studies.
Prevalence: Persons Living with
Diagnosed HIV Infection and
Persons Living with Infection Ever
Classified as Stage 3 (AIDS)
Because of delays in the reporting of deaths, only 5
years of prevalence data are displayed. The data
reflect persons living with diagnosed HIV infection,
regardless of stage of disease, (Tables 22a/b, 24a/b,
28, and 30) and persons living with infection ever
classified as stage 3 (AIDS) (Tables 23a/b, 25a/b, 29,
and 31) at the end of a given year during 2012–2016.
The exclusion of data from the most recent year
allowed at least 18 months for deaths to be reported
and for these deaths to be factored into calculations of
prevalence. For tables presenting prevalence data,
region or area of residence is based on most recent
known address as of the end of the specified year.
Age
The designation “adults and adolescents” refers to
persons aged 13 years and older; the designation
“children” refers to persons aged less than 13 years.
For presentations of data on persons living with diagnosed HIV infection (Tables 22a/b, 24a/b, and 28)
and presentations of data on persons living with infection classified as stage 3 (AIDS) (Tables 23a/b, 25a/b,
and 29), the age-group assignment (e.g., 20–24 years)
or the age designation (e.g., “adults and adolescents”)
is based on the person’s age as of December 31 of the
HIV Surveillance Report
Race and Ethnicity
In the Federal Register [4] for October 30, 1997, the
Office of Management and Budget (OMB) announced
the Revisions to the Standards for the Classification of
Federal Data on Race and Ethnicity. Implementation by
January 1, 2003, was mandated. At a minimum, data on
the following race categories should be collected:
13
Vol. 29
• American Indian or Alaska Native
• Asian
• black or African American
• Native Hawaiian or other Pacific Islander
• white
Additionally, systems must be able to retain information when multiple race categories are reported. In
addition to data on race, data on 2 categories of ethnicity should be collected:
• Hispanic or Latino
• not Hispanic or Latino
The Asian or Pacific Islander category displayed in
annual surveillance reports published prior to the 2007
surveillance report was split into 2 categories:
(1) Asian and (2) Native Hawaiian or other Pacific
Islander. The Asian category (in tables where footnoted) includes the cases in Asians/Pacific Islanders
(referred to as legacy cases) that were reported before
the implementation of the new race categories in 2003
(e.g., cases of HIV infection that were diagnosed and
reported to CDC before 2003 but that were classified
as stage 3 [AIDS] after 2003) and a small percentage
of cases that were reported after 2003 but that were
reported according to the old race category (Asian/
Pacific Islander). In tables of diagnoses of HIV infection during 2012–2017, the Asian category does not
include Asian/Pacific Islander cases because these
cases were diagnosed after 2003 and were reported to
CDC in accordance with OMB’s Revisions to the
Standards for the Classification of Federal Data on
Race and Ethnicity [4].
This report also presents data for persons for whom
multiple race categories are reported. In this report,
persons categorized by race were not Hispanic or
Latino. The number of persons reported in each race
category may, however, include persons whose ethnicity was not reported.
Geographic Designations
Data by region or area of residence reflect the address
at the time of diagnosis of HIV infection or at the time
of stage 3 (AIDS) classification for tables that present
number of diagnoses (Tables 1a/b–17, 26, 27, 30, 31).
For tables presenting prevalence data (22a/b–25a/b,
28–31), region or area of residence is based on most
recent known address as of the end of the specified
HIV Surveillance Report
year. For the death tables (18a/b–21a/b), region or
area of residence is based on residence at death. When
information on residence at death is not available, the
state where a person’s death occurred is used.
The 4 regions of residence used in this report are
defined by the U.S. Census Bureau as follows:
Northeast: Connecticut, Maine, Massachusetts,
New Hampshire, New Jersey, New York,
Pennsylvania, Rhode Island, and Vermont
Midwest: Illinois, Indiana, Iowa, Kansas, Michigan,
Minnesota, Missouri, Nebraska, North Dakota, Ohio,
South Dakota, and Wisconsin
South: Alabama, Arkansas, Delaware, District of
Columbia, Florida, Georgia, Kentucky, Louisiana,
Maryland, Mississippi, North Carolina, Oklahoma,
South Carolina, Tennessee, Texas, Virginia, and
West Virginia
West: Alaska, Arizona, California, Colorado,
Hawaii, Idaho, Montana, Nevada, New Mexico,
Oregon, Utah, Washington, and Wyoming
U.S. dependent areas: American Samoa, Guam, the
Northern Mariana Islands, Puerto Rico, the Republic
of Palau, and the U.S. Virgin Islands
Metropolitan Statistical Areas
In the Federal Register for June 28, 2010, OMB published revised standards for defining MSAs in federal
statistical activities [5]. These standards, which provided for the identification of MSAs in the United
States and Puerto Rico, replaced the 2000 standards.
The adoption of the new standards was effective as of
June 28, 2010. On February 28, 2013, OMB
announced new MSA delineations based on the new
standards and Census 2010 data [6]. Tables 30 (data
on diagnosed HIV infection) and 31 (data on stage 3
[AIDS]) present numbers and rates of diagnoses and
prevalence, by MSA, for areas with populations of
500,000 or more. The MSAs listed in these tables
were defined according to OMB’s most recent update
(February 2013) of statistical areas [6].
Transmission Categories
Transmission category is the term for the classification of cases that summarizes a person’s possible HIV
risk factors; the summary classification results from
selecting, from the presumed hierarchical order of
probability, the 1 (single) risk factor most likely to
have been responsible for transmission. For surveil-
14
Vol. 29
lance purposes, a diagnosis of HIV infection is
counted only once in the hierarchy of transmission
categories. Persons with more than 1 reported risk
factor for HIV infection are classified in the transmission category listed first in the hierarchy. The exception is men who had sexual contact with other men
and injected drugs; this group makes up a separate
transmission category.
Persons whose transmission category is classified as
male-to-male sexual contact include men who have
ever had sexual contact with other men (i.e., homosexual contact) and men who have ever had sexual contact
with both men and women (i.e., bisexual contact). Persons whose transmission category is classified as heterosexual contact are persons who have ever had
heterosexual contact with a person known to have,
or to be at high risk for, HIV infection (e.g., a person
who injects drugs). The heterosexual contact category
excludes men who have ever had sexual contact with
both men and women.
Tables of prevalence data and tables of death data
include a separate transmission category of adults and
adolescents with HIV infection attributed to perinatal
transmission. The category includes persons infected
through perinatal transmission but aged 13 years and
older during the specified year or at death.
Cases of HIV infection reported without a risk factor
listed in the hierarchy of transmission categories are
classified as “no identified risk (NIR).” Cases classified as NIR include cases that are being followed up by
local health department staff; cases in persons whose
risk-factor information is missing because they died,
declined to be interviewed, or were lost to follow-up;
and cases in persons who were interviewed or for
whom other follow-up information was available but
for whom no risk factor was identified.
Because a substantial proportion of cases of HIV
infection are reported to CDC without an identified
risk factor, multiple imputation is used to assign a
transmission category [7]. Multiple imputation is a statistical approach in which each missing transmission
category is replaced with a set of plausible values that
represent the uncertainty about the true, but missing,
value [8]. Each resulting data set containing the plausible values is analyzed by using standard procedures,
and the results from these analyses are then combined
to produce the final results. In tables displaying transmission categories, multiple imputation was used for
adults and adolescents, but not for children (because
HIV Surveillance Report
the number of cases in children is small, missing transmission categories were not imputed).
Rates
Rates per 100,000 population were calculated for
(1) the numbers of diagnoses of HIV infection and
the numbers of infections classified as stage 3
(AIDS), (2) the numbers of deaths of persons with
diagnosed HIV infection and deaths of persons with
infection ever classified as stage 3 (AIDS), and
(3) the numbers of persons living with diagnosed
HIV infection and persons living with infection ever
classified as stage 3 (AIDS).
The population denominators used to compute the
rates for the 50 states, the District of Columbia, and
Puerto Rico were based on the Vintage 2017 postcensal estimates file (for years 2012–2017) from the U.S.
Census Bureau [9]. The population denominators for
American Samoa, Guam, the Northern Mariana
Islands, the Republic of Palau, and the U.S. Virgin
Islands were based on estimates and projections from
the U.S. Census Bureau’s International Data Base
[10]. Each rate was calculated by dividing the total
number of diagnoses (or deaths or prevalence) for the
calendar year by the population for that calendar year
and then multiplying the result by 100,000. The
denominators used for calculating the rates specific to
age, sex, and race/ethnicity were computed by applying the appropriate vintage estimates for age, sex, and
race/ethnicity for the 50 states and the District of
Columbia [9]. The same method was used to calculate
the denominators for Puerto Rico, with the exception
of race/ethnicity estimates; these data are not available
for Puerto Rico (see next paragraph). For the other 5
U.S. dependent areas, estimates from the U.S. Census
Bureau’s International Data Base were used for ageand sex-specific population denominators [10].
CDC currently does not provide subpopulation rates
by race/ethnicity for the 6 U.S. dependent areas
because the U.S. Census Bureau does not collect information from all dependent areas. Rates for transmission categories are not provided in this report because
of the absence of denominator data from the U.S. Census Bureau, the source of data used for calculating all
rates in this report.
15
Vol. 29
REFERENCES
1. Karch DL, Chen M, Tang T. Evaluation of the National
Human Immunodeficiency Virus Surveillance System
for the 2011 diagnosis year. J Public Health Manag
Pract 2014;20(6):598–607. doi: 10.1097/
PHH.0000000000000033.
2. CDC. Revised surveillance case definitions for HIV
infection among adults, adolescents, and children aged
<18 months and for HIV infection and AIDS among
children aged 18 months to <13 years—United States,
2008. MMWR 2008;57(RR-10):1–12.
3. CDC [Selik RM, Mokotoff ED, Branson B, Owen SM,
Whitmore S, Hall HI]. Revised surveillance case definition for HIV infection—United States, 2014. MMWR
2014;63(RR-03):1–10.
4. Office of Management and Budget. Revisions to the
standards for the classification of federal data on race
and ethnicity. Federal Register 1997;62:58782–58790.
http://go.usa.gov/xPg4F. Accessed September 26,
2018.
5. Office of Management and Budget. 2010 Standards for
delineating metropolitan and micropolitan statistical
areas. Federal Register 2010;75(123):37246–39052.
https://go.usa.gov/xn43u. Accessed September 26,
2018.
6. Office of Management and Budget. Revised delineations of metropolitan statistical areas, new definitions of
micropolitan statistical areas and combined statistical
areas, and guidance on uses of the delineations of these
areas. OMB Bulletin 13-01. https://go.usa.gov/xn43h.
Published February 28, 2013. Accessed September 26,
2018.
7. Harrison KM, Kajese T, Hall HI, Song R. Risk factor
redistribution of the national HIV/AIDS surveillance
data: an alternative approach. Public Health Rep
2008;123(5):618–627.
8. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons Inc; 1987.
9. U.S. Census Bureau. Population and Housing Unit Estimates Datasets. https://go.usa.gov/xn4cc. Accessed
September 26, 2018.
10. U.S. Census Bureau. International Data Base.
https://www.census.gov/data-tools/demo/idb/. Updated
August 2017. Accessed September 26, 2018.
HIV Surveillance Report
16
Vol. 29
Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States
2012
2013
2014
2015
2016
2017
No.
Ratea
No.
Ratea
No.
Ratea
No.
Ratea
No.
Ratea
No.
Ratea
241
50
1,919
7,174
6,459
5,458
4,161
4,448
4,290
3,187
1,924
1,049
820
0.5
0.6
9.0
31.8
30.2
26.1
21.3
21.1
19.8
14.1
9.3
5.9
1.9
184
43
1,687
7,054
6,653
5,202
3,964
3,925
3,923
2,968
2,010
1,066
860
0.3
0.5
8.0
30.9
30.8
24.4
20.2
18.8
18.5
13.1
9.5
5.9
1.9
180
32
1,727
7,370
7,187
5,451
4,241
3,793
3,610
2,899
1,933
973
831
0.3
0.4
8.2
32.2
32.7
25.3
21.3
18.4
17.3
12.9
9.0
5.2
1.8
140
25
1,740
7,276
7,596
5,457
4,263
3,417
3,325
3,000
1,874
999
852
0.3
0.3
8.2
32.1
33.9
25.2
21.0
16.9
16.0
13.5
8.6
5.2
1.8
130
25
1,700
6,868
7,930
5,662
4,224
3,264
3,098
2,879
1,886
1,078
845
0.2
0.3
8.0
30.7
34.6
25.9
20.3
16.5
14.8
13.2
8.6
5.5
1.7
99
25
1,711
6,354
7,691
5,614
4,315
2,995
2,964
2,677
1,886
1,086
864
0.2
0.3
8.1
28.7
32.9
25.6
20.3
15.2
14.1
12.5
8.6
5.4
1.7
Race/ethnicity
American Indian/Alaska Native
172
Asian
797
Black/African American
18,196
Hispanic/Latinob
9,196
Native Hawaiian/Other Pacific Islander
51
White
11,041
Multiple races
1,727
7.4
5.1
46.9
17.3
9.8
5.6
28.8
147
792
17,326
8,986
47
10,621
1,620
6.3
4.9
44.3
16.6
8.8
5.4
26.2
182
923
17,533
9,549
44
10,581
1,415
7.7
5.5
44.4
17.3
8.1
5.3
22.2
189
941
17,453
9,643
74
10,403
1,261
8.0
5.4
43.7
17.1
13.3
5.3
19.2
230
972
17,269
9,831
41
10,117
1,129
9.6
5.4
42.9
17.0
7.2
5.1
16.7
212
942
16,690
9,461
57
10,048
871
8.8
5.1
41.1
16.1
9.9
5.1
12.6
26,252
1,440
1,471
—
—
—
25,614
1,353
1,361
—
—
—
26,546
1,272
1,327
—
—
—
26,481
1,313
1,336
—
—
—
26,159
1,226
1,304
—
—
—
25,513
1,335
1,241
—
—
—
3,502
46
32,711
—
—
25.7
3,337
41
31,707
—
—
24.6
3,265
37
32,447
—
—
25.0
3,258
36
32,424
—
—
24.7
3,216
26
31,931
—
—
24.1
2,744
36
30,870
—
—
23.1
Female adult or adolescent
Injection drug use
Heterosexual contactd
Othere
Subtotal
1,146
7,047
35
8,228
—
—
—
6.2
978
6,621
49
7,648
—
—
—
5.7
952
6,614
34
7,600
—
—
—
5.6
1,001
6,370
29
7,400
—
—
—
5.4
950
6,531
47
7,528
—
—
—
5.4
1,009
6,259
44
7,312
—
—
—
5.2
Child (<13 yrs at diagnosis)
Perinatal
Otherf
Subtotal
175
66
241
—
—
0.5
122
62
184
—
—
0.3
134
46
180
—
—
0.3
106
34
140
—
—
0.3
104
26
130
—
—
0.2
73
26
99
—
—
0.2
Region of residenceg
Northeast
Midwest
South
West
7,509
5,489
20,367
7,815
13.4
8.2
17.4
10.6
6,967
5,319
19,967
7,286
12.4
7.9
16.9
9.8
6,938
5,123
20,310
7,856
12.3
7.6
17.0
10.5
6,481
5,246
20,418
7,819
11.5
7.7
16.9
10.3
6,205
5,173
20,287
7,924
11.0
7.6
16.6
10.3
6,011
5,032
19,968
7,270
10.6
7.4
16.1
9.4
Total
41,180
13.1
39,539
12.5
40,227
12.6
39,964
12.4
39,589
12.2
38,281
11.8
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Transmission categoryc
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactd
Othere
Subtotal
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Data for the year 2017 should not be used when assessing trends.
a
Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Hispanics/Latinos can be of any race.
c
d
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
f
g
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
Data are based on residence at time of diagnosis of HIV infection.
HIV Surveillance Report
17
Vol. 29
Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2012–2017—United States and 6 dependent areas
2012
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/Other Pacific Islander
White
Multiple races
Transmission categoryc
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactd
Othere
Subtotal
Female adult or adolescent
Injection drug use
Heterosexual contactd
Othere
Subtotal
Child (<13 yrs at diagnosis)
Perinatal
Otherf
Subtotal
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
Total
2013
2014
2015
2016
2017
No.
Ratea
No.
Ratea
No.
Ratea
No.
Ratea
No.
Ratea
No.
Ratea
241
51
1,940
7,277
6,560
5,559
4,232
4,543
4,389
3,255
1,963
1,072
860
0.5
0.6
9.0
31.8
30.3
26.2
21.4
21.3
20.0
14.2
9.3
5.9
2.0
184
44
1,706
7,144
6,737
5,292
4,031
3,991
4,007
3,041
2,053
1,102
888
0.3
0.5
7.9
30.9
30.9
24.6
20.3
18.9
18.6
13.3
9.6
6.0
2.0
180
32
1,754
7,486
7,282
5,513
4,316
3,872
3,671
2,946
1,978
1,001
857
0.3
0.4
8.2
32.3
32.8
25.3
21.4
18.6
17.4
12.9
9.1
5.3
1.8
140
25
1,748
7,358
7,689
5,517
4,330
3,478
3,389
3,056
1,907
1,015
882
0.3
0.3
8.2
32.0
33.9
25.2
21.0
17.0
16.1
13.5
8.7
5.3
1.8
130
25
1,712
6,942
8,001
5,727
4,296
3,319
3,155
2,926
1,937
1,103
869
0.2
0.3
8.0
30.6
34.5
26.0
20.4
16.6
14.9
13.2
8.7
5.6
1.7
99
25
1,723
6,416
7,755
5,678
4,365
3,032
3,006
2,729
1,918
1,108
885
0.2
0.3
8.1
28.7
32.8
25.6
20.3
15.3
14.2
12.6
8.6
5.5
1.7
172
798
18,200
9,947
54
11,042
1,729
—
—
—
—
—
—
—
147
792
17,343
9,644
48
10,626
1,620
—
—
—
—
—
—
—
182
924
17,549
10,183
46
10,588
1,416
—
—
—
—
—
—
—
189
946
17,462
10,193
77
10,405
1,262
—
—
—
—
—
—
—
230
973
17,275
10,368
47
10,120
1,129
—
—
—
—
—
—
—
212
945
16,694
9,908
59
10,049
872
—
—
—
—
—
—
—
26,561
1,528
1,497
—
—
—
25,910
1,436
1,382
—
—
—
26,882
1,338
1,335
—
—
—
26,781
1,368
1,355
—
—
—
26,448
1,270
1,315
—
—
—
25,748
1,373
1,252
—
—
—
3,641
46
33,274
—
—
25.8
3,454
41
32,223
—
—
24.7
3,369
38
32,961
—
—
25.1
3,344
36
32,885
—
—
24.8
3,321
26
32,379
—
—
24.2
2,829
37
31,239
—
—
23.1
1,169
7,223
35
8,427
—
—
—
6.2
1,003
6,761
49
7,813
—
—
—
5.7
967
6,746
34
7,747
—
—
—
5.6
1,008
6,472
29
7,509
—
—
—
5.4
962
6,625
47
7,633
—
—
—
5.4
1,016
6,341
44
7,401
—
—
—
5.2
175
66
241
—
—
0.5
122
62
184
—
—
0.3
134
46
180
—
—
0.3
106
34
140
—
—
0.3
104
26
130
—
—
0.2
73
26
99
—
—
0.2
7,509
5,489
20,367
7,815
762
41,942
13.4
8.2
17.4
10.6
18.9
13.2
6,967
5,319
19,967
7,286
681
40,220
12.4
7.9
16.9
9.8
17.0
12.6
6,938
5,123
20,310
7,856
661
40,888
12.3
7.6
17.0
10.5
16.8
12.7
6,481
5,246
20,418
7,819
570
40,534
11.5
7.7
16.9
10.3
14.7
12.5
6,205
5,173
20,287
7,924
553
40,142
11.0
7.6
16.6
10.3
14.5
12.3
6,011
5,032
19,968
7,270
458
38,739
10.6
7.4
16.1
9.4
12.3
11.8
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Data for the year 2017 should not be used when assessing trends.
a
Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission
category because of the lack of denominator data.
b Hispanics/Latinos can be of any race.
c
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
d
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
f
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g
Data are based on residence at time of diagnosis of HIV infection.
HIV Surveillance Report
18
Vol. 29
Table 2a. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States
2012
Age at diagnosis (yr)
<13c
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Race/ethnicity
American Indian/Alaska Native
Asiand
Black/African American
Hispanic/Latinoe
Native Hawaiian/
Other Pacific Islander
White
Multiple races
Transmission categoryf
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact
and injection drug use
Heterosexual contactg
Otherh
Subtotal
Female adult or adolescent
Injection drug use
Heterosexual contactg
Otherh
Subtotal
Child (<13 yrs at diagnosis)
Perinatal
Otheri
Subtotal
Region of residencej
Northeast
Midwest
South
West
Totalk
2013
b
2014
b
2015
b
2016
b
Cumulativea
2017
b
b
No.
Rate
No.
Rate
No.
Rate
No.
Rate
No.
Rate
No.
Rate
No.
12
28
360
1,910
2,763
3,247
2,958
3,468
3,680
2,891
1,769
1,011
728
0.0
0.3
1.7
8.5
12.9
15.5
15.2
16.5
17.0
12.8
8.5
5.7
1.7
9
29
401
2,001
2,788
2,928
2,817
3,073
3,313
2,767
1,782
1,030
761
0.0
0.3
1.9
8.8
12.9
13.8
14.4
14.7
15.6
12.3
8.4
5.7
1.7
70
15
187
1,353
2,342
2,412
2,399
2,486
2,681
2,297
1,579
847
736
0.1
0.2
0.9
5.9
10.7
11.2
12.1
12.1
12.9
10.2
7.3
4.6
1.6
39
8
191
1,325
2,410
2,472
2,303
2,260
2,454
2,338
1,514
873
754
0.1
0.1
0.9
5.8
10.7
11.4
11.3
11.2
11.8
10.5
7.0
4.6
1.6
39
14
215
1,278
2,489
2,411
2,368
2,080
2,198
2,214
1,546
920
782
0.1
0.2
1.0
5.7
10.9
11.0
11.4
10.5
10.5
10.1
7.0
4.7
1.6
33
7
202
1,147
2,307
2,430
2,198
1,914
2,068
2,026
1,559
924
789
0.1
0.1
1.0
5.2
9.9
11.1
10.4
9.7
9.9
9.5
7.1
4.6
1.6
9,573
1,474
9,491
54,975
147,146
230,159
247,869
208,520
145,349
89,473
50,822
27,370
23,128
90
350
11,934
5,143
22
3.9
2.2
30.8
9.7
4.2
84
343
11,166
4,995
21
3.6
2.1
28.5
9.2
3.9
82
320
9,054
4,152
17
3.5
1.9
22.9
7.5
3.1
91
335
8,746
4,136
22
3.8
1.9
21.9
7.3
4.0
98
347
8,562
4,192
15
4.1
1.9
21.3
7.3
2.7
72
335
8,341
3,863
27
3.0
1.8
20.5
6.6
4.7
3,576
10,275
515,195
230,895
821
6,085
1,201
3.1
20.0
5,866
1,224
3.0
19.8
4,842
937
2.4
14.7
4,792
819
2.4
12.5
4,579
761
2.3
11.3
4,321
645
2.2
9.3
443,580
40,921
13,134
1,505
1,216
—
—
—
12,944
1,317
1,037
—
—
—
10,396
1,146
795
—
—
—
10,380
1,008
832
—
—
—
10,296
921
797
—
—
—
9,712
941
761
—
—
—
606,446
184,519
89,331
2,709
106
18,670
—
—
14.6
2,567
126
17,990
—
—
14.0
2,181
75
14,593
—
—
11.2
2,046
90
14,356
—
—
10.9
2,089
76
14,178
—
—
10.7
1,837
70
13,321
—
—
10.0
88,985
11,679
980,960
1,171
4,867
105
6,143
—
—
—
4.6
1,014
4,549
137
5,700
—
—
—
4.2
833
3,818
90
4,741
—
—
—
3.5
787
3,680
80
4,546
—
—
—
3.3
742
3,485
110
4,337
—
—
—
3.1
735
3,428
87
4,250
—
—
—
3.0
91,152
157,539
6,125
254,816
9
3
12
—
—
0.0
8
1
9
—
—
0.0
60
10
70
—
—
0.1
30
9
39
—
—
0.1
32
7
39
—
—
0.1
26
7
33
—
—
0.1
8,694
879
9,573
4,714
3,118
12,800
4,193
24,825
8.4
4.6
10.9
5.7
7.9
4,315
2,950
12,510
3,924
23,699
7.7
4.4
10.6
5.3
7.5
3,512
2,480
10,112
3,300
19,404
6.2
3.7
8.4
4.4
6.1
3,314
2,433
9,777
3,417
18,941
5.9
3.6
8.1
4.5
5.9
3,164
2,428
9,557
3,405
18,554
5.6
3.6
7.8
4.4
5.7
2,977
2,217
9,406
3,004
17,604
5.3
3.3
7.6
3.9
5.4
355,402
134,163
508,306
247,478
1,245,349
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
From the beginning of the epidemic through 2017.
b
Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
c
The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).
d
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e
Hispanics/Latinos can be of any race.
f
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
h
Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
i
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
j
Data are based on residence at time of stage 3 (AIDS) classification.
k
Cumulative total includes persons whose race/ethnicity is unknown.
HIV Surveillance Report
19
Vol. 29
Table 2b. Stage 3 (AIDS), by year of diagnosis and selected characteristics, 2012–2017 and cumulative—United States and 6 dependent areas
2012
Age at diagnosis (yr)
<13c
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Race/ethnicity
American Indian/Alaska Native
Asiand
Black/African American
Hispanic/Latinoe
Native Hawaiian/
Other Pacific Islander
White
Multiple races
Transmission categoryf
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact
and injection drug use
Heterosexual contactg
Otherh
Subtotal
Female adult or adolescent
Injection drug use
Heterosexual contactg
Otherh
Subtotal
Child (<13 yrs at diagnosis)
Perinatal
Otheri
Subtotal
Region of residencej
Northeast
Midwest
South
West
U.S. dependent areas
Totalk
2013
No.
Rateb
12
29
361
1,929
2,797
3,288
3,014
3,541
3,761
2,948
1,808
1,032
759
2014
No.
Rateb
0.0
0.3
1.7
8.4
12.9
15.5
15.3
16.6
17.1
12.9
8.6
5.7
1.7
9
30
406
2,022
2,817
2,976
2,868
3,131
3,384
2,834
1,830
1,056
783
90
351
11,944
5,583
23
—
—
—
—
—
6,087
1,201
2015
No.
Rateb
0.0
0.4
1.9
8.7
12.9
13.8
14.4
14.8
15.7
12.4
8.5
5.8
1.7
70
15
192
1,372
2,362
2,451
2,448
2,543
2,734
2,344
1,617
869
752
84
343
11,171
5,436
21
—
—
—
—
—
—
—
5,867
1,224
13,255
1,599
1,237
—
—
—
2,785
109
18,985
2016
No.
Rateb
0.1
0.2
0.9
5.9
10.6
11.3
12.1
12.2
12.9
10.3
7.4
4.6
1.6
39
8
191
1,338
2,432
2,497
2,335
2,295
2,494
2,384
1,537
881
772
82
321
9,062
4,505
18
—
—
—
—
—
—
—
4,844
937
13,078
1,394
1,052
—
—
—
—
—
14.7
2,653
128
18,305
1,196
4,979
107
6,282
—
—
—
4.6
9
3
12
4,714
3,118
12,800
4,193
454
25,279
Cumulativea
2017
No.
Rateb
No.
Rateb
0.1
0.1
0.9
5.8
10.7
11.4
11.3
11.2
11.8
10.6
7.0
4.6
1.6
40
14
217
1,293
2,503
2,436
2,413
2,112
2,243
2,251
1,575
935
800
0.1
0.2
1.0
5.7
10.8
11.0
11.5
10.6
10.6
10.2
7.1
4.7
1.6
33
7
203
1,158
2,315
2,453
2,219
1,939
2,092
2,066
1,579
934
805
0.1
0.1
0.9
5.2
9.8
11.1
10.3
9.8
9.9
9.5
7.1
4.6
1.6
10,002
1,534
9,733
56,435
151,407
237,127
255,167
214,405
149,394
91,939
52,304
28,203
24,137
91
336
8,755
4,384
24
—
—
—
—
—
98
348
8,567
4,459
19
—
—
—
—
—
72
337
8,344
4,054
29
—
—
—
—
—
3,578
10,340
515,685
266,602
851
—
—
4,794
819
—
—
4,580
761
—
—
4,322
645
—
—
443,701
40,944
10,498
1,214
806
—
—
—
10,472
1,054
846
—
—
—
10,387
969
817
—
—
—
9,781
968
766
—
—
—
612,861
198,078
91,982
—
—
14.1
2,252
76
14,846
—
—
11.3
2,095
92
14,559
—
—
11.0
2,150
78
14,401
—
—
10.8
1,877
70
13,462
—
—
10.0
93,163
11,886
1,007,969
1,044
4,650
139
5,832
—
—
—
4.3
861
3,896
96
4,853
—
—
—
3.5
795
3,729
81
4,605
—
—
—
3.3
752
3,528
111
4,391
—
—
—
3.1
740
3,478
90
4,308
—
—
—
3.1
94,269
163,271
6,276
263,816
—
—
0.0
8
1
9
—
—
0.0
60
10
70
—
—
0.1
30
9
39
—
—
0.1
33
7
40
—
—
0.1
26
7
33
—
—
0.1
9,097
905
10,002
8.4
4.6
10.9
5.7
11.2
7.9
4,315
2,950
12,510
3,924
447
24,146
7.7
4.4
10.6
5.3
11.2
7.5
3,512
2,480
10,112
3,300
365
19,769
6.2
3.7
8.4
4.4
9.3
6.1
3,314
2,433
9,777
3,417
262
19,203
5.9
3.6
8.1
4.5
6.8
5.9
3,164
2,428
9,557
3,405
278
18,832
5.6
3.6
7.8
4.4
7.3
5.8
2,977
2,217
9,406
3,004
199
17,803
5.3
3.3
7.6
3.9
5.3
5.4
355,402
134,163
508,306
247,478
36,438
1,281,787
No.
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
From the beginning of the epidemic through 2017.
b
Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission
category because of the lack of denominator data.
c The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).
d
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e
Hispanics/Latinos can be of any race.
f Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
h
Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
i Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
j Data are based on residence at time of stage 3 (AIDS) classification.
k Cumulative total includes persons whose race/ethnicity is unknown.
HIV Surveillance Report
20
Vol. 29
Table 3a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States
American
Indian/
Alaska Native
No.
Rateb
0
0
3
24
54
36
26
21
16
19
5
6
2
Black/African
American
Asian
No.
Rateb
No.
No.
Rateb
0.0
0.0
1.7
12.8
27.4
21.5
17.0
15.0
11.0
12.3
3.2
4.5
0.7
3
0
28
167
179
128
131
91
94
50
33
22
16
0.1
0.0
2.6
12.9
11.3
8.0
8.7
6.3
6.9
4.2
3.1
2.3
0.7
60
0.8
13
1.2
1,047 35.3
3,197 99.5
3,471 102.3
2,278 79.9
1,651 60.6
1,164 46.9
1,078 41.4
1,016 38.4
812 31.2
502 22.6
401
8.7
19
7
354
1,513
1,996
1,614
1,214
829
752
541
311
162
149
125
16
19
—
—
—
747
13
18
—
—
—
9,806
431
263
—
—
—
7
0
167
—
—
17.4
40
1
819
—
—
11.1
1,716
19
12,235
Female adult or adolescent
Injection drug use
Heterosexual contactd
Othere
Subtotal
14
31
0
45
—
—
—
4.5
6
113
1
120
—
—
—
1.4
Child (<13 yrs at diagnosis)
Perinatal
Otherf
Subtotal
0
0
0
—
—
0.0
1
2
3
Region of residenceg
Northeast
Midwest
South
West
2
22
60
128
1.6
5.3
7.5
12.0
Total
212
8.8
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Transmission categoryc
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact
and injection drug use
Heterosexual contactd
Othere
Subtotal
Rateb
Hispanic/
Latinoa
Native
Hawaiian/
Other Pacific
Islander
No.
Rateb
0.1
0.3
7.2
31.3
41.6
35.6
27.5
20.4
20.4
16.9
11.7
7.9
3.5
1
0
1
8
14
12
6
7
3
3
1
0
1
7,208
322
275
—
—
—
—
—
77.6
513
7
8,325
356
4,007
32
4,395
—
—
—
24.9
—
—
0.1
47
13
60
177
111
224
430
4.6
4.9
5.2
5.4
942
5.1
White
Multiple races
No.
Rateb
0.9
0.0
2.5
18.2
27.0
23.9
13.2
18.1
8.2
8.6
3.0
0.0
1.9
10
3
234
1,272
1,786
1,424
1,197
820
959
990
691
378
284
37
1
2
—
—
—
6,982
527
625
—
—
36.4
4
0
44
—
—
18.7
135
978
4
1,117
—
—
—
5.0
1
11
0
12
—
—
0.8
10
9
19
—
—
0.1
2,455
2,419
10,569
1,247
38.4
34.0
44.8
35.3
1,800
609
4,123
2,929
16,690
41.1
9,461
Total
No.
Rateb
No.
Rateb
0.0
0.1
2.1
10.7
13.9
11.5
10.0
7.3
7.5
7.1
4.5
2.6
0.7
6
2
44
173
191
122
90
63
62
58
33
16
11
0.3
0.6
6.1
27.2
36.3
30.1
25.5
21.9
23.3
24.4
14.4
8.4
2.9
99
25
1,711
6,354
7,691
5,614
4,315
2,995
2,964
2,677
1,886
1,086
864
0.2
0.3
8.1
28.7
32.9
25.6
20.3
15.2
14.1
12.5
8.6
5.4
1.7
—
—
—
608
24
39
—
—
—
25,513
1,335
1,241
—
—
—
420
—
9
—
8,564 10.2
45
0
716
—
—
32.5
—
—
—
5.1
471
998
4
1,474
—
—
—
1.7
25
121
3
149
—
—
—
6.4
1,009
6,259
44
7,312
—
—
—
5.2
1
0
1
—
—
0.9
9
1
10
—
—
0.0
5
1
6
—
—
0.3
73
26
99
—
—
0.2
21.9
11.3
18.6
12.6
7
0
14
36
32.3
0.0
15.6
8.3
1,377
1,734
4,596
2,341
3.7
3.4
6.5
6.0
193
137
382
159
20.4
10.4
16.6
6.7
6,011 10.6
5,032 7.4
19,968 16.1
7,270 9.4
16.1
57
9.9
10,048
5.1
871
12.6
38,281 11.8
2,745
—
36
—
30,870 23.1
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a
Hispanics/Latinos can be of any race.
b
Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
c
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
d
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e
Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
f
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g
Data are based on residence at time of diagnosis of HIV infection.
HIV Surveillance Report
21
Vol. 29
Table 3b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas
Hispanic/
Latinoa
Native
Hawaiian/
Other Pacific
Islander
White
Multiple races
Total
No.
No.
No.
No.
No.
No.
3
0
28
167
179
130
132
91
94
50
33
22
16
60
13
1,047
3,197
3,471
2,280
1,651
1,165
1,079
1,016
812
502
401
19
7
365
1,575
2,060
1,674
1,262
865
793
592
342
184
170
1
0
1
8
14
12
6
7
3
4
2
0
1
10
3
235
1,272
1,786
1,424
1,197
820
959
990
691
378
284
6
2
44
173
191
122
91
63
62
58
33
16
11
99
25
1,723
6,416
7,755
5,678
4,365
3,032
3,006
2,729
1,918
1,108
885
125
16
19
750
13
18
9,807
431
263
7,436
360
286
39
1
2
6,982
527
625
609
25
39
25,748
1,373
1,252
7
0
167
40
1
822
1,717
19
12,237
597
7
8,686
4
0
46
420
9
8,564
45
0
717
2,829
37
31,239
Female adult or adolescent
Injection drug use
Heterosexual contactc
Otherd
Subtotal
14
31
0
45
6
113
1
120
356
4,008
32
4,397
141
1,058
4
1,203
1
11
0
12
472
999
4
1,475
25
121
3
149
1,016
6,341
44
7,401
Child (<13 yrs at diagnosis)
Perinatal
Othere
Subtotal
0
0
0
1
2
3
47
13
60
10
9
19
1
0
1
9
1
10
5
1
6
73
26
99
Region of residencef
Northeast
Midwest
South
West
U.S. dependent areas
2
22
60
128
0
177
111
224
430
3
2,455
2,419
10,569
1,247
4
1,800
609
4,123
2,929
447
7
0
14
36
2
1,377
1,734
4,596
2,341
1
193
137
382
159
1
6,011
5,032
19,968
7,270
458
Total
212
945
16,694
9,908
59
10,049
872
38,739
American
Indian/
Alaska Native
Asian
Black/African
American
No.
No.
0
0
3
24
54
36
26
21
16
19
5
6
2
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Transmission categoryb
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact
and injection drug use
Heterosexual contactc
Otherd
Subtotal
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12 should be interpreted with caution.
a Hispanics/Latinos can be of any race.
b Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
c Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
d Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
e Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
f Data are based on residence at time of diagnosis of HIV infection.
HIV Surveillance Report
22
Vol. 29
Table 4a. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States
American
Indian/
Alaska Native
No.
Ratec
2
0
0
3
12
7
10
9
11
12
1
3
2
Asiana
Black/African
American
No.
Ratec
No.
Ratec
0.4
0.0
0.0
1.6
6.1
4.2
6.5
6.4
7.5
7.8
0.6
2.2
0.7
0
0
2
25
48
51
46
40
47
33
23
9
11
0.0
0.0
0.2
1.9
3.0
3.2
3.0
2.8
3.5
2.8
2.1
0.9
0.5
23
3
125
690
1,231
1,140
993
877
901
831
709
460
358
0.3
0.3
4.2
21.5
36.3
40.0
36.4
35.3
34.6
31.4
27.2
20.7
7.8
30
8
9
—
—
—
238
6
9
—
—
—
3,829
417
207
4
0
51
—
—
5.3
24
0
278
—
—
3.8
Female adult or adolescent
Injection drug use
Heterosexual contacte
Otherf
Subtotal
6
13
0
19
—
—
—
1.9
2
54
1
57
Child (<13 yrs at diagnosis)
Perinatal
Otherg
Subtotal
2
0
2
—
—
0.4
Region of residenceh
Northeast
Midwest
South
West
0
6
20
46
Total
72
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact
and injection drug use
Heterosexual contacte
Otherf
Subtotal
Hispanic/
Latinob
Native
Hawaiian/
Other Pacific
Islander
Ratec
No.
Ratec
6
4
49
229
557
671
553
465
455
384
234
149
107
0.0
0.2
1.0
4.7
11.6
14.8
12.5
11.5
12.3
12.0
8.8
7.3
2.5
1
0
0
2
4
7
1
4
5
1
1
0
1
0.9
0.0
0.0
4.5
7.7
13.9
2.2
10.3
13.7
2.9
3.0
0.0
1.9
—
—
—
2,498
234
173
—
—
—
16
0
1
1,201
32
5,685
—
—
36.1
317
15
3,238
—
—
14.2
—
—
—
0.7
325
2,253
55
2,633
—
—
—
14.9
105
495
19
619
0
0
0
—
—
0.0
19
4
23
—
—
0.3
0.0
1.5
2.5
4.3
66
33
91
145
1.7
1.5
2.1
1.8
1,299
1,109
5,424
509
3.0
335
1.8
8,341
White
Multiple races
Ratec
0
0
18
163
368
472
515
453
566
688
530
272
276
—
—
—
2
0
19
—
—
—
2.8
3
3
6
20.3
15.6
23.0
14.4
20.5
Total
No.
Ratec
No.
0.0
0.0
0.2
1.4
2.9
3.8
4.3
4.0
4.4
4.9
3.5
1.9
0.7
1
0
8
35
87
82
80
66
83
77
61
31
34
0.0
0.0
1.1
5.5
16.5
20.2
22.7
22.9
31.2
32.3
26.6
16.3
8.9
33 0.1
7 0.1
202 1.0
1,147 5.2
2,307 9.9
2,430 11.1
2,198 10.4
1,914 9.7
2,068 9.9
2,026 9.5
1,559 7.1
924 4.6
789 1.6
2,757
239
317
—
—
—
343
37
45
—
—
—
—
—
8.1
244
13
3,570
—
—
4.2
45
9
480
—
—
21.8
0
7
0
7
—
—
—
3.0
254
490
7
751
—
—
—
0.9
43
115
6
164
—
—
—
7.0
735
3,428
87
4,250
—
—
—
3.0
—
—
0.0
1
0
1
—
—
0.9
0
0
0
—
—
0.0
1
0
1
—
—
0.0
26
7
33
—
—
0.1
835
247
1,594
1,187
10.1
4.6
7.2
5.1
2
1
9
15
9.2
3.0
10.0
3.5
608
735
1,986
992
1.6
1.4
2.8
2.6
167
86
282
110
17.6
6.5
12.3
4.6
2,977
2,217
9,406
3,004
5.3
3.3
7.6
3.9
3,863
6.6
27
4.7
4,321
2.2
645
9.3
17,604
5.4
No.
No.
9,712
941
761
Ratec
—
—
—
1,837
—
70
—
13,321 10.0
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b
Hispanics/Latinos can be of any race.
c
Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
d
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f
Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
g
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
h
Data are based on residence at time of stage 3 (AIDS) classification.
HIV Surveillance Report
23
Vol. 29
Table 4b. Stage 3 (AIDS), by race/ethnicity and selected characteristics, 2017—United States and 6 dependent areas
Hispanic/
Latinob
Native
Hawaiian/
Other Pacific
Islander
White
Multiple races
Total
No.
No.
No.
No.
No.
0
0
18
163
368
472
515
453
567
688
530
272
276
1
0
8
35
87
82
80
66
83
77
61
31
34
33
7
203
1,158
2,315
2,453
2,219
1,939
2,092
2,066
1,579
934
805
18
0
1
2,757
239
317
343
37
45
9,781
968
766
357
15
3,375
2
0
21
244
13
3,570
45
9
480
1,877
70
13,462
325
2,256
55
2,636
109
542
22
673
0
7
0
7
254
491
7
752
43
115
6
164
740
3,478
90
4,308
0
0
0
19
4
23
3
3
6
1
0
1
0
0
0
1
0
1
26
7
33
0
6
20
46
0
66
33
91
145
2
1,299
1,109
5,424
509
3
835
247
1,594
1,187
191
2
1
9
15
2
608
735
1,986
992
1
167
86
282
110
0
2,977
2,217
9,406
3,004
199
72
337
8,344
4,054
29
4,322
645
17,803
American
Indian/
Alaska Native
Asiana
Black/African
American
No.
No.
No.
2
0
0
3
12
7
10
9
11
12
1
3
2
0
0
2
25
48
53
46
40
47
33
23
9
11
23
3
125
690
1,231
1,140
993
878
903
831
709
460
358
6
4
50
240
565
692
574
489
476
423
253
159
123
1
0
0
2
4
7
1
4
5
2
2
0
1
30
8
9
240
6
9
3,829
417
207
2,564
261
178
4
0
51
24
0
280
1,201
32
5,685
Female adult or adolescent
Injection drug use
Heterosexual contactd
Othere
Subtotal
6
13
0
19
2
54
1
57
Child (<13 yrs at diagnosis)
Perinatal
Otherf
Subtotal
2
0
2
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
Total
Age at diagnosis (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Transmission categoryc
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact
and injection drug use
Heterosexual contactd
Othere
Subtotal
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12 should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g Data are based on residence at time of stage 3 (AIDS) classification.
HIV Surveillance Report
24
Vol. 29
Table 5a. Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—
United States
No.
Male adult or adolescent
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/Other Pacific Islander
White
Multiple races
Region of residencec
Northeast
Midwest
South
West
Subtotal
Female adult or adolescent
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/Other Pacific Islander
White
Multiple races
Region of residencec
Northeast
Midwest
South
West
Subtotal
Total
2012
Ratea
No.
2013
Ratea
No.
2014
Ratea
No.
2015
Ratea
No.
2016
Ratea
No.
2017
Ratea
27
1,567
6,315
5,419
4,358
3,185
3,446
3,294
2,387
1,362
743
608
0.6
14.3
54.7
50.1
41.6
32.8
33.0
30.7
21.5
13.5
8.7
3.2
21
1,383
6,252
5,671
4,204
3,062
3,061
3,019
2,185
1,436
771
642
0.5
12.7
53.5
51.8
39.4
31.3
29.5
28.7
19.7
14.0
8.9
3.3
17
1,413
6,513
6,200
4,438
3,251
2,913
2,821
2,202
1,347
704
628
0.4
13.1
55.5
55.6
41.1
32.7
28.5
27.3
19.9
12.9
7.9
3.1
11
1,496
6,446
6,615
4,468
3,309
2,605
2,559
2,256
1,338
695
626
0.3
13.9
55.4
58.0
41.1
32.6
26.0
24.8
20.6
12.6
7.6
3.0
9
1,445
6,130
6,879
4,612
3,255
2,480
2,313
2,144
1,318
731
615
0.2
13.4
53.3
59.0
41.9
31.3
25.3
22.3
20.0
12.3
7.8
2.8
11
1,467
5,581
6,705
4,621
3,363
2,245
2,204
2,011
1,320
747
595
0.3
13.6
49.2
56.3
41.7
31.7
23.0
21.2
19.1
12.3
7.8
2.6
132
656
12,813
7,974
45
9,688
1,403
14.6
10.5
86.5
39.5
21.4
11.6
76.4
115
646
12,488
7,784
37
9,321
1,316
12.5
10.0
83.1
37.6
17.1
11.2
69.1
145
784
12,814
8,287
35
9,236
1,146
15.6
11.7
84.2
39.1
15.8
11.0
58.0
138
804
12,932
8,477
66
8,961
1,046
14.7
11.6
83.9
39.0
29.2
10.7
51.1
187
814
12,683
8,643
33
8,641
930
19.7
11.4
81.4
38.8
14.3
10.3
43.8
167
819
12,235
8,325
44
8,564
716
17.4
11.1
77.6
36.4
18.7
10.2
32.5
5,690
4,458
15,715
6,848
32,711
25.0
16.3
33.3
22.8
25.7
5,425
4,325
15,554
6,403
31,707
23.7
15.7
32.5
21.0
24.6
5,362
4,228
15,989
6,868
32,447
23.3
15.3
33.0
22.3
25.0
5,033
4,261
16,222
6,908
32,424
21.8
15.3
33.1
22.1
24.7
4,773
4,188
16,074
6,896
31,931
20.6
15.0
32.4
21.8
24.1
4,647
4,072
15,788
6,363
30,870
20.0
14.5
31.5
19.9
23.1
23
352
859
1,040
1,100
976
1,002
996
800
562
306
212
0.6
3.4
7.8
9.8
10.5
10.0
9.5
9.1
7.0
5.2
3.3
0.9
22
304
802
982
998
902
864
904
783
574
295
218
0.5
2.9
7.2
9.2
9.4
9.2
8.2
8.4
6.8
5.3
3.1
0.9
15
314
857
987
1,013
990
880
789
697
586
269
203
0.4
3.1
7.7
9.1
9.5
9.9
8.5
7.5
6.1
5.3
2.8
0.8
14
244
830
981
989
954
812
766
744
536
304
226
0.3
2.4
7.5
8.9
9.2
9.4
8.0
7.3
6.6
4.8
3.1
0.8
16
255
738
1,051
1,050
969
784
785
735
568
347
230
0.4
2.5
6.8
9.3
9.7
9.3
7.9
7.4
6.6
5.0
3.4
0.8
14
244
773
986
993
952
750
760
666
566
339
269
0.3
2.4
7.2
8.6
9.1
9.0
7.6
7.2
6.1
5.0
3.3
1.0
40
127
5,216
1,206
6
1,321
312
4.2
1.8
31.2
6.1
2.9
1.5
15.7
32
130
4,718
1,192
10
1,276
290
3.3
1.8
27.9
5.9
4.7
1.5
14.1
34
129
4,608
1,244
8
1,316
261
3.5
1.7
27.0
6.0
3.7
1.5
12.3
49
127
4,433
1,153
8
1,423
207
5.0
1.6
25.7
5.4
3.6
1.6
9.4
43
148
4,505
1,170
8
1,459
195
4.3
1.8
25.8
5.3
3.5
1.7
8.6
45
120
4,395
1,117
12
1,474
149
4.5
1.4
24.9
5.0
5.1
1.7
6.4
1,783
978
4,544
923
8,228
7.3
3.4
9.1
3.0
6.2
1,514
956
4,337
841
7,648
6.2
3.3
8.6
2.7
5.7
1,559
857
4,227
957
7,600
6.3
3.0
8.3
3.1
5.6
1,423
956
4,131
890
7,400
5.7
3.3
8.0
2.8
5.4
1,419
954
4,147
1,008
7,528
5.7
3.3
7.9
3.1
5.4
1,354
943
4,122
893
7,312
5.4
3.2
7.8
2.7
5.2
40,939
15.7
39,355
14.9
40,047
15.1
39,824
14.8
39,459
14.6
38,182
14.0
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers
less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
Rates are per 100,000 population.
b
Hispanics/Latinos can be of any race.
c Data are based on residence at time of diagnosis of HIV infection.
HIV Surveillance Report
25
Vol. 29
Table 5b. Diagnoses of HIV infection among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—
United States and 6 dependent areas
No.
Male adult or adolescent
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/Other Pacific Islander
White
Multiple races
Region of residencec
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Female adult or adolescent
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
Race/ethnicity
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/Other Pacific Islander
White
Multiple races
Region of residencec
Northeast
Midwest
South
West
U.S. dependent areas
Subtotal
Total
2012
Ratea
No.
2013
Ratea
No.
2014
Ratea
No.
2015
Ratea
No.
2016
Ratea
No.
2017
Ratea
27
1,583
6,400
5,506
4,436
3,233
3,518
3,363
2,431
1,388
756
633
0.6
14.2
54.7
50.3
41.8
32.9
33.2
31.0
21.7
13.6
8.7
3.3
21
1,399
6,329
5,743
4,280
3,106
3,112
3,076
2,234
1,461
798
664
0.5
12.7
53.5
51.9
39.6
31.4
29.7
28.9
20.0
14.1
9.1
3.3
17
1,432
6,617
6,288
4,483
3,302
2,968
2,864
2,236
1,379
728
647
0.4
13.1
55.7
55.8
41.0
32.9
28.7
27.4
20.0
13.1
8.1
3.1
11
1,501
6,517
6,697
4,521
3,365
2,651
2,608
2,297
1,360
710
647
0.3
13.7
55.3
58.1
41.1
32.7
26.2
25.0
20.8
12.7
7.7
3.0
9
1,454
6,198
6,943
4,668
3,309
2,521
2,355
2,182
1,354
750
636
0.2
13.3
53.3
58.9
42.0
31.5
25.4
22.4
20.1
12.5
8.0
2.9
11
1,476
5,638
6,757
4,678
3,402
2,276
2,232
2,053
1,342
763
611
0.3
13.5
49.1
56.2
41.8
31.7
23.1
21.3
19.3
12.4
7.9
2.7
132
657
12,815
8,528
48
9,689
1,405
—
—
—
—
—
—
—
115
646
12,497
8,286
38
9,325
1,316
—
—
—
—
—
—
—
145
785
12,825
8,781
36
9,242
1,147
—
—
—
—
—
—
—
138
809
12,937
8,923
69
8,963
1,046
—
—
—
—
—
—
—
187
815
12,689
9,075
39
8,644
930
—
—
—
—
—
—
—
167
822
12,237
8,686
46
8,564
717
—
—
—
—
—
—
—
5,690
4,458
15,715
6,848
563
33,274
25.0
16.3
33.3
22.8
35.2
25.8
5,425
4,325
15,554
6,403
516
32,223
23.7
15.7
32.5
21.0
32.4
24.7
5,362
4,228
15,989
6,868
514
32,961
23.3
15.3
33.0
22.3
32.6
25.1
5,033
4,261
16,222
6,908
461
32,885
21.8
15.3
33.1
22.1
29.6
24.8
4,773
4,188
16,074
6,896
448
32,379
20.6
15.0
32.4
21.8
29.2
24.2
4,647
4,072
15,788
6,363
369
31,239
20.0
14.5
31.5
19.9
24.4
23.1
24
357
877
1,054
1,123
999
1,025
1,026
824
575
316
227
0.6
3.4
7.8
9.9
10.6
10.1
9.6
9.2
7.1
5.3
3.4
0.9
23
307
815
994
1,012
925
879
931
807
592
304
224
0.6
2.9
7.2
9.2
9.4
9.3
8.3
8.6
6.9
5.4
3.2
0.9
15
322
869
994
1,030
1,014
904
807
710
599
273
210
0.4
3.1
7.7
9.1
9.5
10.0
8.6
7.6
6.1
5.4
2.8
0.8
14
247
841
992
996
965
827
781
759
547
305
235
0.3
2.4
7.5
8.9
9.1
9.4
8.0
7.3
6.6
4.8
3.0
0.9
16
258
744
1,058
1,059
987
798
800
744
583
353
233
0.4
2.5
6.8
9.3
9.7
9.4
7.9
7.5
6.6
5.1
3.4
0.8
14
247
778
998
1,000
963
756
774
676
576
345
274
0.3
2.4
7.1
8.6
9.1
9.0
7.6
7.2
6.1
5.0
3.3
1.0
40
127
5,218
1,403
6
1,321
312
—
—
—
—
—
—
—
32
130
4,726
1,348
10
1,277
290
—
—
—
—
—
—
—
34
129
4,613
1,384
9
1,317
261
—
—
—
—
—
—
—
49
127
4,437
1,257
8
1,423
208
—
—
—
—
—
—
—
43
148
4,505
1,275
8
1,459
195
—
—
—
—
—
—
—
45
120
4,397
1,203
12
1,475
149
—
—
—
—
—
—
—
1,783
978
4,544
923
199
8,427
7.3
3.4
9.1
3.0
11.3
6.2
1,514
956
4,337
841
165
7,813
6.2
3.3
8.6
2.7
9.4
5.7
1,559
857
4,227
957
147
7,747
6.3
3.0
8.3
3.1
8.4
5.6
1,423
956
4,131
890
109
7,509
5.7
3.3
8.0
2.8
6.3
5.4
1,419
954
4,147
1,008
105
7,633
5.7
3.3
7.9
3.1
6.1
5.4
1,354
943
4,122
893
89
7,401
5.4
3.2
7.8
2.7
5.3
5.2
41,701
15.8
40,036
15.0
40,708
15.1
40,394
14.9
40,012
14.6
38,640
14.0
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends. Numbers
less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.
b Hispanics/Latinos can be of any race.
c
Data are based on residence at time of diagnosis of HIV infection.
HIV Surveillance Report
26
Vol. 29
Table 6a. Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States
2012
No.
Ratea
Male adult or adolescent
Age at diagnosis (yr)
13–14
12
15–19
272
20–24
1,640
25–29
2,246
30–34
2,445
35–39
2,091
40–44
2,531
45–49
2,769
50–54
2,150
55–59
1,257
60–64
716
65
541
Race/ethnicity
American Indian/Alaska Native
67
Asian
290
Black/African American
7,935
Hispanic/Latinob
4,262
Native Hawaiian/Other Pacific Islander
19
White
5,192
Multiple races
905
Region of residencec
Northeast
3,334
Midwest
2,457
South
9,245
West
3,634
Subtotal
18,670
Female adult or adolescent
Age at diagnosis (yr)
13–14
16
15–19
88
20–24
270
25–29
517
30–34
802
35–39
867
40–44
937
45–49
911
50–54
741
55–59
512
60–64
295
65
187
Race/ethnicity
American Indian/Alaska Native
23
Asian
59
Black/African American
3,990
Hispanic/Latinob
880
Native Hawaiian/Other Pacific Islander
3
White
892
Multiple races
296
Region of residencec
Northeast
1,377
Midwest
659
South
3,550
West
557
Subtotal
6,143
Total
24,813
2013
No.
Ratea
2014
No.
Ratea
2015
No.
Ratea
2016
No.
Ratea
2017
No.
Ratea
0.3
2.5
14.2
20.7
23.3
21.5
24.2
25.8
19.4
12.5
8.4
2.9
12
294
1,695
2,302
2,260
2,062
2,256
2,456
2,058
1,279
741
575
0.3
2.7
14.5
21.0
21.2
21.1
21.8
23.4
18.6
12.4
8.5
2.9
7
132
1,135
1,931
1,854
1,725
1,789
2,011
1,700
1,143
617
549
0.2
1.2
9.7
17.3
17.2
17.4
17.5
19.5
15.4
11.0
7.0
2.7
4
145
1,109
1,998
1,921
1,663
1,635
1,806
1,774
1,122
627
552
0.1
1.3
9.5
17.5
17.7
16.4
16.3
17.5
16.2
10.6
6.9
2.6
7
162
1,061
2,095
1,910
1,708
1,507
1,656
1,687
1,128
671
586
0.2
1.5
9.2
18.0
17.4
16.4
15.4
15.9
15.7
10.6
7.2
2.7
3
158
961
1,935
1,938
1,595
1,356
1,493
1,496
1,145
650
591
0.1
1.5
8.5
16.3
17.5
15.0
13.9
14.4
14.2
10.7
6.8
2.6
7.4
4.6
53.6
21.1
9.0
6.2
49.3
65
292
7,557
4,142
16
5,026
892
7.1
4.5
50.3
20.0
7.4
6.0
46.8
60
261
6,018
3,434
14
4,102
704
6.5
3.9
39.5
16.2
6.3
4.9
35.6
55
280
5,916
3,462
20
4,020
603
5.9
4.0
38.4
15.9
8.8
4.8
29.4
73
286
5,904
3,492
12
3,848
563
7.7
4.0
37.9
15.7
5.2
4.6
26.5
51
278
5,685
3,238
19
3,570
480
5.3
3.8
36.1
14.2
8.1
4.2
21.8
14.6
9.0
19.6
12.1
14.6
3,084
2,381
9,081
3,444
17,990
13.4
8.6
19.0
11.3
14.0
2,483
1,927
7,353
2,830
14,593
10.8
7.0
15.2
9.2
11.2
2,401
1,955
7,082
2,918
14,356
10.4
7.0
14.4
9.3
10.9
2,285
1,896
7,082
2,915
14,178
9.9
6.8
14.3
9.2
10.7
2,125
1,690
6,919
2,587
13,321
9.1
6.0
13.8
8.1
10.0
0.4
0.8
2.4
4.9
7.7
8.9
8.9
8.3
6.4
4.8
3.2
0.8
17
107
306
486
668
755
817
857
709
503
289
186
0.4
1.0
2.7
4.6
6.3
7.7
7.8
8.0
6.2
4.6
3.1
0.7
8
55
218
411
558
674
697
670
597
436
230
187
0.2
0.5
2.0
3.8
5.2
6.8
6.7
6.4
5.2
3.9
2.4
0.7
4
46
216
412
551
640
625
648
564
392
246
202
0.1
0.4
2.0
3.7
5.1
6.3
6.1
6.2
5.0
3.5
2.5
0.8
7
53
217
394
501
660
573
542
527
418
249
196
0.2
0.5
2.0
3.5
4.6
6.3
5.8
5.1
4.7
3.7
2.4
0.7
4
44
186
372
492
603
558
575
530
414
274
198
0.1
0.4
1.7
3.2
4.5
5.7
5.6
5.4
4.9
3.7
2.6
0.7
2.4
0.8
23.9
4.4
1.4
1.0
14.9
19
51
3,604
851
5
840
330
2.0
0.7
21.3
4.2
2.3
1.0
16.0
21
59
2,988
705
3
734
231
2.2
0.8
17.5
3.4
1.4
0.8
10.9
36
53
2,802
669
2
769
215
3.7
0.7
16.2
3.1
0.9
0.9
9.8
24
60
2,632
698
3
726
194
2.4
0.7
15.1
3.2
1.3
0.8
8.6
19
57
2,633
619
7
751
164
1.9
0.7
14.9
2.8
3.0
0.9
7.0
5.6
2.3
7.1
1.8
4.6
9.5
1,229
568
3,424
479
5,700
23,690
5.0
2.0
6.8
1.5
4.2
9.0
1,023
539
2,716
463
4,741
19,334
4.1
1.9
5.3
1.5
3.5
7.3
903
469
2,677
497
4,546
18,902
3.6
1.6
5.2
1.6
3.3
7.0
873
525
2,456
483
4,337
18,515
3.5
1.8
4.7
1.5
3.1
6.8
847
522
2,468
413
4,250
17,571
3.4
1.8
4.7
1.3
3.0
6.4
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population.
b Hispanics/Latinos can be of any race.
c Data are based on residence at time of stage 3 (AIDS) classification.
HIV Surveillance Report
27
Vol. 29
Table 6b. Stage 3 (AIDS) among adults and adolescents, by year of diagnosis, sex, and selected characteristics, 2012–2017—United States and
6 dependent areas
No.
2012
Ratea
Male adult or adolescent
Age at diagnosis (yr)
13–14
12
15–19
273
20–24
1,655
25–29
2,274
30–34
2,471
35–39
2,133
40–44
2,584
45–49
2,826
50–54
2,187
55–59
1,283
60–64
725
65
562
Race/ethnicity
American Indian/Alaska Native
67
Asian
291
Black/African American
7,943
Hispanic/Latinob
4,565
Native Hawaiian/Other Pacific Islander
20
White
5,194
Multiple races
905
Region of residencec
Northeast
3,334
Midwest
2,457
South
9,245
West
3,634
U.S. dependent areas
315
Subtotal
18,985
Female adult or adolescent
Age at diagnosis (yr)
13–14
17
15–19
88
20–24
274
25–29
523
30–34
817
35–39
881
40–44
957
45–49
935
50–54
761
55–59
525
60–64
307
65
197
Race/ethnicity
American Indian/Alaska Native
23
Asian
59
Black/African American
3,992
Hispanic/Latinob
1,017
Native Hawaiian/Other Pacific Islander
3
White
892
Multiple races
296
Region of residencec
Northeast
1,377
Midwest
659
South
3,550
West
557
U.S. dependent areas
139
Subtotal
6,282
Total
25,267
No.
2013
Ratea
No.
2014
Ratea
No.
2015
Ratea
No.
2016
Ratea
No.
2017
Ratea
0.3
2.5
14.2
20.8
23.3
21.7
24.4
26.0
19.5
12.6
8.4
2.9
13
296
1,715
2,326
2,298
2,097
2,296
2,496
2,105
1,310
762
591
0.3
2.7
14.5
21.0
21.3
21.2
21.9
23.5
18.8
12.6
8.7
3.0
7
134
1,150
1,946
1,873
1,761
1,825
2,054
1,733
1,167
636
560
0.2
1.2
9.7
17.3
17.1
17.5
17.7
19.6
15.5
11.1
7.1
2.7
4
145
1,121
2,018
1,939
1,687
1,662
1,835
1,812
1,140
634
562
0.1
1.3
9.5
17.5
17.6
16.4
16.4
17.6
16.4
10.7
6.9
2.6
7
164
1,074
2,106
1,934
1,742
1,533
1,690
1,718
1,148
682
603
0.2
1.5
9.2
17.9
17.4
16.6
15.5
16.1
15.8
10.6
7.2
2.7
3
158
967
1,941
1,956
1,611
1,373
1,505
1,527
1,159
660
602
0.1
1.4
8.4
16.1
17.5
15.0
13.9
14.3
14.4
10.7
6.8
2.6
—
—
—
—
—
—
—
65
292
7,559
4,454
16
5,027
892
—
—
—
—
—
—
—
60
262
6,024
3,678
15
4,103
704
—
—
—
—
—
—
—
55
281
5,922
3,654
22
4,022
603
—
—
—
—
—
—
—
73
287
5,906
3,708
15
3,849
563
—
—
—
—
—
—
—
51
280
5,685
3,375
21
3,570
480
—
—
—
—
—
—
—
14.6
9.0
19.6
12.1
19.7
14.7
3,084
2,381
9,081
3,444
315
18,305
13.4
8.6
19.0
11.3
19.8
14.1
2,483
1,927
7,353
2,830
253
14,846
10.8
7.0
15.2
9.2
16.1
11.3
2,401
1,955
7,082
2,918
203
14,559
10.4
7.0
14.4
9.3
13.0
11.0
2,285
1,896
7,082
2,915
223
14,401
9.9
6.8
14.3
9.2
14.5
10.8
2,125
1,690
6,919
2,587
141
13,462
9.1
6.0
13.8
8.1
9.3
10.0
0.4
0.8
2.4
4.9
7.7
8.9
8.9
8.4
6.5
4.8
3.3
0.8
17
110
307
491
678
771
835
888
729
520
294
192
0.4
1.1
2.7
4.6
6.3
7.7
7.8
8.2
6.3
4.7
3.1
0.8
8
58
222
416
578
687
718
680
611
450
233
192
0.2
0.6
2.0
3.8
5.3
6.8
6.8
6.4
5.3
4.0
2.4
0.7
4
46
217
414
558
648
633
659
572
397
247
210
0.1
0.4
1.9
3.7
5.1
6.3
6.1
6.2
5.0
3.5
2.5
0.8
7
53
219
397
502
671
579
553
533
427
253
197
0.2
0.5
2.0
3.5
4.6
6.4
5.8
5.2
4.7
3.7
2.5
0.7
4
45
191
374
497
608
566
587
539
420
274
203
0.1
0.4
1.8
3.2
4.5
5.7
5.7
5.5
4.9
3.7
2.6
0.7
—
—
—
—
—
—
—
19
51
3,607
980
5
840
330
—
—
—
—
—
—
—
21
59
2,990
814
3
735
231
—
—
—
—
—
—
—
36
53
2,805
725
2
769
215
—
—
—
—
—
—
—
24
60
2,634
749
4
726
194
—
—
—
—
—
—
—
19
57
2,636
673
7
752
164
—
—
—
—
—
—
—
5.6
2.3
7.1
1.8
7.9
4.6
9.6
1,229
568
3,424
479
132
5,832
24,137
5.0
2.0
6.8
1.5
7.5
4.3
9.0
1,023
539
2,716
463
112
4,853
19,699
4.1
1.9
5.3
1.5
6.4
3.5
7.3
903
469
2,677
497
59
4,605
19,164
3.6
1.6
5.2
1.6
3.4
3.3
7.1
873
525
2,456
483
54
4,391
18,792
3.5
1.8
4.7
1.5
3.2
3.1
6.9
847
522
2,468
413
58
4,308
17,770
3.4
1.8
4.7
1.3
3.4
3.1
6.4
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.
b
Hispanics/Latinos can be of any race.
c
Data are based on residence at time of stage 3 (AIDS) classification.
HIV Surveillance Report
28
Vol. 29
Table 7a.Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
4
21
15
13
8
14
9
6
1
0
1
0
1
18
23
12
6
7
7
6
0
1
2
0
4
30
28
18
6
10
10
7
2
0
1
0
5
32
24
17
14
6
7
5
4
0
0
0
2
27
39
31
12
13
7
5
3
4
1
0
2
19
35
21
15
12
8
10
2
2
0
0
1
1
5
3
2
1
1
1
0
0
0
0
0
0
1
2
1
0
1
1
0
0
0
0
0
1
1
1
0
1
2
2
0
0
0
0
1
3
1
0
3
0
0
0
0
0
0
0
0
4
7
4
2
0
0
1
0
1
0
0
0
2
7
5
1
1
1
0
0
1
1
Region of residencea
Northeast
Midwest
South
West
5
7
29
51
1
6
20
55
4
9
27
76
3
9
34
65
7
15
37
85
2
13
34
76
1
2
1
10
0
1
1
5
0
3
1
4
0
0
2
6
0
2
6
12
0
4
10
5
Total
91
81
116
112
144
125
15
7
8
9
19
19
Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
13
84
127
86
96
69
52
26
9
7
7
0
7
96
109
98
78
88
52
20
12
6
4
0
15
129
144
116
93
74
60
31
10
6
7
1
21
127
169
109
73
82
63
37
14
4
5
0
20
113
169
126
85
88
53
32
20
8
11
0
27
154
153
108
91
74
70
32
21
10
8
0
0
1
3
5
2
6
1
0
0
0
0
0
0
1
1
1
1
2
1
0
0
0
0
0
1
2
3
3
3
6
0
1
0
0
0
0
0
4
3
3
2
3
2
1
0
0
0
0
1
3
1
2
2
0
1
1
0
0
1
0
0
3
3
5
1
0
2
2
0
0
0
Region of residencea
Northeast
Midwest
South
West
104
40
115
316
88
48
140
292
121
55
137
373
110
83
159
354
139
71
154
361
142
85
169
351
6
2
2
7
4
0
1
3
3
6
3
8
2
2
5
9
3
4
1
6
1
1
2
14
Total
574
567
686
705
726
747
17
8
19
19
14
18
HIV Surveillance Report
29
Vol. 29
Table 7a.Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
8
881
3,007
1,891
1,006
689
697
601
400
207
115
68
11
796
3,059
2,066
1,068
664
589
524
375
188
100
65
3
800
3,179
2,332
1,201
692
524
486
340
231
110
82
7
867
3,013
2,520
1,224
750
492
477
370
208
90
85
4
815
2,888
2,623
1,247
748
473
405
365
225
100
62
4
841
2,556
2,584
1,402
813
464
384
358
217
115
68
1
14
53
40
44
32
24
31
23
13
13
3
0
17
76
64
39
19
23
28
22
16
8
4
0
14
56
50
38
24
23
15
21
14
10
4
0
12
61
48
38
31
18
16
10
14
3
5
0
14
60
64
42
30
12
16
13
8
8
4
0
10
39
63
38
37
16
13
23
14
5
5
Region of residencea
Northeast
Midwest
South
West
1,285
1,627
5,884
775
1,251
1,605
5,903
748
1,305
1,624
6,250
800
1,256
1,585
6,403
859
1,187
1,633
6,219
917
1,216
1,544
6,218
828
51
52
141
46
50
51
174
39
48
40
137
43
31
36
149
39
32
58
142
40
35
42
138
49
Total
9,570
9,507
9,980
10,103
9,957
9,806
290
314
269
256
272
263
Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
4
324
1,325
1,327
1,162
746
679
523
284
129
68
43
2
264
1,265
1,372
1,104
762
640
514
300
154
60
49
5
281
1,440
1,479
1,202
867
660
539
293
139
75
54
1
296
1,482
1,571
1,197
921
607
541
352
166
58
57
1
292
1,423
1,778
1,301
923
619
472
357
153
72
53
5
298
1,288
1,680
1,294
909
572
508
342
172
72
67
1
13
73
65
75
50
41
29
15
3
4
1
0
11
57
74
58
39
35
15
16
7
1
2
0
16
45
57
67
44
30
26
9
7
2
2
0
12
64
72
63
38
29
22
10
5
2
3
0
11
58
61
61
40
32
12
15
5
4
2
0
6
52
69
48
38
20
18
10
9
3
2
Region of residencea
Northeast
Midwest
South
West
1,243
503
2,528
2,341
1,256
485
2,572
2,175
1,285
505
2,793
2,451
1,269
486
3,019
2,475
1,202
465
3,206
2,570
1,233
481
3,153
2,340
80
27
113
151
72
24
102
118
50
15
110
129
53
27
109
129
43
25
102
131
34
21
95
126
Total
6,615
6,487
7,034
7,248
7,442
7,208
370
316
305
319
300
275
HIV Surveillance Report
30
Vol. 29
Table 7a.Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
10
4
9
4
1
3
4
3
0
0
0
1
2
9
9
3
3
4
2
0
0
0
0
1
6
3
6
7
3
3
1
0
1
1
0
2
9
12
10
7
3
6
4
3
0
0
0
1
1
7
3
6
4
1
2
0
0
1
0
1
8
10
8
2
5
1
2
0
0
0
0
0
0
1
2
0
0
1
0
0
0
0
0
0
0
2
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
2
2
0
0
0
0
0
0
1
0
0
0
0
0
1
1
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
3
1
7
28
1
2
2
28
0
1
7
24
2
1
18
35
3
2
4
17
3
0
8
26
0
1
0
3
1
0
1
1
0
0
0
1
0
0
1
1
1
0
0
4
0
0
1
1
Total
38
33
32
55
26
37
5
3
1
2
5
2
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2
149
979
1,189
1,115
822
1,052
1,150
837
475
229
206
1
135
973
1,127
1,029
790
943
1,044
770
515
298
231
3
143
992
1,288
1,015
827
818
949
815
461
236
206
0
153
969
1,291
1,034
756
721
770
817
422
249
195
0
165
916
1,257
1,013
710
635
744
747
462
240
201
1
177
981
1,303
952
785
528
646
713
450
251
195
0
10
92
115
118
91
81
80
49
24
7
6
0
11
106
133
104
72
74
48
40
24
12
8
0
9
75
144
114
80
79
62
49
22
10
3
0
16
100
147
116
95
47
49
56
31
11
4
0
16
88
141
113
75
64
51
37
30
12
9
0
12
76
150
106
93
54
52
34
24
16
9
Region of residencea
Northeast
Midwest
South
West
1,284
1,413
3,412
2,095
1,210
1,385
3,346
1,915
1,186
1,323
3,316
1,928
1,046
1,272
3,123
1,936
999
1,231
3,092
1,769
916
1,230
3,134
1,703
91
106
222
255
69
86
251
225
63
107
250
226
73
120
250
229
56
119
241
218
71
107
252
195
Total
8,203
7,856
7,753
7,377
7,091
6,982
674
631
646
671
635
625
HIV Surveillance Report
31
Vol. 29
Table 7a.Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2
78
321
220
146
111
100
76
53
33
10
12
0
70
295
223
141
98
73
81
42
32
16
10
0
69
233
202
126
95
70
64
49
25
5
9
0
47
229
222
114
83
51
47
40
21
14
11
0
43
199
186
111
64
45
43
34
26
16
7
0
37
138
155
92
54
38
35
33
14
8
4
0
4
22
12
19
10
8
11
4
7
4
0
0
6
23
14
14
8
3
6
6
1
0
1
0
5
20
20
6
8
10
5
4
2
0
0
0
3
11
17
17
3
4
4
2
1
1
0
0
3
12
12
12
7
2
5
4
1
1
0
0
0
9
10
3
7
3
3
1
1
0
0
Region of residencea
Northeast
Midwest
South
West
259
194
504
202
282
145
450
206
212
126
419
188
213
116
363
188
180
94
331
170
127
98
269
115
17
17
33
32
14
13
34
21
16
11
28
24
13
9
17
21
12
12
22
14
8
6
19
7
1,160
1,083
945
880
774
608
99
83
79
62
59
39
Total
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
16
1,449
5,746
4,773
3,537
2,476
2,612
2,416
1,609
856
428
336
14
1,275
5,708
4,929
3,462
2,401
2,343
2,226
1,514
900
481
361
11
1,312
6,010
5,475
3,683
2,587
2,159
2,111
1,536
867
433
361
9
1,392
5,860
5,809
3,705
2,603
1,961
1,910
1,625
838
416
353
5
1,339
5,567
6,058
3,833
2,548
1,878
1,725
1,542
889
440
337
9
1,383
5,144
5,921
3,877
2,669
1,693
1,651
1,489
877
458
341
3
42
242
240
265
187
160
154
92
46
29
10
0
44
264
289
218
141
137
100
85
48
22
15
0
45
200
275
228
159
148
110
87
44
22
9
0
44
243
287
236
174
100
93
79
51
18
11
0
44
226
288
235
156
110
85
71
45
25
17
0
28
180
301
206
178
96
90
70
50
25
17
Region of residencea
Northeast
4,182
Midwest
3,785
South
12,478
West
5,807
4,088
3,675
12,432
5,418
4,114
3,643
12,950
5,840
3,899
3,552
13,119
5,911
3,717
3,511
13,043
5,889
3,639
3,451
12,985
5,438
245
208
513
505
211
175
564
412
180
183
528
436
173
196
534
434
146
220
514
424
149
180
517
396
Total
25,614
26,546
26,481
26,159
25,513
1,471
1,361
1,327
1,336
1,304
1,241
26,252
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a Data are based on residence at time of diagnosis of HIV infection.
b
Hispanics/Latinos can be of any race.
HIV Surveillance Report
32
Vol. 29
Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States and 6 dependent areas
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
4
21
15
13
8
14
9
6
1
0
1
0
1
18
23
12
6
7
7
6
0
1
2
0
4
30
28
18
6
10
10
7
2
0
1
0
5
32
24
17
14
6
7
5
4
0
0
0
2
27
39
31
12
13
7
5
3
4
1
0
2
19
35
21
15
12
8
10
2
2
0
0
1
1
5
3
2
1
1
1
0
0
0
0
0
0
1
2
1
0
1
1
0
0
0
0
0
1
1
1
0
1
2
2
0
0
0
0
1
3
1
0
3
0
0
0
0
0
0
0
0
4
7
4
2
0
0
1
0
1
0
0
0
2
7
5
1
1
1
0
0
1
1
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
5
7
29
51
0
1
6
20
55
0
4
9
27
76
0
3
9
34
65
0
7
15
37
85
0
2
13
34
76
0
1
2
1
10
0
0
1
1
5
0
0
3
1
4
0
0
0
2
6
0
0
2
6
12
0
0
4
10
5
0
Total
91
81
116
112
144
125
15
7
8
9
19
19
Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
13
84
127
86
97
69
52
26
9
7
7
0
7
96
109
98
78
88
52
20
12
6
4
0
15
129
144
116
93
74
60
32
10
6
7
1
21
127
171
110
73
82
63
37
14
4
5
0
20
113
169
126
86
88
53
32
20
8
11
0
27
154
153
110
92
74
70
32
21
10
8
0
0
1
3
5
2
6
1
0
0
0
0
0
0
1
1
1
1
2
1
0
0
0
0
0
1
2
3
3
3
6
0
1
0
0
0
0
0
4
3
3
2
3
2
1
0
0
0
0
1
3
1
2
2
0
1
1
0
0
1
0
0
3
3
5
1
0
2
2
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
104
40
115
316
1
88
48
140
292
0
121
55
137
373
1
110
83
159
354
4
139
71
154
361
1
142
85
169
351
3
6
2
2
7
0
4
0
1
3
0
3
6
3
8
0
2
2
5
9
0
3
4
1
6
0
1
1
2
14
0
Total
575
567
687
709
727
750
17
8
19
19
14
18
HIV Surveillance Report
33
Vol. 29
Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
8
881
3,007
1,891
1,006
689
698
601
400
207
115
68
11
796
3,060
2,067
1,068
665
590
524
375
188
100
65
3
800
3,179
2,332
1,202
693
524
487
340
231
111
82
7
867
3,014
2,521
1,224
751
493
478
370
208
90
85
4
815
2,889
2,623
1,248
748
474
405
365
225
100
62
4
841
2,556
2,584
1,403
813
465
384
358
217
115
68
1
14
53
40
44
32
24
31
23
13
13
3
0
17
76
64
39
19
23
28
22
16
8
4
0
14
56
50
38
24
23
15
21
14
10
4
0
12
61
48
38
31
18
16
10
14
3
5
0
14
60
64
42
30
12
16
13
8
8
4
0
10
39
63
38
37
16
13
23
14
5
5
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1,285
1,627
5,884
775
1
1,251
1,605
5,903
748
4
1,305
1,624
6,250
800
4
1,256
1,585
6,403
859
5
1,187
1,633
6,219
917
3
1,216
1,544
6,218
828
1
51
52
141
46
0
50
51
174
39
0
48
40
137
43
0
31
36
149
39
0
32
58
142
40
0
35
42
138
49
0
Total
9,571
9,511
9,984
10,108
9,960
9,807
290
314
269
256
272
263
Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
4
336
1,398
1,392
1,208
768
707
548
298
136
73
48
2
278
1,331
1,429
1,154
784
670
532
315
157
70
53
5
298
1,529
1,546
1,234
901
693
558
306
146
80
59
1
299
1,540
1,638
1,230
956
636
567
367
174
66
64
1
300
1,483
1,830
1,343
958
639
490
379
168
75
55
5
306
1,336
1,723
1,333
930
588
523
364
182
76
70
1
13
76
70
80
55
43
31
19
4
4
1
0
11
59
75
64
40
39
17
20
7
1
2
0
16
47
58
67
46
31
26
9
7
2
3
0
12
68
74
64
42
33
23
11
5
2
5
0
11
58
63
63
43
34
13
15
6
4
2
0
6
52
72
50
40
20
21
10
9
3
2
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1,243
503
2,528
2,341
301
1,256
485
2,572
2,175
289
1,285
505
2,793
2,451
323
1,269
486
3,019
2,475
289
1,202
465
3,206
2,570
279
1,233
481
3,153
2,340
228
80
27
113
151
27
72
24
102
118
20
50
15
110
129
9
53
27
109
129
19
43
25
102
131
10
34
21
95
126
11
Total
6,916
6,776
7,357
7,537
7,721
7,436
397
336
313
338
311
286
HIV Surveillance Report
34
Vol. 29
Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
2
10
5
10
4
1
3
4
3
0
0
0
1
2
9
10
3
3
4
2
0
0
0
0
1
6
3
6
7
4
3
1
0
1
1
0
2
10
13
10
7
3
6
5
3
0
0
0
1
3
7
5
6
4
1
2
0
0
1
0
1
8
10
8
2
5
1
3
1
0
0
0
0
0
1
2
0
0
1
0
0
0
0
0
0
0
2
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
3
2
0
0
0
0
0
0
1
0
0
0
0
0
1
1
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
3
1
7
28
3
1
2
2
28
1
0
1
7
24
1
2
1
18
35
2
3
2
4
17
4
3
0
8
26
2
0
1
0
3
0
1
0
1
1
0
0
0
0
1
0
0
0
1
1
0
1
0
0
4
1
0
0
1
1
0
Total
41
34
33
58
29
39
5
3
1
2
6
2
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2
149
979
1,189
1,115
822
1,053
1,150
837
475
229
206
1
135
973
1,127
1,031
790
943
1,044
770
515
298
231
3
143
993
1,289
1,016
827
820
949
815
462
236
206
0
153
969
1,291
1,034
756
721
770
818
422
249
195
0
165
917
1,257
1,014
710
635
744
747
462
240
201
1
177
981
1,303
952
785
528
646
713
450
251
195
0
10
92
115
118
91
81
80
49
24
7
6
0
11
106
133
104
72
74
48
40
24
12
8
0
9
75
144
114
80
79
62
49
22
10
3
0
16
100
147
116
95
47
49
56
31
11
4
0
16
88
141
113
75
64
51
37
30
12
9
0
12
76
150
106
93
54
52
34
24
16
9
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1,284
1,413
3,412
2,095
1
1,210
1,385
3,346
1,915
3
1,186
1,323
3,316
1,928
6
1,046
1,272
3,123
1,936
1
999
1,231
3,092
1,769
2
916
1,230
3,134
1,703
0
91
106
222
255
0
69
86
251
225
0
63
107
250
226
0
73
120
250
229
0
56
119
241
218
0
71
107
252
195
0
Total
8,204
7,859
7,758
7,378
7,093
6,982
674
631
646
671
635
625
HIV Surveillance Report
35
Vol. 29
Table 7b. Diagnoses of HIV infection attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by
selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2
79
321
220
147
111
100
76
53
33
10
12
0
70
295
223
141
98
73
81
42
32
16
10
0
70
233
202
126
95
70
64
49
25
5
9
0
47
229
222
114
83
51
47
40
21
14
11
0
43
199
186
111
64
45
43
34
26
16
7
0
37
138
155
92
55
38
35
33
14
8
4
0
4
22
12
19
10
8
11
4
7
4
0
0
6
23
14
14
8
3
6
6
1
0
1
0
5
20
20
6
8
10
5
4
2
0
0
0
3
11
17
17
3
4
4
2
1
1
0
0
3
12
12
12
7
2
5
4
1
1
0
0
0
9
10
3
7
3
3
1
1
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
259
194
504
202
2
282
145
450
206
0
212
126
419
188
1
213
116
363
188
0
180
94
331
170
0
127
98
269
115
1
17
17
33
32
0
14
13
34
21
0
16
11
28
24
0
13
9
17
21
0
12
12
22
14
0
8
6
19
7
0
1,162
1,083
946
880
774
609
99
83
79
62
59
39
Total
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
16
1,463
5,819
4,838
3,585
2,498
2,641
2,441
1,623
862
433
341
14
1,289
5,775
4,988
3,515
2,424
2,375
2,244
1,529
904
491
365
11
1,331
6,100
5,544
3,717
2,622
2,195
2,131
1,550
876
438
366
9
1,395
5,920
5,880
3,739
2,640
1,992
1,937
1,641
846
423
360
5
1,347
5,632
6,110
3,879
2,583
1,899
1,743
1,564
904
444
338
9
1,391
5,192
5,964
3,918
2,692
1,709
1,666
1,513
887
462
344
3
42
245
246
269
192
162
156
96
47
29
10
0
44
266
290
224
141
141
102
89
48
22
15
0
45
203
276
229
161
149
110
87
44
22
10
0
44
246
289
238
178
104
94
80
51
18
13
0
44
226
291
237
159
112
87
71
46
25
17
0
28
180
304
208
181
96
92
70
50
25
17
Region of residencea
Northeast
4,182
Midwest
3,785
South
12,478
West
5,807
U.S. dependent areas
309
4,088
3,675
12,432
5,418
296
4,114
3,643
12,950
5,840
336
3,899
3,552
13,119
5,911
300
3,717
3,511
13,043
5,889
289
3,639
3,451
12,985
5,438
235
245
208
513
505
27
211
175
564
412
21
180
183
528
436
9
173
196
534
434
19
146
220
514
424
11
149
180
517
396
11
Total
25,910
26,882
26,781
26,448
25,748
1,497
1,382
1,335
1,355
1,315
1,252
26,561
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a Data are based on residence at time of diagnosis of HIV infection.
b
Hispanics/Latinos can be of any race.
HIV Surveillance Report
36
Vol. 29
Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
2
2
1
0
5
1
0
2
0
0
0
0
2
1
3
0
3
3
1
1
0
1
0
0
1
2
0
0
3
2
3
0
0
0
0
0
0
2
2
1
0
0
1
1
0
0
0
0
3
4
0
1
2
2
0
2
0
0
0
0
0
6
4
0
2
0
2
0
1
0
0
0
1
0
3
1
2
3
0
2
1
1
0
0
1
0
2
0
3
1
2
0
1
0
0
0
0
2
2
1
2
1
0
1
1
0
0
0
1
2
2
1
2
2
0
1
1
0
0
0
1
2
1
2
1
1
4
0
0
0
0
1
1
1
2
2
1
2
3
1
0
1
Region of residencea
Northeast
Midwest
South
West
1
2
1
10
0
1
3
11
0
1
4
6
0
0
2
5
0
0
3
12
0
1
3
12
0
4
1
8
1
3
2
6
0
2
3
5
0
0
3
9
0
1
0
11
0
0
4
10
Total
13
15
11
7
15
16
13
11
10
12
12
14
Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
0
1
2
6
5
1
1
1
0
0
0
0
2
2
3
3
5
3
1
1
1
0
0
1
0
2
3
4
3
2
2
1
1
2
0
0
0
1
8
1
3
2
2
0
1
1
0
0
0
1
1
3
1
3
3
1
0
1
0
0
0
2
1
3
2
3
2
1
0
0
0
0
1
2
0
2
0
1
0
0
1
0
0
0
0
0
1
1
0
1
1
2
0
0
0
0
0
0
0
2
1
0
0
2
1
0
0
0
0
1
1
1
1
0
0
0
1
0
0
0
1
2
1
1
1
1
0
0
0
0
0
0
0
2
1
1
0
1
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
4
0
4
10
7
2
6
6
6
2
8
4
7
0
3
9
4
1
3
7
5
0
4
5
2
1
1
3
1
2
2
3
2
1
1
2
1
1
2
3
1
0
2
3
1
0
1
3
Total
18
22
20
19
15
13
7
7
7
6
7
6
HIV Surveillance Report
37
Vol. 29
Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
9
32
43
56
52
66
92
115
88
50
37
0
7
29
40
42
52
51
94
95
83
45
29
0
6
31
37
42
38
48
67
67
78
43
40
1
5
33
34
40
39
50
47
68
63
34
32
0
5
24
39
38
52
41
48
61
45
37
30
0
6
24
44
52
48
37
51
49
56
34
31
2
14
45
41
56
61
62
72
83
52
28
19
1
9
27
30
40
37
45
57
56
60
23
11
0
10
28
38
37
37
38
52
49
46
21
17
1
6
27
42
34
34
34
44
41
35
27
14
0
7
20
40
38
30
25
31
48
39
27
12
0
9
26
38
40
44
41
43
39
33
27
17
Region of residencea
Northeast
Midwest
South
West
202
67
324
46
184
61
280
41
157
47
262
32
128
48
227
42
123
53
195
47
153
56
192
30
150
70
275
40
91
62
215
28
100
50
187
38
93
47
163
36
71
48
165
33
94
60
170
32
Total
639
566
497
445
418
431
535
396
374
339
317
356
Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
3
12
34
55
56
57
52
47
25
23
14
0
4
20
34
49
43
45
58
31
37
9
11
0
3
17
33
41
37
51
47
34
27
13
8
0
1
26
37
46
42
39
37
36
30
9
13
0
3
20
34
51
39
26
38
40
24
12
15
0
4
19
37
55
44
42
37
38
24
13
10
0
4
19
20
30
25
18
25
16
13
7
3
0
6
14
23
22
18
21
18
18
9
5
5
0
7
20
15
23
21
28
16
17
15
7
7
0
5
25
10
17
16
17
15
13
9
3
4
0
5
10
28
23
12
18
16
15
12
5
6
0
4
16
16
24
18
17
14
13
7
3
4
Region of residencea
Northeast
Midwest
South
West
158
20
115
86
134
18
97
94
103
11
90
105
107
19
98
90
104
12
89
95
115
13
99
95
90
9
42
37
69
12
42
36
68
10
49
47
47
7
45
36
49
11
45
46
47
8
39
40
Total
378
342
308
314
300
322
179
159
175
134
150
135
HIV Surveillance Report
38
Vol. 29
Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1
1
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
0
0
0
0
0
0
0
1
1
0
0
0
1
0
1
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
2
1
0
0
0
Total
0
1
1
3
0
1
0
0
1
1
2
1
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
7
32
37
46
26
45
54
57
21
15
7
0
2
26
36
46
36
43
58
46
38
18
13
0
2
26
40
54
48
60
52
52
28
21
12
0
1
46
81
77
53
54
64
55
32
20
10
0
3
30
76
66
69
46
48
50
28
19
16
0
3
44
87
94
74
49
61
40
39
22
15
0
10
27
52
50
43
47
44
37
30
11
3
0
9
36
47
58
34
46
47
41
23
13
5
0
11
39
55
62
44
37
39
26
19
5
6
1
8
49
90
84
53
61
46
41
24
12
6
0
5
40
90
64
62
45
41
39
21
12
9
0
7
43
89
90
75
51
36
38
29
10
4
Region of residencea
Northeast
Midwest
South
West
67
46
134
100
64
49
145
104
65
51
156
124
74
136
156
125
84
82
163
120
101
94
216
116
75
44
165
71
69
61
158
70
57
40
168
77
74
132
191
76
82
81
180
84
88
90
209
85
Total
347
362
396
492
450
527
354
358
343
473
427
471
HIV Surveillance Report
39
Vol. 29
Table 8a. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
3
3
4
4
5
5
11
6
4
2
0
0
1
4
5
4
10
6
8
3
3
2
0
0
1
7
7
4
4
4
4
3
2
2
0
1
3
6
5
2
2
3
4
3
1
4
0
1
2
4
0
4
4
3
6
3
1
0
0
0
0
2
4
4
4
4
1
4
2
1
0
4
4
7
6
7
8
9
5
5
2
2
0
1
3
5
4
5
8
5
6
4
3
1
0
2
2
2
6
7
6
5
7
2
2
2
0
2
2
3
9
2
2
4
3
8
1
1
0
1
2
3
2
7
4
7
3
4
1
1
0
1
4
2
3
4
4
2
4
1
0
0
Region of residencea
Northeast
Midwest
South
West
19
4
11
11
11
2
23
10
10
8
9
11
8
7
13
5
7
3
11
7
7
3
7
8
21
7
26
5
14
8
18
8
13
2
20
8
6
6
15
8
8
4
15
9
8
3
9
6
Total
45
45
37
33
28
24
58
47
43
36
36
25
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
20
81
120
163
143
181
205
231
143
92
59
0
13
79
118
149
138
157
223
181
164
76
56
0
12
77
121
147
131
168
172
162
137
81
63
1
8
109
160
177
137
148
152
167
130
65
59
0
12
79
158
156
168
120
140
159
103
69
62
0
13
88
178
209
172
134
155
132
123
72
57
2
31
97
122
146
138
138
153
140
102
49
27
1
25
82
105
127
95
122
131
124
98
46
22
0
30
89
113
131
112
112
113
100
84
37
31
2
20
104
148
146
107
116
111
98
78
45
26
0
18
74
165
129
113
93
96
111
77
45
28
0
22
90
149
160
144
114
97
96
71
40
26
Region of residencea
Northeast
Midwest
South
West
451
139
588
262
399
133
555
267
342
120
530
281
325
210
500
278
323
151
465
287
381
168
521
265
338
134
509
165
244
147
437
149
240
106
428
178
220
193
420
169
212
144
406
188
239
161
433
175
1,440
1,353
1,272
1,313
1,226
1,335
1,146
978
952
1,001
950
1,009
Total
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanics/Latinos can be of any race.
HIV Surveillance Report
40
Vol. 29
Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and
6 dependent areas
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
2
2
1
0
5
1
0
2
0
0
0
0
2
1
3
0
3
3
1
1
0
1
0
0
1
2
0
0
3
2
3
0
0
0
0
0
0
2
2
1
0
0
1
1
0
0
0
0
3
4
0
1
2
2
0
2
0
0
0
0
0
6
4
0
2
0
2
0
1
0
0
0
1
0
3
1
2
3
0
2
1
1
0
0
1
0
2
0
3
1
2
0
1
0
0
0
0
2
2
1
2
1
0
1
1
0
0
0
1
2
2
1
2
2
0
1
1
0
0
0
1
2
1
2
1
1
4
0
0
0
0
1
1
1
2
2
1
2
3
1
0
1
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1
2
1
10
0
0
1
3
11
0
0
1
4
6
0
0
0
2
5
0
0
0
3
12
0
0
1
3
12
0
0
4
1
8
0
1
3
2
6
0
0
2
3
5
0
0
0
3
9
0
0
1
0
11
0
0
0
4
10
0
Total
13
15
11
7
15
16
13
11
10
12
12
14
Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
0
1
2
6
5
1
1
1
0
0
0
0
2
2
3
3
5
3
1
1
1
0
0
1
0
2
3
4
3
2
2
1
1
2
0
0
0
1
8
2
3
2
2
0
1
1
0
0
0
1
1
3
1
3
3
1
0
1
0
0
0
2
1
3
2
3
2
1
0
0
0
0
1
2
0
2
0
1
0
0
1
0
0
0
0
0
1
1
0
1
1
2
0
0
0
0
0
0
0
2
1
0
0
2
1
0
0
0
0
1
1
1
1
0
0
0
1
0
0
0
1
2
1
1
1
1
0
0
0
0
0
0
0
2
1
1
0
1
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
4
0
4
10
0
7
2
6
6
0
6
2
8
4
0
7
0
3
9
1
4
1
3
7
0
5
0
4
5
0
2
1
1
3
0
1
2
2
3
0
2
1
1
2
0
1
1
2
3
0
1
0
2
3
0
1
0
1
3
0
Total
18
22
20
20
15
13
7
7
7
6
7
6
HIV Surveillance Report
41
Vol. 29
Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and
6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
9
32
43
56
52
66
93
115
88
50
37
0
7
29
40
42
52
51
94
95
83
45
30
0
6
31
37
42
38
48
67
67
79
45
40
1
5
33
34
40
39
50
47
68
63
34
32
0
5
24
39
38
52
41
48
61
45
37
30
0
6
24
44
52
48
37
51
49
56
34
31
2
14
45
41
56
61
62
72
83
52
28
19
1
9
27
30
40
37
45
57
56
60
23
12
0
10
28
38
37
37
38
52
49
46
21
17
1
6
27
42
34
34
34
44
41
35
27
14
0
7
20
40
38
30
25
31
48
39
27
12
0
9
26
38
40
44
41
43
39
33
27
17
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
202
67
324
46
0
184
61
280
41
1
157
47
262
32
2
128
48
227
42
0
123
53
195
47
0
153
56
192
30
0
150
70
275
40
0
91
62
215
28
1
100
50
187
38
0
93
47
163
36
0
71
48
165
33
0
94
60
170
32
0
Total
639
567
500
445
419
431
535
397
374
339
317
356
Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
4
17
42
67
64
73
69
55
31
25
19
0
4
22
39
57
54
53
73
43
49
15
15
0
3
20
41
44
44
57
59
40
37
17
10
0
2
28
39
53
47
45
43
45
38
13
15
0
4
22
36
53
45
30
43
43
32
16
19
0
4
20
38
59
46
45
40
49
28
17
15
0
4
23
21
33
28
19
29
18
15
9
3
0
6
14
25
24
25
23
23
21
10
7
6
0
7
21
15
25
25
31
17
18
16
7
8
0
5
27
10
18
18
18
15
14
9
3
4
0
5
11
30
24
14
19
17
16
12
6
6
0
4
16
16
25
18
17
16
14
8
4
4
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
158
20
115
86
88
134
18
97
94
81
103
11
90
105
64
107
19
98
90
53
104
12
89
95
43
115
13
99
95
38
90
9
42
37
23
69
12
42
36
25
68
10
49
47
15
47
7
45
36
7
49
11
45
46
11
47
8
39
40
6
Total
467
423
372
367
343
360
201
184
189
141
161
141
HIV Surveillance Report
42
Vol. 29
Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and
6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1
1
0
1
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
1
0
1
1
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
2
0
1
0
0
0
0
Total
0
1
1
4
1
1
0
0
1
1
2
1
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
7
32
37
46
26
45
54
57
21
15
7
0
2
26
36
46
36
43
59
46
38
18
13
0
2
26
40
54
48
60
52
52
28
21
12
0
1
46
81
77
53
54
64
56
32
20
10
0
3
30
76
66
69
46
48
50
28
19
16
0
3
44
87
94
74
49
61
40
39
22
15
0
10
27
52
50
43
47
44
37
30
11
3
0
9
36
47
58
34
46
47
41
23
13
5
0
11
39
55
62
44
37
39
26
19
5
6
1
8
49
90
84
53
61
46
41
24
12
6
0
5
40
90
64
62
45
41
39
21
12
9
0
7
43
89
90
75
51
36
38
29
10
4
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
67
46
134
100
0
64
49
145
104
1
65
51
156
124
0
74
136
156
125
1
84
82
163
120
0
101
94
216
116
0
75
44
165
71
0
69
61
158
70
0
57
40
168
77
0
74
132
191
76
0
82
81
180
84
0
88
90
209
85
0
Total
347
363
396
493
450
527
354
358
343
473
427
472
HIV Surveillance Report
43
Vol. 29
Table 8b. Diagnoses of HIV infection attributed to injection drug use, by selected characteristics, 2012–2017—United States and
6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
3
3
4
4
5
5
11
6
4
2
0
0
1
4
5
4
10
6
8
3
3
2
0
0
1
7
7
4
4
4
4
3
2
2
0
1
3
6
5
2
2
3
4
3
1
4
0
1
2
4
0
4
4
3
6
3
1
0
0
0
0
2
4
4
4
4
1
4
2
1
0
4
4
7
6
7
8
9
5
5
2
2
0
1
3
5
4
5
8
5
6
4
3
1
0
2
2
2
6
7
6
5
7
2
2
2
0
2
2
3
9
2
2
4
3
8
1
1
0
1
2
3
2
7
4
7
3
4
1
1
0
1
4
2
3
4
4
2
4
1
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
19
4
11
11
0
11
2
23
10
0
10
8
9
11
0
8
7
13
5
0
7
3
11
7
0
7
3
7
8
0
21
7
26
5
0
14
8
18
8
0
13
2
20
8
0
6
6
15
8
0
8
4
15
9
0
8
3
9
6
0
Total
45
45
37
33
28
25
58
47
43
36
36
25
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
21
86
128
174
151
198
222
238
150
94
65
0
13
81
122
156
149
165
238
193
176
81
60
0
12
80
129
151
138
174
184
168
148
87
66
1
9
110
163
185
143
154
158
177
138
69
62
0
13
82
160
158
174
125
146
162
112
73
66
0
13
89
179
214
174
137
158
143
127
76
61
2
31
101
123
149
141
139
157
143
104
51
27
1
25
82
107
129
101
124
136
127
100
49
24
0
30
90
113
133
116
115
114
101
85
37
32
2
20
105
148
147
109
117
111
99
78
45
26
0
18
75
167
130
116
94
97
112
78
46
28
0
22
90
149
160
144
114
99
97
72
41
27
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
451
139
588
262
88
399
133
555
267
83
342
120
530
281
66
325
210
500
278
55
323
151
465
287
44
381
168
521
265
38
338
134
509
165
23
244
147
437
149
25
240
106
428
178
15
220
193
420
169
7
212
144
406
188
11
239
161
433
175
7
1,528
1,436
1,338
1,368
1,270
1,373
1,169
1,003
967
1,008
962
1,016
Total
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanics/Latinos can be of any race.
HIV Surveillance Report
44
Vol. 29
Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
1
0
2
0
1
4
0
1
2
0
0
0
1
2
3
1
0
3
1
0
0
0
0
0
0
0
3
1
1
3
0
1
0
0
0
0
1
0
1
1
0
3
2
1
0
0
0
0
0
0
1
2
1
1
1
0
0
2
0
0
0
0
2
3
0
0
0
0
0
0
0
0
3
2
6
4
4
4
1
1
2
1
0
1
3
1
2
3
2
2
6
1
0
2
0
3
1
6
1
3
2
1
5
3
0
0
0
1
2
7
7
5
5
3
4
4
0
1
0
0
1
5
3
7
6
3
1
2
2
1
0
0
2
5
2
4
5
5
5
2
2
0
Region of residencea
Northeast
Midwest
South
West
1
2
3
7
3
5
1
2
2
1
1
7
2
1
3
4
0
1
3
5
0
0
3
3
2
7
6
12
0
5
5
11
0
3
8
13
1
7
16
13
4
1
9
17
0
3
6
22
13
11
10
10
9
7
27
21
24
37
31
31
Total
Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
2
6
8
9
6
7
1
6
2
0
0
1
5
6
5
9
10
6
4
2
1
0
1
1
7
13
7
6
6
8
2
1
5
0
0
0
6
4
19
9
8
6
5
0
4
0
0
3
3
11
12
5
7
4
3
4
6
0
0
2
2
4
10
2
6
3
3
5
3
0
6
10
24
21
21
14
8
7
4
6
0
1
2
8
20
23
23
16
13
6
7
2
3
0
1
9
19
19
23
20
9
8
7
4
1
0
3
12
16
22
19
15
11
7
5
7
5
1
0
10
17
32
26
15
11
10
7
4
5
0
1
8
16
9
25
13
12
12
8
7
4
Region of residencea
Northeast
Midwest
South
West
13
6
13
14
10
6
17
16
17
9
16
15
10
7
24
19
8
10
24
16
10
4
12
14
22
8
34
56
21
18
38
45
22
13
35
52
20
16
44
40
34
14
43
48
16
21
34
42
Total
46
49
57
60
57
40
119
123
121
121
139
113
HIV Surveillance Report
45
Vol. 29
Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
35
172
179
240
235
302
350
306
218
124
128
1
34
140
195
217
225
241
302
266
206
127
128
2
30
163
211
215
216
268
252
257
201
111
123
1
35
173
251
214
229
251
252
262
213
128
104
0
40
163
251
235
224
224
222
232
183
126
121
0
26
122
193
197
202
182
191
202
177
116
106
13
213
489
598
648
553
548
562
447
307
170
110
8
189
462
568
567
515
485
493
416
319
144
125
5
184
474
561
539
553
487
437
369
327
151
125
8
146
477
537
529
549
435
401
397
288
174
134
6
147
413
568
556
562
436
445
391
310
196
126
5
141
418
539
545
506
423
396
344
312
204
173
Region of residencea
Northeast
Midwest
South
West
482
186
1,560
63
411
206
1,378
86
424
168
1,362
95
375
189
1,452
96
325
191
1,415
92
273
177
1,204
62
876
563
2,961
259
694
531
2,842
224
777
480
2,712
243
717
502
2,586
270
690
522
2,629
314
675
513
2,584
234
Total
2,290
2,081
2,048
2,112
2,023
1,716
4,659
4,291
4,212
4,074
4,155
4,007
Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
6
39
53
98
77
89
76
66
43
26
33
0
7
34
78
105
98
84
72
62
50
21
22
0
3
36
60
97
103
98
83
68
42
23
21
0
6
32
52
83
99
81
68
62
44
27
35
0
5
51
69
88
86
79
77
54
37
28
23
0
8
23
62
71
75
79
55
47
34
31
27
0
46
105
143
131
132
129
118
84
62
29
41
2
42
93
147
131
126
118
121
117
62
40
29
1
43
127
131
154
152
121
111
90
73
37
24
0
37
115
130
131
141
120
109
107
58
39
29
2
30
100
135
156
124
122
101
100
68
42
38
1
32
114
132
120
129
98
119
91
64
40
37
Region of residencea
Northeast
Midwest
South
West
181
36
290
98
165
41
317
110
157
34
342
100
145
38
314
90
146
38
305
106
114
23
278
98
323
64
395
240
332
62
406
228
308
70
414
272
278
49
465
224
304
57
437
219
249
59
448
222
Total
606
633
633
587
596
513
1,021
1,027
1,064
1,016
1,017
978
HIV Surveillance Report
46
Vol. 29
Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
1
0
2
0
1
1
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
1
1
0
0
1
0
0
0
1
0
0
0
1
3
1
0
0
1
0
0
0
0
0
4
0
1
0
0
1
3
0
1
0
0
1
1
0
1
1
1
0
1
1
1
0
0
1
2
0
1
0
1
0
1
1
0
0
0
0
1
0
1
2
0
0
2
0
0
0
0
0
0
3
3
3
0
1
0
1
0
0
Region of residencea
Northeast
Midwest
South
West
0
0
0
2
0
0
0
0
1
0
0
0
0
0
1
4
0
1
1
0
1
0
1
2
1
0
1
4
0
0
5
5
1
0
1
6
0
2
2
3
0
0
1
5
2
0
4
5
Total
2
0
1
6
2
4
6
10
8
7
6
11
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
3
21
41
35
40
74
71
62
47
26
29
0
3
15
39
31
43
75
67
57
53
32
45
0
3
15
40
43
30
56
63
74
41
28
38
0
2
15
36
38
36
48
64
43
48
37
47
0
3
31
40
45
46
50
46
74
51
34
42
0
1
16
40
44
47
50
47
60
49
34
32
2
33
112
122
112
100
139
119
100
69
32
23
3
19
103
110
114
112
97
113
88
71
52
27
3
29
118
125
134
119
105
102
111
80
29
16
0
22
95
118
124
107
105
113
111
90
34
27
0
34
108
140
150
113
97
110
107
91
54
23
2
31
111
117
137
123
88
117
105
99
44
26
Region of residencea
Northeast
Midwest
South
West
94
71
209
76
90
62
227
80
93
52
208
79
79
47
227
59
83
49
259
69
65
50
232
73
143
165
490
163
151
151
456
152
152
152
502
164
128
161
505
152
136
167
528
195
132
158
543
166
Total
449
459
432
412
461
420
962
910
970
945
1,026
998
HIV Surveillance Report
47
Vol. 29
Table 9a. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
2
7
8
9
17
17
10
10
6
8
2
0
2
8
12
11
8
13
16
11
9
7
6
0
1
5
7
6
16
8
19
8
9
2
3
0
1
9
11
9
8
5
5
9
6
2
7
0
0
7
10
6
11
12
8
6
5
3
2
0
1
2
4
6
4
6
6
6
4
3
4
2
14
36
25
32
26
30
30
18
17
17
8
0
16
31
29
31
28
22
28
24
15
10
7
0
11
33
31
34
26
31
15
14
10
10
4
0
9
17
22
29
25
13
18
20
11
5
4
1
7
23
19
20
20
14
18
14
12
4
7
1
4
19
19
14
18
8
12
14
9
2
3
Region of residencea
Northeast
Midwest
South
West
34
12
40
10
43
8
45
8
28
8
35
12
19
8
36
7
24
7
33
4
11
8
22
4
74
28
130
21
66
32
120
21
52
26
117
22
51
17
87
17
32
34
80
12
32
18
51
20
Total
96
104
83
70
68
45
254
240
217
171
158
121
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
48
241
283
390
377
491
517
451
315
192
196
1
46
199
331
373
380
422
469
403
322
189
202
2
38
219
325
377
373
437
427
415
297
165
190
1
44
229
356
349
393
395
401
384
317
194
196
0
48
255
373
387
382
371
362
370
278
195
195
0
36
166
301
325
342
320
306
318
267
189
173
17
311
755
914
952
838
863
841
657
459
256
183
13
268
704
874
869
806
740
772
659
475
248
193
9
272
764
872
881
877
767
675
596
500
231
170
8
218
720
830
841
845
695
655
645
457
258
199
10
217
655
884
918
854
691
688
623
489
301
200
9
210
672
830
829
807
635
663
569
494
299
242
Region of residencea
Northeast
Midwest
South
West
805
313
2,114
270
722
328
1,986
302
722
272
1,963
308
632
291
2,056
279
587
297
2,040
293
474
262
1,752
257
1,441
836
4,017
753
1,265
800
3,871
686
1,312
744
3,788
771
1,195
753
3,704
719
1,200
794
3,727
810
1,107
772
3,670
710
Total
3,502
3,337
3,265
3,258
3,216
2,744
7,047
6,621
6,614
6,370
6,531
6,259
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk
for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanics/Latinos can be of any race.
HIV Surveillance Report
48
Vol. 29
Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and
6 dependent areas
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
1
0
2
0
1
4
0
1
2
0
0
0
1
2
3
1
0
3
1
0
0
0
0
0
0
0
3
1
1
3
0
1
0
0
0
0
1
0
1
1
0
3
2
1
0
0
0
0
0
0
1
2
1
1
1
0
0
2
0
0
0
0
2
3
0
0
0
0
0
0
0
0
3
2
6
4
4
4
1
1
2
1
0
1
3
1
2
3
2
2
6
1
0
2
0
3
1
6
1
3
2
1
5
3
0
0
0
1
2
7
7
5
5
3
4
4
0
1
0
0
1
5
3
7
6
3
1
2
2
1
0
0
2
5
2
4
5
5
5
2
2
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1
2
3
7
0
3
5
1
2
0
2
1
1
7
0
2
1
3
4
0
0
1
3
5
0
0
0
3
3
0
2
7
6
12
0
0
5
5
11
0
0
3
8
13
0
1
7
16
13
0
4
1
9
17
0
0
3
6
22
0
13
11
10
10
9
7
27
21
24
37
31
31
Total
Asian
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
2
6
8
9
6
7
1
6
2
0
0
1
5
6
5
9
10
6
4
2
1
0
1
1
7
13
7
6
6
8
2
1
5
0
0
0
6
4
19
9
8
6
5
0
4
0
0
3
3
11
12
5
7
4
3
4
6
0
0
2
2
4
10
2
6
3
3
5
3
0
6
10
24
21
21
14
8
7
4
6
0
1
2
8
20
23
23
16
13
6
7
2
3
0
1
9
19
19
23
20
9
8
7
4
1
0
3
12
16
22
19
15
11
7
5
7
5
1
0
10
17
32
26
15
11
10
7
4
5
0
1
8
16
9
25
13
12
12
8
7
4
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
13
6
13
14
0
10
6
17
16
0
17
9
16
15
0
10
7
24
19
0
8
10
24
16
0
10
4
12
14
0
22
8
34
56
0
21
18
38
45
0
22
13
35
52
0
20
16
44
40
0
34
14
43
48
0
16
21
34
42
0
Total
46
49
57
60
58
40
119
123
121
121
139
113
HIV Surveillance Report
49
Vol. 29
Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and
6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
35
172
179
240
235
302
350
306
218
124
128
1
34
140
196
217
226
241
302
267
206
128
128
2
30
163
211
215
216
268
252
259
201
111
124
1
35
173
251
214
229
251
252
262
213
128
104
0
40
163
251
235
224
224
223
232
183
128
121
0
26
122
193
198
202
182
191
202
177
116
106
13
213
489
598
649
553
549
562
447
307
170
110
8
189
463
569
567
515
485
495
416
320
145
125
5
184
474
561
540
554
487
438
370
328
151
125
8
146
477
539
529
549
435
401
397
288
174
136
6
147
413
568
556
562
436
445
391
310
196
126
5
141
418
539
546
506
423
397
344
312
204
173
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
482
186
1,560
63
1
411
206
1,378
86
4
424
168
1,362
95
5
375
189
1,452
96
0
325
191
1,415
92
3
273
177
1,204
62
1
876
563
2,961
259
2
694
531
2,842
224
7
777
480
2,712
243
5
717
502
2,586
270
4
690
522
2,629
314
0
675
513
2,584
234
2
Total
2,291
2,085
2,053
2,112
2,025
1,717
4,660
4,298
4,217
4,078
4,155
4,008
Hispanic/Latinob
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
8
43
61
112
89
113
100
84
55
32
47
0
9
40
84
114
108
92
93
79
59
32
35
0
3
44
71
104
110
108
94
79
54
36
29
0
7
38
58
93
108
86
83
75
50
30
45
0
5
52
75
95
95
93
93
66
48
38
37
0
9
31
67
80
87
91
63
55
41
39
35
1
51
119
156
150
152
150
144
106
73
37
56
3
45
105
156
143
142
131
141
138
77
44
33
1
51
137
138
167
171
142
127
101
84
41
29
0
40
124
139
137
150
134
124
121
69
40
36
2
33
105
140
164
139
135
115
108
83
47
41
1
34
119
144
126
140
104
130
100
73
45
42
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
181
36
290
98
139
165
41
317
110
112
157
34
342
100
99
145
38
314
90
85
146
38
305
106
100
114
23
278
98
84
323
64
395
240
175
332
62
406
228
131
308
70
414
272
125
278
49
465
224
97
304
57
437
219
94
249
59
448
222
80
Total
744
746
732
673
697
597
1,196
1,159
1,189
1,113
1,111
1,058
HIV Surveillance Report
50
Vol. 29
Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and
6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
1
0
2
0
1
2
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
1
1
0
0
1
0
0
0
1
0
0
0
1
3
1
0
0
1
0
0
0
0
0
4
0
1
0
0
1
3
0
1
0
0
1
2
0
1
1
1
0
1
1
1
0
0
1
2
0
1
0
1
0
1
1
0
0
0
0
1
0
1
2
0
0
2
0
0
0
0
0
0
3
3
3
0
1
0
1
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
0
0
0
2
0
0
0
0
0
0
1
0
0
0
0
0
0
1
4
0
0
1
1
0
0
1
0
1
2
0
1
0
1
4
0
0
0
5
5
0
1
0
1
6
1
0
2
2
3
0
0
0
1
5
0
2
0
4
5
0
Total
2
0
1
6
3
4
6
10
8
7
6
11
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
3
21
41
35
40
74
71
62
47
26
29
0
3
15
39
31
43
75
67
57
53
32
45
0
3
15
40
43
30
56
63
74
41
28
38
0
2
15
36
38
36
48
64
43
48
37
47
0
3
31
40
45
46
50
46
74
51
34
43
0
1
16
40
44
47
50
47
60
49
34
32
2
33
112
122
112
100
139
119
100
69
32
23
3
19
103
110
114
112
97
113
88
71
53
27
3
29
118
125
134
119
105
102
111
80
29
17
0
22
95
118
124
107
105
113
111
90
34
27
0
34
108
140
150
113
97
110
107
91
54
23
2
32
111
117
137
123
88
117
105
99
44
26
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
94
71
209
76
0
90
62
227
80
0
93
52
208
79
0
79
47
227
59
1
83
49
259
69
1
65
50
232
73
0
143
165
490
163
0
151
151
456
152
1
152
152
502
164
1
128
161
505
152
0
136
167
528
195
0
132
158
543
166
1
Total
449
459
432
413
462
420
962
911
971
945
1,026
999
HIV Surveillance Report
51
Vol. 29
Table 9b. Diagnoses of HIV infection attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and
6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
2
7
8
9
17
17
10
10
6
8
2
0
2
8
12
11
8
13
16
11
9
7
6
0
1
5
7
6
16
8
19
8
9
2
3
0
1
9
11
9
8
5
5
9
6
2
7
0
0
7
10
6
11
12
8
6
5
3
2
0
1
2
4
6
4
6
6
6
4
3
4
2
14
36
25
32
26
30
30
18
17
17
8
0
16
31
29
31
28
22
28
24
15
10
7
0
11
33
31
34
26
31
15
14
10
10
4
0
9
18
22
29
25
13
18
20
11
5
4
1
7
23
19
20
20
14
18
14
12
4
7
1
4
19
19
14
18
8
12
14
9
2
3
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
34
12
40
10
0
43
8
45
8
0
28
8
35
12
0
19
8
36
7
0
24
7
33
4
0
11
8
22
4
0
74
28
130
21
0
66
32
120
21
0
52
26
117
22
0
51
17
87
17
1
32
34
80
12
0
32
18
51
20
0
Total
96
104
83
70
68
45
254
240
217
172
158
121
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
49
245
291
404
389
515
542
470
328
198
210
1
48
205
338
383
391
429
490
421
331
201
216
2
38
227
336
385
380
448
437
429
309
178
199
1
45
236
362
358
402
400
415
398
323
197
205
0
48
256
379
393
392
384
379
383
290
207
210
0
37
173
306
335
353
332
314
325
275
197
182
18
316
769
927
972
858
885
867
679
470
264
198
14
271
717
884
881
823
753
794
680
492
254
197
9
280
774
879
896
897
788
692
608
512
235
176
8
221
729
841
847
854
709
670
659
468
259
207
10
220
660
889
926
870
703
702
631
504
306
203
9
212
677
842
836
818
641
675
578
503
304
246
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
805
313
2,114
270
139
722
328
1,986
302
117
722
272
1,963
308
104
632
291
2,056
279
86
587
297
2,040
293
104
474
262
1,752
257
85
1,441
836
4,017
753
176
1,265
800
3,871
686
140
1,312
744
3,788
771
132
1,195
753
3,704
719
102
1,200
794
3,727
810
94
1,107
772
3,670
710
82
Total
3,641
3,454
3,369
3,344
3,321
2,829
7,223
6,761
6,746
6,472
6,625
6,341
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk
for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.
a Data are based on residence at time of diagnosis of HIV infection.
b Hispanics/Latinos can be of any race.
HIV Surveillance Report
52
Vol. 29
Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
3
5
12
2
8
3
6
1
0
1
0
0
4
5
9
2
10
4
7
0
0
1
0
0
2
5
8
4
9
5
6
2
0
1
0
1
6
5
6
5
4
3
3
2
1
1
0
0
3
12
11
9
7
6
3
3
1
2
0
0
1
7
3
7
5
4
3
0
1
0
0
0
2
2
2
1
2
2
0
0
0
0
0
0
0
0
2
0
1
0
1
2
0
0
0
0
0
0
0
0
0
2
2
0
0
0
0
1
2
1
0
1
0
2
0
0
0
0
0
0
3
2
0
0
1
0
0
0
0
0
0
0
2
2
0
0
2
1
1
0
1
0
Region of residencea
Northeast
Midwest
South
West
2
3
12
25
1
3
8
29
1
2
9
29
0
3
16
18
3
9
15
28
0
4
8
19
0
1
0
9
1
0
0
5
0
1
1
2
0
0
1
6
0
1
1
4
0
0
6
3
Total
42
41
40
36
56
30
11
7
4
8
7
9
Asianb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
2
9
30
31
43
39
38
19
11
6
4
0
1
20
36
38
33
51
32
20
8
3
4
0
0
16
25
33
40
38
37
12
4
3
5
0
3
14
37
35
25
46
31
29
13
1
4
0
2
16
50
41
24
37
30
20
9
2
8
0
2
22
37
38
31
30
33
21
15
5
5
0
0
1
2
0
2
4
1
1
0
1
0
0
0
0
1
1
2
4
0
0
0
0
0
0
0
0
2
0
3
6
0
0
0
0
0
0
0
0
0
1
0
2
1
1
0
0
0
0
0
0
0
0
2
0
0
2
0
0
1
0
0
0
0
1
1
2
1
2
0
0
0
Region of residencea
Northeast
Midwest
South
West
33
17
48
133
35
23
52
135
41
26
46
100
50
29
34
127
42
24
56
117
49
21
62
107
2
1
3
6
2
2
0
2
0
3
2
6
1
3
0
3
1
0
1
2
0
0
1
8
Total
231
245
213
239
239
238
12
7
12
7
5
9
HIV Surveillance Report
53
Vol. 29
Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2
147
849
917
730
521
565
534
350
202
96
64
2
156
920
990
690
487
467
482
364
196
104
63
0
82
590
841
582
413
378
369
287
192
91
60
0
83
572
864
628
426
346
359
313
166
81
74
0
86
544
957
602
447
327
317
304
185
90
61
1
85
508
875
682
418
328
299
278
190
99
66
0
4
22
28
45
38
40
66
58
24
17
6
0
1
24
35
31
27
40
47
42
38
17
4
0
3
13
21
25
14
25
31
29
25
11
6
0
2
10
27
20
22
22
27
31
23
14
10
0
2
12
22
34
25
20
28
28
19
22
9
0
1
13
29
27
25
21
21
27
25
12
8
Region of residencea
Northeast
Midwest
South
West
646
790
3,128
411
668
800
3,088
365
492
630
2,458
303
491
621
2,490
310
487
658
2,446
329
469
589
2,481
291
62
56
185
45
44
48
177
36
27
34
113
29
28
35
125
20
30
33
126
31
29
33
119
26
Total
4,976
4,922
3,883
3,911
3,920
3,829
348
305
204
208
220
207
Hispanic/Latinoc
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
44
346
514
574
431
413
382
205
122
60
33
1
49
284
507
515
490
416
376
236
108
46
44
0
16
232
424
457
418
320
315
181
104
54
41
0
16
226
425
464
415
319
307
215
109
52
33
1
22
230
470
481
444
302
280
225
115
54
56
1
36
177
429
494
355
292
274
224
117
55
45
1
2
22
23
42
46
43
43
30
9
6
1
0
4
15
29
42
41
31
28
22
7
5
3
0
1
10
27
33
21
23
18
13
12
6
4
0
1
10
38
31
31
25
28
18
12
6
2
0
1
14
16
29
28
27
21
19
5
5
4
0
1
9
31
23
31
15
20
15
17
8
4
Region of residencea
Northeast
Midwest
South
West
563
239
1,188
1,133
568
234
1,208
1,062
455
202
1,022
884
454
209
1,012
905
424
192
1,113
951
411
160
1,055
873
64
20
80
101
43
18
86
80
30
13
59
66
33
19
68
82
27
11
61
69
32
13
49
80
Total
3,124
3,071
2,562
2,580
2,681
2,498
265
226
168
202
168
173
HIV Surveillance Report
54
Vol. 29
Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
2
3
2
2
1
3
3
1
0
0
0
0
0
5
2
2
2
1
2
0
0
0
0
0
0
0
3
3
1
2
1
0
1
0
0
0
2
3
0
2
1
3
3
0
0
0
0
0
1
2
1
4
0
0
0
0
0
0
0
0
2
3
3
0
3
4
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
1
1
2
13
0
0
0
14
0
1
2
8
1
0
3
10
0
0
0
8
0
0
6
10
0
0
0
1
0
0
0
0
0
0
0
1
1
0
0
1
1
0
0
0
0
0
1
0
Total
17
14
11
14
8
16
1
0
1
2
1
1
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
22
158
362
456
415
619
730
624
335
211
165
0
18
177
333
403
426
591
667
607
386
228
167
0
6
112
264
327
329
412
561
519
315
179
166
0
11
107
277
336
325
364
477
560
334
188
187
0
10
91
251
327
283
338
442
522
354
208
173
0
13
114
243
297
303
272
360
460
336
168
191
0
1
20
41
62
63
84
111
61
31
10
10
0
0
16
39
57
51
64
70
60
33
18
10
0
1
18
30
38
38
51
58
59
26
13
5
0
2
14
29
49
54
44
46
54
30
17
7
0
1
13
30
43
51
46
47
53
31
14
7
0
0
6
40
49
50
30
43
35
36
17
11
Region of residencea
Northeast
Midwest
South
West
598
763
1,691
1,043
541
739
1,731
991
443
602
1,369
775
439
602
1,266
859
413
564
1,220
800
372
490
1,244
651
64
58
180
191
35
67
164
150
39
52
120
124
32
60
128
127
37
49
116
133
25
54
120
118
Total
4,095
4,002
3,189
3,166
2,997
2,757
494
416
336
347
335
317
HIV Surveillance Report
55
Vol. 29
Table 10a. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
5
79
104
104
74
81
78
57
46
14
9
0
25
113
91
86
86
60
79
49
32
20
11
0
6
58
94
60
54
61
62
47
31
11
14
0
3
45
88
53
58
44
50
41
25
14
11
0
5
36
65
62
49
27
48
50
32
13
11
0
3
21
62
59
43
33
36
30
27
15
15
0
0
8
4
15
9
14
18
6
6
3
1
0
1
4
8
9
10
9
15
9
6
3
2
0
0
2
11
12
8
7
10
8
9
5
1
0
1
5
8
8
2
8
6
10
5
5
1
0
2
5
7
9
8
6
5
10
4
4
2
0
0
1
2
3
10
3
7
5
6
5
3
Region of residencea
Northeast
Midwest
South
West
162
80
298
111
134
89
299
128
94
78
230
96
109
64
180
80
99
46
156
95
79
53
152
60
17
11
36
21
12
11
33
21
12
9
27
23
9
7
21
21
9
11
27
13
6
7
22
11
Total
650
650
498
433
396
343
85
77
71
59
61
45
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
3
221
1,445
1,935
1,908
1,488
1,726
1,768
1,264
717
387
275
3
249
1,517
1,968
1,742
1,525
1,597
1,641
1,284
730
400
289
0
110
1,009
1,654
1,469
1,259
1,218
1,351
1,053
648
338
286
0
117
972
1,699
1,522
1,256
1,124
1,230
1,164
650
338
309
1
125
920
1,806
1,523
1,259
1,038
1,123
1,124
698
368
310
2
139
844
1,655
1,575
1,158
962
1,010
1,017
685
342
322
1
8
74
100
166
159
186
241
156
70
36
18
0
6
59
112
141
131
148
160
134
86
42
19
0
5
44
90
109
84
112
119
111
72
35
16
0
7
41
103
111
111
101
110
116
70
42
20
0
6
46
78
115
114
100
100
111
58
46
23
0
2
31
104
102
117
74
93
84
85
43
27
Region of residencea
Northeast
Midwest
South
West
2,005
1,892
6,367
2,869
1,947
1,888
6,385
2,724
1,526
1,540
5,136
2,195
1,544
1,527
5,000
2,309
1,468
1,491
5,007
2,329
1,378
1,316
5,008
2,010
211
148
483
374
137
146
460
294
109
112
323
252
104
124
344
260
106
106
333
252
92
107
316
246
13,134
12,944
10,396
10,380
10,296
9,712
1,216
1,037
795
832
797
761
Total
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a Data are based on residence at time of stage 3 (AIDS) classification.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
HIV Surveillance Report
56
Vol. 29
Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States and 6 dependent areas
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
3
5
12
2
8
3
6
1
0
1
0
0
4
5
9
2
10
4
7
0
0
1
0
0
2
5
8
4
9
5
6
2
0
1
0
1
6
5
6
5
4
3
3
2
1
1
0
0
3
12
11
9
7
6
3
3
1
2
0
0
1
7
3
7
5
4
3
0
1
0
0
0
2
2
2
1
2
2
0
0
0
0
0
0
0
0
2
0
1
0
1
2
0
0
0
0
0
0
0
0
0
2
2
0
0
0
0
1
2
1
0
1
0
2
0
0
0
0
0
0
3
2
0
0
1
0
0
0
0
0
0
0
2
2
0
0
2
1
1
0
1
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
2
3
12
25
0
1
3
8
29
0
1
2
9
29
0
0
3
16
18
0
3
9
15
28
0
0
4
8
19
0
0
1
0
9
0
1
0
0
5
0
0
1
1
2
0
0
0
1
6
0
0
1
1
4
0
0
0
6
3
0
Total
42
41
40
36
56
30
11
7
4
8
7
9
Asianb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
2
9
30
31
44
39
38
19
11
6
4
0
1
20
36
38
33
51
32
20
8
3
4
0
0
16
25
33
40
38
37
13
4
3
5
0
3
14
38
35
25
46
31
29
13
1
4
0
2
16
50
41
24
37
30
20
9
2
8
0
2
22
37
40
31
30
33
21
15
5
5
0
0
1
2
0
2
4
1
1
0
1
0
0
0
0
1
1
2
4
0
0
0
0
0
0
0
0
2
0
3
6
0
0
0
0
0
0
0
0
0
1
0
2
1
1
0
0
0
0
0
0
0
0
2
0
0
2
0
0
1
0
0
0
0
1
1
2
1
2
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
33
17
48
133
1
35
23
52
135
0
41
26
46
100
1
50
29
34
127
1
42
24
56
117
0
49
21
62
107
2
2
1
3
6
0
2
2
0
2
0
0
3
2
6
0
1
3
0
3
0
1
0
1
2
0
0
0
1
8
0
Total
232
245
214
240
239
240
12
7
12
7
5
9
HIV Surveillance Report
57
Vol. 29
Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2
147
849
918
730
522
566
534
350
202
96
64
2
156
920
990
690
487
467
482
364
196
104
63
0
82
590
841
582
413
379
370
287
192
91
60
0
83
573
864
628
428
346
360
313
166
81
74
0
86
544
957
602
447
327
317
304
185
90
61
1
85
508
875
682
418
328
299
278
190
99
66
0
4
22
28
45
38
40
66
58
24
17
6
0
1
24
35
31
27
40
47
42
38
17
4
0
3
13
21
25
14
25
31
29
25
11
6
0
2
10
27
20
23
22
27
31
23
14
10
0
2
12
22
34
25
20
28
28
19
22
9
0
1
13
29
27
25
21
21
27
25
12
8
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
646
790
3,128
411
3
668
800
3,088
365
0
492
630
2,458
303
2
491
621
2,490
310
4
487
658
2,446
329
0
469
589
2,481
291
0
62
56
185
45
0
44
48
177
36
0
27
34
113
29
0
28
35
125
20
0
30
33
126
31
0
29
33
119
26
0
Total
4,979
4,922
3,885
3,915
3,920
3,829
348
305
204
208
220
207
Hispanic/Latinoc
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
44
357
535
584
442
432
402
216
127
62
37
1
50
298
526
539
504
436
389
253
111
52
48
0
18
246
434
471
429
332
329
188
107
60
45
0
16
235
440
474
425
332
316
225
115
53
35
1
24
239
478
493
464
311
292
236
118
56
57
1
36
178
435
503
361
301
280
240
124
57
48
1
2
22
25
43
53
46
46
31
11
6
3
0
4
18
29
44
44
34
29
25
7
5
3
0
1
10
27
33
23
27
20
15
12
6
4
0
1
10
38
32
32
27
28
24
15
7
3
0
1
14
16
31
31
33
23
21
8
6
4
0
1
9
31
25
32
15
20
16
18
8
4
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
563
239
1,188
1,133
114
568
234
1,208
1,062
135
455
202
1,022
884
98
454
209
1,012
905
86
424
192
1,113
951
88
411
160
1,055
873
65
64
20
80
101
21
43
18
86
80
14
30
13
59
66
10
33
19
68
82
14
27
11
61
69
19
32
13
49
80
5
Total
3,237
3,206
2,659
2,666
2,769
2,564
286
240
178
216
188
178
HIV Surveillance Report
58
Vol. 29
Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
2
3
3
2
1
3
3
1
0
0
0
0
0
5
2
2
2
1
2
0
0
0
0
0
0
0
3
3
2
2
1
0
1
0
0
0
2
4
0
2
1
3
4
0
0
0
0
0
2
2
2
4
0
0
0
0
0
0
0
0
2
3
3
0
3
4
2
1
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1
1
2
13
1
0
0
0
14
0
0
1
2
8
1
1
0
3
10
1
0
0
0
8
2
0
0
6
10
2
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
1
0
0
1
0
1
0
0
0
0
0
0
1
0
0
Total
18
14
12
15
10
18
1
0
1
2
1
1
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
22
158
362
456
415
620
730
624
335
212
165
0
18
177
333
403
426
591
667
607
386
228
167
0
6
112
264
327
329
412
561
519
316
179
166
0
11
107
277
336
325
364
477
561
334
188
187
0
10
91
251
328
283
338
442
522
354
208
173
0
13
114
243
297
303
272
360
460
336
168
191
0
1
20
41
62
63
84
111
61
31
10
10
0
0
16
39
57
51
64
70
60
33
18
10
0
1
18
30
38
38
51
58
59
26
13
5
0
2
14
29
49
54
44
46
54
30
17
7
0
1
13
30
43
51
46
47
53
31
14
7
0
0
6
40
49
50
30
43
35
36
17
11
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
598
763
1,691
1,043
2
541
739
1,731
991
0
443
602
1,369
775
1
439
602
1,266
859
1
413
564
1,220
800
1
372
490
1,244
651
0
64
58
180
191
0
35
67
164
150
0
39
52
120
124
0
32
60
128
127
0
37
49
116
133
0
25
54
120
118
0
Total
4,097
4,002
3,190
3,167
2,998
2,757
494
416
336
347
335
317
HIV Surveillance Report
59
Vol. 29
Table 10b. Stage 3 (AIDS) attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by selected
characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male-to-male sexual contact
Male-to-male sexual contact and injection drug use
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
5
79
104
104
74
81
78
57
46
14
9
0
25
113
91
86
86
60
79
49
32
20
11
0
6
58
94
60
54
61
62
47
31
11
14
0
3
45
88
53
58
44
50
41
25
14
11
0
5
36
65
62
49
27
48
50
32
13
11
0
3
21
62
59
43
33
36
30
27
15
15
0
0
8
4
15
9
14
18
6
6
3
1
0
1
4
8
9
10
9
15
9
6
3
2
0
0
2
11
12
8
7
10
8
9
5
1
0
1
5
8
8
2
8
6
10
5
5
1
0
2
5
7
9
8
6
5
10
4
4
2
0
0
1
2
3
10
3
7
5
6
5
3
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
162
80
298
111
0
134
89
299
128
0
94
78
230
96
0
109
64
180
80
0
99
46
156
95
0
79
53
152
60
0
17
11
36
21
0
12
11
33
21
0
12
9
27
23
0
9
7
21
21
0
9
11
27
13
0
6
7
22
11
0
Total
650
650
498
433
396
343
85
77
71
59
61
45
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
3
221
1,456
1,957
1,919
1,501
1,746
1,788
1,275
722
390
280
3
250
1,531
1,987
1,766
1,539
1,617
1,654
1,301
733
407
293
0
112
1,023
1,664
1,483
1,270
1,232
1,366
1,061
652
345
290
0
117
982
1,716
1,532
1,268
1,137
1,240
1,175
656
339
311
1
127
930
1,814
1,537
1,279
1,047
1,135
1,135
701
370
311
2
139
845
1,661
1,586
1,164
971
1,016
1,034
693
344
325
1
8
74
102
167
166
189
244
157
72
36
20
0
6
62
112
143
134
151
161
136
86
42
19
0
5
44
90
109
86
116
121
113
72
35
16
0
7
41
103
112
111
103
110
122
73
43
21
0
6
46
78
117
117
106
102
113
61
47
23
0
2
31
104
104
118
74
93
85
86
43
27
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
2,005
1,892
6,367
2,869
121
1,947
1,888
6,385
2,724
135
1,526
1,540
5,136
2,195
102
1,544
1,527
5,000
2,309
93
1,468
1,491
5,007
2,329
91
1,378
1,316
5,008
2,010
69
211
148
483
374
21
137
146
460
294
15
109
112
323
252
10
104
124
344
260
14
106
106
333
252
19
92
107
316
246
5
13,255
13,078
10,498
10,472
10,387
9,781
1,237
1,052
806
846
817
766
Total
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a
Data are based on residence at time of stage 3 (AIDS) classification.
b
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c
Hispanics/Latinos can be of any race.
HIV Surveillance Report
60
Vol. 29
Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
2
1
0
1
2
1
1
0
0
0
0
0
0
1
0
1
2
1
0
0
1
0
0
0
2
1
0
4
1
2
1
0
0
0
0
0
0
2
0
1
0
2
1
0
0
0
0
0
0
0
0
1
3
0
1
0
0
0
0
0
2
3
0
2
0
1
0
0
0
0
0
0
0
2
2
0
1
0
5
1
1
0
0
0
1
1
1
0
1
0
0
1
0
0
0
0
0
1
3
2
0
1
0
1
0
0
0
0
1
1
2
1
1
2
1
1
0
0
0
1
1
1
0
1
1
0
2
0
0
0
0
0
1
0
1
0
1
2
1
0
1
Region of residencea
Northeast
Midwest
South
West
1
2
1
3
0
0
2
4
0
1
4
6
1
0
0
5
0
0
0
4
0
1
0
7
1
4
3
3
0
0
2
4
0
0
3
5
0
2
5
4
0
2
1
5
0
0
2
5
Total
7
7
11
6
5
8
11
6
8
10
7
6
Asianb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
2
5
4
1
1
0
0
0
0
0
0
0
1
1
1
2
0
1
1
0
0
0
0
0
1
2
2
0
1
0
0
1
0
0
0
0
4
2
2
1
2
0
1
1
0
0
0
1
2
1
1
2
1
1
1
1
0
0
0
1
1
0
1
1
1
0
0
1
0
0
0
0
0
2
1
1
0
0
0
0
0
0
0
0
1
0
1
0
1
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
3
0
4
7
2
0
3
2
3
1
5
1
5
0
2
6
5
2
2
4
2
1
2
1
3
0
0
1
0
0
1
2
0
0
1
2
1
0
0
2
1
1
0
1
1
0
1
1
14
8
9
13
13
6
4
3
3
3
3
2
Total
HIV Surveillance Report
61
Vol. 29
Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
2
9
23
37
50
85
111
162
138
69
52
0
2
7
19
35
41
50
111
138
108
73
49
0
1
5
11
20
41
43
80
90
89
64
51
0
1
4
20
19
33
38
57
91
86
59
41
0
1
2
11
20
40
37
51
64
67
53
41
0
1
7
13
21
35
30
52
53
85
63
57
0
2
12
25
45
70
93
110
109
76
34
24
0
2
8
23
40
53
59
81
84
83
35
20
0
2
7
17
22
31
59
77
77
59
20
17
0
1
10
18
24
33
40
51
57
42
35
15
0
1
4
16
25
37
40
42
56
51
34
22
0
2
8
17
24
38
40
42
57
41
41
16
Region of residencea
Northeast
Midwest
South
West
209
79
416
37
192
65
336
39
137
38
291
28
124
52
253
20
111
48
204
24
128
49
213
27
162
78
324
37
110
69
279
30
107
61
198
24
94
31
174
26
78
46
182
23
77
44
180
25
Total
741
633
494
450
388
417
601
488
390
325
328
325
Hispanic/Latinoc
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
4
19
42
45
49
76
64
35
29
13
0
1
8
14
34
34
48
69
52
37
22
12
0
0
2
15
24
45
43
43
48
40
14
13
0
0
8
13
27
35
37
34
35
26
16
16
0
0
5
15
25
32
26
32
30
31
21
21
0
1
3
12
28
25
24
37
38
30
23
14
0
0
5
12
17
24
31
36
27
18
12
3
0
2
6
11
20
20
28
30
23
13
12
8
0
1
5
12
14
17
19
22
25
16
6
4
0
0
6
7
14
17
19
22
16
10
8
7
0
0
3
5
12
21
15
20
16
10
6
9
0
1
2
8
9
15
17
15
17
6
9
6
Region of residencea
Northeast
Midwest
South
West
181
18
109
67
166
15
83
65
123
12
85
65
100
20
68
61
97
11
76
55
94
12
65
63
96
12
44
32
96
6
48
24
66
6
41
27
67
6
38
16
52
8
32
25
51
6
30
17
Total
376
330
286
248
238
234
184
174
141
127
117
105
HIV Surveillance Report
62
Vol. 29
Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total
0
1
0
0
1
0
0
0
0
0
0
0
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
9
17
18
21
43
63
63
31
17
7
0
0
2
8
24
25
31
58
58
44
21
13
0
1
7
12
21
32
46
53
45
36
19
17
0
0
5
18
22
17
37
46
51
25
20
11
0
0
5
18
20
18
34
38
45
31
17
12
0
0
5
11
24
29
27
37
42
31
23
11
0
1
2
21
32
44
45
52
51
30
15
4
0
0
1
16
31
30
42
55
53
24
16
7
0
0
11
23
14
28
41
38
41
23
13
5
0
2
6
23
26
40
37
40
37
29
11
8
0
0
4
24
36
42
34
32
32
23
11
5
0
0
10
18
29
44
33
34
41
30
11
5
Region of residencea
Northeast
Midwest
South
West
50
39
115
85
58
23
122
81
49
33
115
93
50
27
103
72
52
26
96
66
47
31
97
65
74
32
136
55
54
37
132
51
47
23
111
55
43
41
114
60
45
39
114
45
41
44
125
43
Total
289
284
290
252
238
239
297
274
236
259
242
254
HIV Surveillance Report
63
Vol. 29
Table 11a. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
2
6
2
7
14
16
15
10
4
0
0
0
0
2
2
14
8
12
3
7
7
0
0
1
2
6
5
3
6
9
14
6
5
0
0
0
4
1
1
3
9
6
6
4
4
0
0
0
2
1
2
1
4
8
6
6
8
0
0
2
2
0
2
6
5
6
8
3
5
0
1
2
7
7
10
13
17
8
5
2
1
0
1
1
5
7
8
14
10
9
9
4
3
0
0
1
3
4
7
7
11
10
5
5
3
0
0
2
2
14
4
9
9
12
9
4
1
0
0
0
3
7
5
2
7
9
7
3
1
0
0
0
2
3
4
7
9
7
6
3
1
Region of residencea
Northeast
Midwest
South
West
40
5
26
8
21
2
24
7
25
5
17
9
13
3
18
5
19
3
14
2
14
1
16
6
26
11
25
11
25
3
35
6
25
5
18
8
11
9
29
14
17
8
14
6
15
4
17
7
Total
79
55
56
39
38
37
74
69
55
63
45
43
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
3
23
63
106
123
189
267
307
221
125
77
0
2
18
42
97
104
145
251
260
193
122
81
0
2
15
42
73
124
142
184
195
181
103
86
0
1
18
56
75
88
118
147
186
145
100
74
0
2
12
48
68
95
100
129
149
137
98
83
0
2
17
41
76
91
89
131
140
154
112
87
0
5
21
65
104
153
182
216
195
134
65
33
0
5
16
56
98
112
144
176
170
129
69
38
0
3
25
55
55
86
128
150
154
104
45
29
0
3
23
51
78
95
106
122
124
92
59
33
0
1
12
49
82
106
93
103
113
92
54
37
0
2
21
46
66
103
97
101
123
84
64
29
Region of residencea
Northeast
Midwest
South
West
483
143
671
208
440
106
571
200
337
89
516
203
292
103
443
170
285
89
392
154
285
95
393
169
362
137
533
139
286
116
496
116
245
95
372
121
216
89
360
121
193
103
343
104
184
98
355
98
1,505
1,317
1,146
1,008
921
941
1,171
1,014
833
787
742
735
Total
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a Data are based on residence at time of stage 3 (AIDS) classification.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
HIV Surveillance Report
64
Vol. 29
Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
2
1
0
1
2
1
1
0
0
0
0
0
0
1
0
1
2
1
0
0
1
0
0
0
2
1
0
4
1
2
1
0
0
0
0
0
0
2
0
1
0
2
1
0
0
0
0
0
0
0
0
1
3
0
1
0
0
0
0
0
2
3
0
2
0
1
0
0
0
0
0
0
0
2
2
0
1
0
5
1
1
0
0
0
1
1
1
0
1
0
0
1
0
0
0
0
0
1
3
2
0
1
0
1
0
0
0
0
1
1
2
1
1
2
1
1
0
0
0
1
1
1
0
1
1
0
2
0
0
0
0
0
1
0
1
0
1
2
1
0
1
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1
2
1
3
0
0
0
2
4
0
0
1
4
6
0
1
0
0
5
0
0
0
0
4
0
0
1
0
7
0
1
4
3
3
0
0
0
2
4
0
0
0
3
5
0
0
2
5
4
0
0
2
1
5
0
0
0
2
5
0
Total
7
7
11
6
5
8
11
6
8
10
7
6
Asianb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
2
5
4
1
1
0
0
0
0
0
0
0
1
1
1
2
0
1
1
0
0
0
0
0
1
2
2
0
1
0
0
1
0
0
0
0
4
2
2
1
2
0
1
1
0
0
0
1
2
2
1
2
1
1
1
1
0
0
0
1
1
0
1
1
1
0
0
1
0
0
0
0
0
2
1
1
0
0
0
0
0
0
0
0
1
0
1
0
1
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
3
0
4
7
0
2
0
3
2
0
3
1
5
1
0
5
0
2
6
0
5
2
2
4
1
2
1
2
1
0
3
0
0
1
0
0
0
1
2
0
0
0
1
2
0
1
0
0
2
0
1
1
0
1
0
1
0
1
1
0
14
8
9
13
14
6
4
3
3
3
3
2
Total
HIV Surveillance Report
65
Vol. 29
Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
2
9
23
37
50
85
111
162
138
69
53
0
2
7
19
35
41
50
111
138
108
73
49
0
1
5
11
20
41
44
80
90
89
65
51
0
1
4
20
19
33
39
57
91
86
59
41
0
1
2
11
20
40
37
51
64
67
53
41
0
1
7
13
21
35
30
52
53
85
63
57
0
2
12
25
46
70
93
110
109
76
34
24
0
2
8
23
40
53
59
81
84
83
35
20
0
2
7
17
22
31
59
77
77
59
20
17
0
1
10
18
24
33
40
51
57
42
35
15
0
1
4
16
25
37
41
42
56
51
34
22
0
2
8
17
24
38
40
43
57
41
41
16
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
209
79
416
37
1
192
65
336
39
0
137
38
291
28
1
124
52
253
20
0
111
48
204
24
0
128
49
213
27
0
162
78
324
37
0
110
69
279
30
0
107
61
198
24
0
94
31
174
26
0
78
46
182
23
1
77
44
180
25
0
Total
741
633
495
450
388
417
601
488
390
325
329
325
Hispanic/Latinoc
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
5
21
52
58
66
94
78
46
29
19
0
1
10
18
42
46
55
82
66
49
25
14
0
0
2
16
27
60
49
57
62
51
16
14
0
0
8
14
32
41
42
43
43
33
19
17
0
0
6
15
29
37
31
40
40
37
25
25
0
1
3
12
29
30
26
40
46
34
26
15
0
0
5
12
20
27
35
43
30
21
14
3
0
2
6
14
20
24
29
43
28
16
13
8
0
1
5
13
21
20
24
26
29
20
6
4
0
0
6
7
15
20
19
23
17
10
9
8
0
0
3
6
13
24
15
23
16
11
6
9
0
1
2
8
10
15
17
16
17
7
9
6
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
181
18
109
67
93
166
15
83
65
77
123
12
85
65
68
100
20
68
61
45
97
11
76
55
47
94
12
65
63
27
96
12
44
32
25
96
6
48
24
30
66
6
41
27
28
67
6
38
16
8
52
8
32
25
9
51
6
30
17
4
Total
469
406
353
293
285
261
210
203
169
135
126
109
HIV Surveillance Report
66
Vol. 29
Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total
0
1
0
1
2
0
0
0
0
0
0
0
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
9
17
18
21
43
63
63
31
17
7
0
0
2
8
24
25
31
59
58
44
21
13
0
1
7
12
21
32
46
53
45
36
19
17
0
0
5
18
22
17
37
46
51
25
20
11
0
0
5
18
20
18
34
38
45
31
17
12
0
0
5
11
24
29
27
37
42
31
23
11
0
1
2
21
32
44
45
52
51
30
15
4
0
0
1
16
31
30
42
55
53
24
16
7
0
0
11
23
14
28
41
38
41
23
13
5
0
2
6
23
26
40
37
40
37
29
11
8
0
0
4
24
36
42
34
32
32
23
11
5
0
0
10
18
29
44
33
34
41
30
11
5
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
50
39
115
85
0
58
23
122
81
1
49
33
115
93
0
50
27
103
72
1
52
26
96
66
0
47
31
97
65
0
74
32
136
55
0
54
37
132
51
0
47
23
111
55
0
43
41
114
60
0
45
39
114
45
0
41
44
125
43
0
Total
289
284
290
252
238
239
297
274
236
259
242
254
HIV Surveillance Report
67
Vol. 29
Table 11b. Stage 3 (AIDS) attributed to injection drug use, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
2
6
2
7
14
16
15
10
4
0
0
0
0
2
2
14
8
12
3
7
7
0
0
1
2
6
5
3
6
9
14
6
5
0
0
0
4
1
1
3
9
6
6
4
4
0
0
0
2
1
2
1
4
8
6
6
8
0
0
2
2
0
2
6
5
6
8
3
5
0
1
2
7
7
10
13
17
8
5
2
1
0
1
1
5
7
8
14
10
9
9
4
3
0
0
1
3
4
7
7
11
10
5
5
3
0
0
2
2
14
4
9
9
12
9
4
1
0
0
0
3
7
5
2
7
9
7
3
1
0
0
0
2
3
4
7
9
7
6
3
1
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
40
5
26
8
0
21
2
24
7
0
25
5
17
9
0
13
3
18
5
0
19
3
14
2
0
14
1
16
6
0
26
11
25
11
0
25
3
35
6
0
25
5
18
8
0
11
9
29
14
0
17
8
14
6
0
15
4
17
7
0
Total
79
55
56
39
38
37
74
69
55
63
45
43
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
3
24
65
116
136
207
286
321
232
125
84
0
2
20
46
105
116
152
265
274
205
125
83
0
2
15
43
76
139
148
198
209
192
106
87
0
1
18
57
79
95
123
156
195
152
103
75
0
2
13
48
72
100
106
137
159
144
102
87
0
2
17
41
77
96
91
134
148
158
115
88
0
5
21
65
107
156
186
223
198
137
67
33
0
5
16
58
98
116
146
189
175
132
70
38
0
3
25
56
62
89
133
154
158
108
45
29
0
3
23
51
79
98
106
123
125
92
60
34
0
1
12
50
83
109
94
106
113
93
54
37
0
2
21
46
67
103
98
102
123
85
64
29
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
483
143
671
208
94
440
106
571
200
77
337
89
516
203
69
292
103
443
170
46
285
89
392
154
49
285
95
393
169
27
362
137
533
139
25
286
116
496
116
30
245
95
372
121
29
216
89
360
121
8
193
103
343
104
10
184
98
355
98
5
1,599
1,394
1,214
1,054
969
968
1,196
1,044
861
795
752
740
Total
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
a Data are based on residence at time of stage 3 (AIDS) classification.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
HIV Surveillance Report
68
Vol. 29
Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
2
0
0
1
0
2
1
1
0
0
0
1
2
3
0
3
1
0
1
0
0
0
0
0
1
0
1
0
0
1
0
0
0
0
0
1
2
0
0
1
1
0
0
0
0
0
0
0
1
2
0
1
0
0
0
1
0
0
0
0
0
1
0
2
1
0
0
0
0
0
1
0
3
2
1
2
0
2
1
1
0
0
0
2
3
0
1
1
3
2
0
3
0
0
0
1
2
1
2
0
4
1
2
0
0
0
1
5
2
4
3
3
4
4
1
0
0
0
0
1
2
5
5
1
1
2
0
0
0
0
0
0
1
1
1
3
4
1
1
1
Region of residencea
Northeast
Midwest
South
West
1
1
1
4
1
6
1
4
1
0
0
3
0
0
1
4
0
1
1
4
0
1
1
2
1
2
1
8
0
4
4
6
1
2
2
8
0
4
16
5
1
6
4
6
0
0
3
9
Total
7
11
4
5
6
4
12
13
13
26
17
13
Asianb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
3
2
8
4
7
2
6
0
0
0
0
4
3
5
6
5
5
2
2
0
0
0
0
2
4
4
5
4
5
1
0
1
0
0
0
2
2
4
5
1
2
2
0
1
0
0
0
1
1
8
2
6
4
3
1
3
0
0
0
2
3
4
1
6
1
3
2
2
0
2
3
6
9
12
11
5
4
0
3
0
0
1
0
5
6
14
8
6
1
2
2
3
0
0
6
8
5
12
5
7
4
6
2
1
0
0
2
3
7
10
8
8
1
5
3
4
0
0
2
3
9
20
7
4
3
5
3
2
0
0
3
7
8
8
6
6
7
4
2
3
Region of residencea
Northeast
Midwest
South
West
13
6
5
7
7
3
9
14
3
6
10
9
6
6
3
6
6
6
10
6
5
4
10
6
12
8
11
24
11
9
11
16
7
7
16
25
8
9
14
17
16
9
12
19
9
7
16
22
Total
32
32
27
21
28
24
54
47
54
49
56
54
HIV Surveillance Report
69
Vol. 29
Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
8
48
92
158
207
286
344
285
164
108
117
0
8
44
105
160
176
237
260
246
176
119
108
2
3
33
80
124
162
194
230
224
161
91
105
0
2
31
72
121
129
191
202
191
179
92
89
0
11
37
89
122
148
175
184
195
161
107
107
0
2
33
81
111
142
138
170
169
153
103
98
2
39
154
308
482
496
508
465
378
246
152
101
0
35
154
304
392
420
450
461
349
253
129
88
1
19
109
238
340
376
374
349
298
209
130
105
2
18
109
241
329
355
338
342
273
190
119
115
0
18
108
215
266
359
320
284
253
192
130
90
0
15
95
193
271
333
318
316
248
214
141
112
Region of residencea
Northeast
Midwest
South
West
341
151
1,273
52
292
150
1,142
56
275
110
976
46
242
115
888
54
226
129
920
61
208
105
848
40
584
329
2,264
154
509
288
2,122
115
446
287
1,703
110
396
235
1,663
139
329
263
1,512
130
363
270
1,527
93
Total
1,817
1,640
1,408
1,299
1,336
1,201
3,330
3,034
2,546
2,432
2,234
2,253
Hispanic/Latinoc
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
10
26
69
68
73
76
57
41
21
29
0
0
14
41
79
76
66
66
63
38
22
28
0
0
8
37
46
61
65
59
45
35
21
22
0
0
9
28
62
49
63
55
59
35
22
25
0
0
16
38
48
57
49
67
46
31
21
17
0
2
7
17
49
50
51
43
33
21
25
18
0
2
32
67
84
95
100
92
76
55
34
28
0
8
35
56
89
101
96
89
86
35
32
27
1
6
15
45
77
96
86
77
52
48
24
17
0
1
22
48
59
86
79
77
66
35
29
18
1
6
30
50
74
81
72
60
75
55
22
35
1
2
19
51
66
75
67
66
57
43
29
20
Region of residencea
Northeast
Midwest
South
West
154
32
224
62
138
27
245
82
114
18
203
63
104
28
215
59
97
26
209
58
76
15
170
56
230
42
281
113
234
35
276
109
183
32
227
103
152
27
234
106
192
33
219
117
153
35
211
97
Total
472
492
398
406
390
317
665
653
544
519
560
495
HIV Surveillance Report
70
Vol. 29
Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
1
0
1
1
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
1
0
0
1
1
0
0
0
0
0
1
0
0
0
0
2
2
0
0
0
0
0
0
0
1
0
0
0
0
1
1
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
1
1
0
0
1
0
0
0
0
0
0
1
4
1
0
0
0
1
0
0
Region of residencea
Northeast
Midwest
South
West
0
0
0
1
0
0
0
1
0
0
1
1
0
0
0
3
0
1
1
0
1
0
1
0
0
0
0
3
0
0
3
2
0
0
1
2
0
1
0
1
0
0
0
3
1
1
1
4
Total
1
1
2
4
2
2
3
5
3
2
3
7
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
6
15
22
24
45
50
58
34
22
18
0
0
5
14
17
27
44
46
47
39
26
34
0
0
3
15
20
20
34
43
53
31
25
22
0
0
1
18
16
19
26
40
39
33
28
24
0
0
4
16
22
18
33
34
46
33
24
36
0
0
5
13
13
22
33
28
41
38
20
31
0
5
13
37
78
74
101
96
70
64
30
15
0
2
22
40
59
67
82
90
74
58
44
17
0
2
16
40
58
69
73
64
67
60
16
23
0
0
14
39
53
63
65
73
84
58
27
27
0
2
18
36
43
69
55
68
64
62
31
25
0
4
16
41
59
67
57
64
67
58
33
24
Region of residencea
Northeast
Midwest
South
West
69
49
135
42
64
29
153
51
69
32
117
48
52
33
120
39
52
30
144
40
45
34
121
43
101
102
295
84
89
91
292
84
74
82
263
70
61
81
278
83
67
79
247
81
74
78
272
67
Total
295
297
266
244
266
244
582
555
489
503
474
490
HIV Surveillance Report
71
Vol. 29
Table 12a. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
3
6
7
15
13
13
13
7
6
2
0
0
3
4
13
8
9
18
14
13
4
9
0
0
2
3
6
8
11
19
9
12
2
4
0
0
2
5
7
4
5
15
12
6
3
8
0
0
2
5
7
5
7
9
11
6
5
3
0
0
1
5
3
7
6
7
7
4
2
3
0
4
13
26
39
35
29
32
15
12
9
8
0
5
27
16
20
39
36
30
25
23
13
9
0
1
10
14
18
33
27
22
18
6
10
9
0
0
8
15
20
24
26
22
13
8
8
5
0
0
6
16
19
19
21
22
17
9
8
6
0
2
3
9
14
13
12
19
23
10
4
7
Region of residencea
Northeast
Midwest
South
West
28
11
44
2
31
7
52
4
23
10
39
5
23
5
35
5
17
6
30
7
16
2
20
7
63
25
112
22
64
16
142
21
45
21
91
12
38
16
80
15
34
17
73
17
34
15
50
17
Total
86
93
76
68
60
45
221
242
169
149
141
115
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
12
68
138
261
317
425
487
420
249
164
167
0
8
66
169
274
294
361
397
376
268
174
180
2
3
46
137
201
254
312
355
336
241
138
155
0
2
44
126
210
206
291
315
306
255
145
147
0
11
59
148
202
239
266
303
302
234
157
167
0
4
47
118
180
226
229
257
252
220
151
153
2
51
216
444
695
713
750
693
544
378
230
152
0
52
239
423
567
641
671
679
539
372
219
147
2
28
155
346
500
588
567
519
443
330
185
156
2
19
156
352
470
544
518
525
440
300
186
168
1
25
163
321
414
553
480
439
414
325
193
158
1
23
136
302
422
498
460
474
406
330
209
168
Region of residencea
Northeast
Midwest
South
West
606
250
1,682
170
533
222
1,601
211
484
176
1,346
176
427
187
1,262
170
398
199
1,316
175
351
161
1,172
154
990
508
2,963
407
906
442
2,848
353
755
431
2,302
330
655
374
2,284
367
638
406
2,067
373
633
406
2,080
309
Total
2,709
2,567
2,181
2,046
2,089
1,837
4,867
4,549
3,818
3,680
3,485
3,428
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk
for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.
a Data are based on residence at time of stage 3 (AIDS) classification.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
HIV Surveillance Report
72
Vol. 29
Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
2
0
0
1
0
2
1
1
0
0
0
1
2
3
0
3
1
0
1
0
0
0
0
0
1
0
1
0
0
1
0
0
0
0
0
1
2
0
0
1
1
0
0
0
0
0
0
0
1
2
0
1
0
0
0
1
0
0
0
0
0
1
0
2
1
0
0
0
0
0
1
0
3
2
1
2
0
2
1
1
0
0
0
2
3
0
1
1
3
2
0
3
0
0
0
1
2
1
2
0
4
1
2
0
0
0
1
5
2
4
3
3
4
4
1
0
0
0
0
1
2
5
5
1
1
2
0
0
0
0
0
0
1
1
1
3
4
1
1
1
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
1
1
1
4
0
1
6
1
4
0
1
0
0
3
0
0
0
1
4
0
0
1
1
4
0
0
1
1
2
0
1
2
1
8
0
0
4
4
6
0
1
2
2
8
0
0
4
16
5
0
1
6
4
6
0
0
0
3
9
0
Total
7
11
4
5
6
4
12
13
13
26
17
13
Asianb
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
3
2
8
4
7
2
6
0
0
0
0
4
3
5
6
5
5
2
2
0
0
0
0
2
4
4
5
4
5
1
0
1
0
0
0
2
2
4
5
1
2
2
0
1
0
0
0
1
1
8
2
6
4
3
1
3
0
0
0
2
3
4
1
6
1
3
2
2
0
2
3
6
9
12
11
5
4
0
3
0
0
1
0
5
6
14
8
6
1
2
2
3
0
0
6
8
5
12
5
7
4
6
2
1
0
0
2
3
7
10
8
8
1
5
3
4
0
0
2
3
9
20
7
4
3
5
3
2
0
0
3
7
8
8
6
6
7
4
2
3
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
13
6
5
7
0
7
3
9
14
0
3
6
10
9
0
6
6
3
6
0
6
6
10
6
0
5
4
10
6
0
12
8
11
24
0
11
9
11
16
0
7
7
16
25
0
8
9
14
17
0
16
9
12
19
0
9
7
16
22
0
Total
32
32
27
21
28
24
54
47
54
49
56
54
HIV Surveillance Report
73
Vol. 29
Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Black/African American
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
8
48
92
158
207
287
344
285
164
108
119
0
8
44
105
160
176
237
260
246
177
120
108
2
3
33
80
124
162
194
230
226
161
91
105
0
2
31
73
121
130
192
202
191
179
92
89
0
11
37
89
122
148
175
185
195
161
107
107
0
2
33
81
111
142
138
170
169
153
103
98
2
39
154
308
483
497
508
465
378
246
152
101
0
35
154
304
392
420
450
463
349
254
129
88
1
19
109
238
340
376
374
349
299
209
131
105
2
18
109
242
329
355
338
343
273
190
119
116
0
18
108
215
266
359
320
284
253
193
130
90
0
15
95
193
271
333
319
317
248
214
141
112
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
341
151
1,273
52
3
292
150
1,142
56
2
275
110
976
46
3
242
115
888
54
2
226
129
920
61
2
208
105
848
40
0
584
329
2,264
154
2
509
288
2,122
115
3
446
287
1,703
110
2
396
235
1,663
139
3
329
263
1,512
130
1
363
270
1,527
93
3
Total
1,820
1,642
1,411
1,301
1,338
1,201
3,332
3,037
2,548
2,435
2,235
2,256
Hispanic/Latinoc
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
11
28
73
77
84
91
68
48
27
36
0
0
15
42
83
82
76
78
77
53
33
38
0
0
8
41
48
69
76
71
51
44
31
28
0
0
11
28
63
54
69
65
70
37
24
31
0
0
16
41
52
62
55
79
54
38
25
29
0
2
12
17
53
54
57
46
38
22
30
25
0
2
35
73
95
105
116
109
93
65
44
38
0
10
36
58
99
113
112
105
101
48
36
33
1
8
16
48
90
105
102
83
61
58
26
22
0
1
23
48
65
91
87
86
73
40
29
24
1
6
31
52
74
89
76
68
81
62
26
36
1
3
21
53
70
80
73
74
66
48
29
25
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
154
32
224
62
73
138
27
245
82
84
114
18
203
63
68
104
28
215
59
45
97
26
209
58
60
76
15
170
56
40
230
42
281
113
110
234
35
276
109
97
183
32
227
103
76
152
27
234
106
47
192
33
219
117
41
153
35
211
97
47
Total
545
576
466
451
450
357
775
751
620
566
601
542
HIV Surveillance Report
74
Vol. 29
Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Native Hawaiian/Other Pacific Islander
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
1
0
1
2
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
1
0
0
1
1
0
0
0
0
0
1
0
0
0
0
2
2
0
0
0
0
0
0
0
1
0
0
0
0
1
1
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
1
1
1
0
1
0
0
0
0
0
0
1
4
1
0
0
0
1
0
0
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
0
0
0
1
0
0
0
0
1
0
0
0
1
1
0
0
0
0
3
0
0
1
1
0
0
1
0
1
0
0
0
0
0
3
0
0
0
3
2
0
0
0
1
2
0
0
1
0
1
0
0
0
0
3
1
1
1
1
4
0
Total
1
1
2
4
2
2
3
5
3
2
4
7
White
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
6
15
22
24
45
50
58
34
22
18
0
0
5
14
17
27
44
46
47
39
26
34
0
0
3
15
20
20
34
43
53
31
25
22
0
0
1
18
16
19
26
40
40
33
28
24
0
0
4
16
22
18
33
34
46
33
24
36
0
0
5
13
13
22
33
28
41
38
20
31
0
5
13
37
78
74
101
96
70
64
30
15
0
2
22
40
59
67
82
90
74
58
44
17
0
2
16
40
58
70
73
64
67
60
16
23
0
0
14
39
53
63
65
73
84
58
27
27
0
2
18
36
43
69
55
68
64
62
31
25
0
4
16
41
59
67
57
65
67
58
33
24
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
69
49
135
42
0
64
29
153
51
0
69
32
117
48
0
52
33
120
39
1
52
30
144
40
0
45
34
121
43
0
101
102
295
84
0
89
91
292
84
0
74
82
263
70
1
61
81
278
83
0
67
79
247
81
0
74
78
272
67
1
Total
295
297
266
245
266
244
582
555
490
503
474
491
HIV Surveillance Report
75
Vol. 29
Table 12b. Stage 3 (AIDS) attributed to heterosexual contact, by selected characteristics, 2012–2017—United States and 6 dependent areas (cont)
Male
Female
2012
2013
2014
2015
2016
2017
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
No.
Multiple races
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
1
3
6
7
15
13
13
13
7
6
2
0
0
3
4
13
8
9
18
14
13
4
9
0
0
2
3
6
8
11
19
9
12
2
4
0
0
2
5
7
4
5
15
12
6
3
8
0
0
2
5
7
5
7
9
11
6
5
3
0
0
1
5
3
7
6
7
7
4
2
3
0
4
13
26
39
35
29
32
15
12
9
8
0
5
27
16
20
39
36
30
25
23
13
9
0
1
10
14
18
33
27
22
18
6
10
9
0
0
8
15
20
24
26
22
13
8
8
5
0
0
6
16
19
19
21
22
17
9
8
6
0
2
3
9
14
13
12
19
23
10
4
7
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
28
11
44
2
0
31
7
52
4
0
23
10
39
5
0
23
5
35
5
0
17
6
30
7
0
16
2
20
7
0
63
25
112
22
0
64
16
142
21
0
45
21
91
12
0
38
16
80
15
0
34
17
73
17
0
34
15
50
17
0
Total
86
93
76
68
60
45
221
242
169
149
141
115
Total
Age at diagnosis (yr)
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
0
12
69
140
265
326
437
503
431
256
170
175
0
8
67
170
278
300
372
409
390
284
185
190
2
3
46
141
203
262
323
367
345
250
148
161
0
2
46
127
211
212
297
325
318
257
147
153
0
11
59
151
206
245
272
315
310
241
162
179
0
4
52
118
184
230
235
260
257
221
156
160
2
51
219
450
707
724
766
710
561
388
240
162
0
54
240
425
577
653
688
697
554
386
223
153
2
30
156
349
513
597
583
525
453
340
188
161
2
19
157
353
476
549
526
535
447
305
186
175
1
25
164
323
414
561
485
447
420
333
197
159
1
24
138
304
426
503
467
484
415
335
209
173
Region of residencea
Northeast
Midwest
South
West
U.S. dependent areas
606
250
1,682
170
76
533
222
1,601
211
87
484
176
1,346
176
71
427
187
1,262
170
48
398
199
1,316
175
62
351
161
1,172
154
40
990
508
2,963
407
112
906
442
2,848
353
100
755
431
2,302
330
78
655
374
2,284
367
50
638
406
2,067
373
43
633
406
2,080
309
50
Total
2,785
2,653
2,252
2,095
2,150
1,877
4,979
4,650
3,896
3,729
3,528
3,478
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as heterosexual contact are persons who have ever had heterosexual contact with a person known to have, or to be at high risk
for, HIV infection (e.g., a person who injects drugs). The heterosexual contact category excludes men who have ever had sexual contact with both men and women.
a Data are based on residence at time of stage 3 (AIDS) classification.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
HIV Surveillance Report
76
Vol. 29
HIV Surveillance Report
Table 13a. Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States
2012
Race/ethnicity
2013
a
2014
a
2015
No.
Rate
No.
Rate
No.
Rate
0
0.0
0
0.0
3
14
0.6
16
0.6
167
2.3
120
16
0.1
10
0
0.0
White
32
Multiple races
American Indian/Alaska Native
Asian
Black/African American
Hispanic/Latinob
Native Hawaiian/Other Pacific Islander
Total
a
2016
a
2017
a
Rate
No.
Rate
No.
0.7
2
0.4
0
0.0
0
0.0
10
0.4
10
0.4
10
0.4
3
0.1
1.7
111
1.5
88
1.2
81
1.1
60
0.8
0.1
18
0.1
13
0.1
18
0.1
19
0.1
0
0.0
1
1.0
0
0.0
0
0.0
1
0.9
0.1
24
0.1
29
0.1
19
0.1
17
0.1
10
0.0
12
0.6
14
0.6
8
0.4
8
0.3
4
0.2
6
0.3
241
0.5
184
0.3
180
0.3
140
0.3
130
0.2
99
0.2
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when
assessing trends.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population.
b Hispanics/Latinos can be of any race.
77
Table 13b. Diagnoses of HIV infection among children aged <13 years, by race/ethnicity, 2012–2017—United States and
6 dependent areas
Race/ethnicity
American Indian/Alaska Native
Asian
2012
2013
2014
2015
2016
2017
No.
No.
No.
No.
No.
No.
0
0
3
2
0
0
14
16
10
10
10
3
167
120
111
88
81
60
16
10
18
13
18
19
0
0
1
0
0
1
White
32
24
29
19
17
10
Multiple races
12
14
8
8
4
6
241
184
180
140
130
99
Black/African American
Hispanic/Latinoa
Native Hawaiian/Other Pacific Islander
Total
Ratea
No.
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not
be used when assessing trends.
Vol. 29
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
a
Hispanics/Latinos can be of any race.
HIV Surveillance Report
Table 14a. Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States
2012
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/Other Pacific Islander
White
Multiple races
Totale
2013
2014
2015
2016
Cumulativea
2017
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
0
1
9
1
0
1
0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0
0
5
2
0
0
2
0.0
0.0
0.1
0.0
0.0
0.0
0.1
1
0
48
13
0
6
2
0.2
0.0
0.7
0.1
0.0
0.0
0.1
0
2
28
5
0
3
1
0.0
0.1
0.4
0.0
0.0
0.0
0.0
1
1
26
2
0
5
4
0.2
0.0
0.4
0.0
0.0
0.0
0.2
2
0
23
6
1
0
1
0.4
0.0
0.3
0.0
0.9
0.0
0.0
29
51
5,635
2,031
6
1,521
299
12
0.0
9
0.0
70
0.1
39
0.1
39
0.1
33
0.1
9,573
No.
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).
a
From the beginning of the epidemic through 2017.
b
Rates are per 100,000 population.
c
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d
Hispanics/Latinos can be of any race.
e
Cumulative total includes persons whose race/ethnicity is unknown.
78
Table 14b. Stage 3 (AIDS) among children aged <13 years, by race/ethnicity, 2012–2017 and cumulative—United States and 6 dependent areas
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/Other Pacific Islander
White
Multiple races
Totald
2012
2013
2014
2015
2016
2017
Cumulativea
No.
No.
No.
No.
No.
No.
No.
0
1
9
1
0
1
0
0
0
5
2
0
0
2
1
0
48
13
0
6
2
0
2
28
5
0
3
1
1
1
27
2
0
5
4
2
0
23
6
1
0
1
29
52
5,647
2,445
7
1,521
300
12
9
70
39
40
33
10,002
Vol. 29
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see Technical Notes).
a
From the beginning of the epidemic through 2017.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c
Hispanics/Latinos can be of any race.
d
Cumulative total includes persons whose race/ethnicity is unknown.
Table 15. Stage 3 (AIDS) among children aged <13 years, by year of
diagnosis, 1992–2017—United States and 6 dependent areas
United States
United States and
dependent areas
Year of diagnosis
No.
No.
1992
901
950
1993
885
923
1994
813
839
1995
671
693
1996
516
530
1997
336
348
1998
249
256
1999
201
206
2000
133
135
2001
128
129
2002
108
115
2003
75
77
2004
58
60
2005
55
55
2006
40
43
2007
35
36
2008
39
40
2009
16
17
2010
23
23
2011
18
19
2012
12
12
2013
9
9
2014
70
70
2015
39
39
2016
39
40
2017
33
33
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month
reporting delay. Data for the year 2017 should not be used when assessing trends.
Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
The criteria for stage 3 (AIDS) classification among pediatric cases were expanded in 2014 (see
Technical Notes).
HIV Surveillance Report
79
Vol. 29
Table 16. Diagnoses of HIV infection among adult and adolescent Hispanics/Latinos, by transmission category and place of birth,
2017—United States and 6 dependent areas
Central
America
Transmission categorya
Cuba
Mexico
Puerto Rico
South America
United States
Total
%
No.
%
No.
%
No.
%
No.b
%
880
86.6
372
66.7
619
92.7
2,432
86.9
7,436
85.6
1.0
25
2.5
62
11.2
4
0.6
123
4.4
360
4.1
1
0.4
28
2.7
17
3.1
7
1.1
123
4.4
286
3.3
11.3
32
10.8
82
8.1
104
18.6
38
5.7
120
4.3
597
6.9
0.0
0
0.0
1
0.1
3
0.4
0
0.0
2
0.1
7
0.1
No.
%
No.
%
390
83.6
258
87.7
Injection drug use
11
2.4
3
Male-to-male sexual contact
and injection drug use
13
2.7
Heterosexual contactc
53
0
No.
Male adult or adolescent
Male-to-male sexual contact
Otherd
Subtotal
466
100
294
100
1,016 100
557
100
668
100
2,800 100
8,686 100
Female adult or adolescent
Injection drug use
Heterosexual contactc
Otherd
Subtotal
Total
3
3.0
1
2.1
3
2.9
16
11.4
2
2.8
68
20.0
141
11.7
96
96.8
37
97.9
91
97.0
121
87.8
56
96.4
271
79.8
1,058
88.0
0
0.2
0
0.0
0
0.1
1
0.9
1
0.9
1
0.2
4
0.3
99
100
38
100
94 100
138
100
58
100
340 100
1,203 100
565
100
332
100
1,110 100
695
100
726
100
3,140 100
9,889 100
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.
a
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
b Total include persons whose place of birth is not among those listed and persons whose place of birth is unknown.
c
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
d
Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
HIV Surveillance Report
80
Vol. 29
Table 17. Stage 3 (AIDS) among adult and adolescent Hispanics/Latinos, by transmission category and place of birth, 2017—
United States and 6 dependent areas
Central
America
Transmission categorya
Cuba
Mexico
Puerto Rico
South America
United States
Total
%
No.b
%
905
75.2
2,564
76.0
1.8
99
8.2
261
7.7
3
1.9
97
8.1
178
5.3
19.0
16
9.5
93
7.7
357
10.6
0.5
0
0.0
10
0.8
15
0.4
No.
%
No.
%
No.
%
No.
%
No.
%
167
76.3
78
78.3
405
78.9
116
48.7
150
86.8
12
5.6
2
2.4
24
4.6
59
24.6
3
5
2.1
2
2.1
20
4.0
17
7.3
35
16.0
17
17.2
64
12.4
45
0
0.0
0
0.0
1
0.1
1
No.
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact
and injection drug use
Heterosexual contactc
Otherd
Subtotal
219
100
100
100
513
100
238
100
173
100
1,204 100
3,375 100
Female adult or adolescent
Injection drug use
Heterosexual contactc
Otherd
Subtotal
Total
2
2.8
1
8.6
4
6.3
16
17.1
0
2.1
60
24.1
109
16.2
62
95.5
13
91.4
52
93.8
73
79.7
19
97.4
177
70.5
542
80.5
1
1.7
0
0.0
0
0.0
3
3.3
0
0.5
14
5.4
22
3.3
65
100
14
100
56
100
92
100
19
100
251 100
673 100
284
100
114
100
569
100
330
100
192
100
1,455 100
4,048 100
Note. Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12, and percentages based on these numbers, should be interpreted with caution.
a
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
b Totals include persons whose place of birth is not among those listed and persons whose place of birth is unknown.
c
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
d
Includes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified.
HIV Surveillance Report
81
Vol. 29
HIV Surveillance Report
Table 18a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States
2012
2013
82
No.
Ratea
Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
4
2
23
171
414
695
954
1,627
2,634
3,123
2,666
1,864
2,006
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/Other Pacific Islander
White
Multiple races
2014
No.
Ratea
0.0
0.0
0.1
0.8
1.9
3.3
4.9
7.7
12.1
13.8
12.8
10.5
4.6
1
1
9
171
423
629
853
1,470
2,443
3,083
2,732
1,952
2,250
54
72
7,635
2,471
7
5,080
843
2.3
0.5
19.7
4.7
1.3
2.6
14.0
6,363
2,527
1,281
1,642
39
76
11,929
2015
No.
Ratea
0.0
0.0
0.0
0.7
2.0
3.0
4.3
7.0
11.5
13.7
12.9
10.8
5.0
1
3
13
171
365
642
888
1,363
2,208
2,988
2,919
2,222
2,462
64
75
7,454
2,558
10
4,922
930
2.7
0.5
19.0
4.7
1.9
2.5
15.0
—
—
—
6,467
2,407
1,329
—
—
—
9.4
1,625
37
77
11,943
2016
No.
Ratea
No.
Ratea
0.0
0.0
0.1
0.7
1.7
3.0
4.5
6.6
10.6
13.3
13.6
12.0
5.3
4
0
11
150
400
594
821
1,239
2,011
2,976
2,866
2,167
2,731
0.0
0.0
0.1
0.7
1.8
2.7
4.0
6.1
9.7
13.3
13.2
11.4
5.7
1
1
10
146
427
614
777
1,071
1,694
2,679
2,816
2,298
2,894
0.0
0.0
0.0
0.7
1.9
2.8
3.7
5.4
8.1
12.3
12.8
11.8
5.9
61
63
7,416
2,667
8
5,078
948
2.6
0.4
18.8
4.8
1.5
2.6
14.9
62
81
7,222
2,508
6
5,100
985
2.6
0.5
18.1
4.4
1.1
2.6
15.0
46
95
6,795
2,497
12
5,038
944
1.9
0.5
16.9
4.3
2.1
2.5
14.0
—
—
—
6,577
2,451
1,332
—
—
—
6,653
2,311
1,383
—
—
—
6,506
2,133
1,299
—
—
—
—
—
—
9.3
1,584
32
63
12,039
—
—
—
9.3
1,595
29
79
12,051
—
—
—
9.2
1,591
36
59
11,624
—
—
—
8.8
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
Vol. 29
HIV Surveillance Report
Table 18a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States (cont)
2012
No.
Female adult or adolescent
Injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
Child (<13 yrs at death)
Perinatal
Otherf
Subtotal
83
Region of residenceg
Northeast
Midwest
South
West
Totalh
2013
Ratea
No.
2014
Ratea
No.
2015
Ratea
No.
2016
Ratea
Ratea
1,499
2,676
41
34
4,250
—
—
—
—
3.2
1,504
2,509
33
27
4,073
—
—
—
—
3.0
1,459
2,682
32
33
4,205
—
—
—
—
3.1
1,357
2,484
47
28
3,915
—
—
—
—
2.9
1,322
2,409
45
26
3,803
—
—
—
—
2.7
3
1
4
—
—
0.0
1
0
1
—
—
0.0
1
0
1
—
—
0.0
2
2
4
—
—
0.0
0
1
1
—
—
0.0
3,856
1,909
7,933
2,485
6.9
2.8
6.8
3.4
3,893
1,788
7,784
2,552
6.9
2.6
6.6
3.4
3,779
1,840
8,032
2,594
6.7
2.7
6.7
3.5
3,625
1,818
7,924
2,603
6.4
2.7
6.5
3.4
3,630
1,720
7,474
2,604
6.4
2.5
6.1
3.4
16,183
5.2
16,017
5.1
16,245
5.1
15,970
5.0
15,428
4.8
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c
No.
Hispanics/Latinos can be of any race.
d
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g
Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
h
Includes persons whose race/ethnicity is unknown.
Vol. 29
HIV Surveillance Report
Table 18b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States and
6 dependent areas
2012
2013
84
No.
Ratea
Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
4
2
24
175
427
725
999
1,675
2,714
3,205
2,721
1,909
2,070
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/Other Pacific Islander
White
Multiple races
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
2014
2015
2016
No.
Ratea
No.
Ratea
0.0
0.0
0.1
0.7
1.7
3.0
4.5
6.7
10.8
13.5
13.8
12.2
5.4
4
0
11
152
405
616
841
1,276
2,065
3,073
2,933
2,214
2,789
0.0
0.0
0.1
0.7
1.8
2.8
4.1
6.2
9.8
13.6
13.3
11.5
5.8
1
1
11
150
433
623
801
1,101
1,742
2,737
2,886
2,349
2,972
0.0
0.0
0.1
0.7
1.9
2.8
3.8
5.5
8.2
12.4
13.0
11.9
5.9
61
65
7,425
3,129
8
5,078
948
—
—
—
—
—
—
—
62
82
7,228
2,907
7
5,101
986
—
—
—
—
—
—
—
46
95
6,804
2,863
14
5,039
945
—
—
—
—
—
—
—
—
—
—
6,664
2,595
1,358
—
—
—
6,731
2,447
1,412
—
—
—
6,578
2,250
1,327
—
—
—
—
—
—
9.4
1,665
32
65
12,379
—
—
—
9.4
1,654
30
80
12,353
—
—
—
9.3
1,657
42
59
11,913
—
—
—
8.9
No.
Ratea
No.
Ratea
0.0
0.0
0.1
0.8
2.0
3.4
5.1
7.9
12.4
14.0
12.9
10.6
4.7
1
1
11
174
432
653
884
1,507
2,532
3,174
2,796
2,001
2,319
0.0
0.0
0.1
0.8
2.0
3.0
4.4
7.1
11.8
13.9
13.0
10.9
5.1
1
3
13
173
372
658
908
1,401
2,271
3,086
3,005
2,283
2,544
54
74
7,646
2,923
7
5,081
844
—
—
—
—
—
—
—
64
75
7,460
3,014
12
4,924
932
—
—
—
—
—
—
—
6,422
2,692
1,310
—
—
—
6,551
2,554
1,356
1,730
41
77
12,273
—
—
—
9.5
1,710
39
78
12,288
Vol. 29
HIV Surveillance Report
Table 18b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2012–2016—United States and
6 dependent areas (cont)
2012
No.
Female adult or adolescent
Injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
85
Totalh
Rate
No.
2014
Ratea
No.
2015
Ratea
No.
2016
Ratea
No.
Ratea
1,533
2,760
43
36
4,373
—
—
—
—
3.2
1,546
2,588
34
27
4,196
—
—
—
—
3.1
1,500
2,773
33
33
4,338
—
—
—
—
3.1
1,380
2,567
48
28
4,022
—
—
—
—
2.9
1,352
2,467
47
26
3,893
—
—
—
—
2.8
3
1
4
—
—
0.0
1
0
1
—
—
0.0
1
0
1
—
—
0.0
2
2
4
—
—
0.0
0
1
1
—
—
0.0
3,856
1,909
7,933
2,485
467
6.9
2.8
6.8
3.4
11.6
3,893
1,788
7,784
2,552
468
6.9
2.6
6.6
3.4
11.7
3,779
1,840
8,032
2,594
473
6.7
2.7
6.7
3.5
12.0
3,625
1,818
7,924
2,603
409
6.4
2.7
6.5
3.4
10.6
3,630
1,720
7,474
2,604
379
6.4
2.5
6.1
3.4
10.0
16,650
5.2
16,485
5.1
16,718
5.2
16,379
5.0
15,807
4.8
Child (<13 yrs at death)
Perinatal
Otherf
Subtotal
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
2013
a
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category
because of the lack of denominator data.
b
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
d
e
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
h
Includes persons whose race/ethnicity is unknown.
Vol. 29
HIV Surveillance Report
Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and
cumulative—United States
2012
2013
2014
2015
Cumulativea
2016
86
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
1
16
128
318
554
779
1,342
2,229
2,584
2,186
1,502
1,541
0.0
0.0
0.1
0.6
1.5
2.6
4.0
6.4
10.3
11.4
10.5
8.4
3.6
1
0
6
124
313
511
701
1,218
2,039
2,559
2,247
1,583
1,748
0.0
0.0
0.0
0.5
1.5
2.4
3.6
5.8
9.6
11.3
10.6
8.7
3.9
0
1
8
117
270
493
713
1,116
1,823
2,505
2,366
1,803
1,917
0.0
0.0
0.0
0.5
1.2
2.3
3.6
5.4
8.7
11.1
11.0
9.7
4.1
2
0
6
109
299
456
646
1,000
1,664
2,494
2,358
1,739
2,094
0.0
0.0
0.0
0.5
1.3
2.1
3.2
5.0
8.0
11.2
10.8
9.1
4.4
0
0
4
87
282
452
607
864
1,407
2,211
2,314
1,822
2,237
0.0
0.0
0.0
0.4
1.2
2.1
2.9
4.4
6.7
10.1
10.5
9.3
4.5
4,958
293
1,305
10,154
47,771
102,990
129,693
124,680
99,894
72,613
48,255
29,702
31,105
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/Other Pacific Islander
White
Multiple races
41
61
6,200
2,114
6
4,038
721
1.8
0.4
16.0
4.0
1.2
2.0
12.0
52
66
6,019
2,180
7
3,914
811
2.2
0.4
15.4
4.0
1.3
2.0
13.1
43
48
5,980
2,253
5
3,996
807
1.8
0.3
15.1
4.1
0.9
2.0
12.7
51
63
5,766
2,118
4
4,024
841
2.2
0.4
14.4
3.7
0.7
2.0
12.8
37
78
5,406
2,074
8
3,895
789
1.6
0.4
13.4
3.6
1.4
2.0
11.7
2,017
3,614
290,379
108,240
374
283,168
15,575
5,162
2,081
1,097
—
—
—
5,204
1,987
1,131
—
—
—
5,273
2,008
1,139
—
—
—
5,313
1,905
1,169
—
—
—
5,085
1,749
1,083
—
—
—
329,489
135,457
54,702
1,334
36
64
9,774
—
—
—
7.7
1,306
32
58
9,718
—
—
—
7.6
1,286
28
53
9,787
—
—
—
7.5
1,268
26
66
9,747
—
—
—
7.4
1,277
31
47
9,272
—
—
—
7.0
40,243
489
8,822
569,201
Transmission categorye
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactf
Perinatal
Otherg
Subtotal
Vol. 29
HIV Surveillance Report
Table 19a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and
cumulative—United States (cont)
2012
No.
Female adult or adolescent
Injection drug use
Heterosexual contactf
Perinatal
Otherg
Subtotal
Child (<13 yrs at death)
Perinatal
Otherg
Subtotal
87
Region of residenceh
Northeast
Midwest
South
West
Totali
2013
Rateb
No.
2014
Rateb
No.
2015
Rateb
No.
Rateb
No.
Rateb
No.
1,238
2,099
41
28
3,406
—
—
—
—
2.5
1,258
2,019
32
22
3,331
—
—
—
—
2.5
1,194
2,095
31
25
3,345
—
—
—
—
2.5
1,106
1,944
45
23
3,118
—
—
—
—
2.3
1,074
1,874
44
22
3,015
—
—
—
—
2.2
60,273
64,676
631
3,673
129,254
1
0
1
—
—
0.0
1
0
1
—
—
0.0
0
0
0
—
—
0.0
0
2
2
—
—
0.0
0
0
0
—
—
0.0
4,500
458
4,958
3,200
1,500
6,417
2,064
5.7
2.2
5.5
2.8
3,209
1,424
6,308
2,109
5.7
2.1
5.3
2.8
3,041
1,441
6,499
2,151
5.4
2.1
5.4
2.9
2,922
1,428
6,372
2,145
5.2
2.1
5.3
2.8
2,872
1,338
5,962
2,115
5.1
2.0
4.9
2.8
215,127
75,420
277,909
134,957
13,181
4.2
13,050
4.1
13,132
4.1
12,867
4.0
12,287
3.8
703,413
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a
From the beginning of the epidemic through 2016.
b Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
c
Cumulativea
2016
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d
Hispanics/Latinos can be of any race.
e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
g
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
h
Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
i Includes persons whose race/ethnicity is unknown.
Vol. 29
HIV Surveillance Report
Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and
cumulative—United States and 6 dependent areas
2012
2013
2014
2015
Cumulativea
2016
88
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Age at death (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
1
1
17
131
325
572
805
1,381
2,290
2,649
2,227
1,536
1,586
0.0
0.0
0.1
0.6
1.5
2.7
4.1
6.5
10.4
11.6
10.6
8.5
3.6
1
0
8
127
315
526
720
1,243
2,103
2,625
2,295
1,622
1,796
0.0
0.0
0.0
0.5
1.4
2.4
3.6
5.9
9.8
11.5
10.7
8.8
4.0
0
1
8
119
273
506
729
1,140
1,867
2,581
2,435
1,849
1,980
0.0
0.0
0.0
0.5
1.2
2.3
3.6
5.5
8.8
11.3
11.2
9.8
4.2
2
0
6
111
303
473
659
1,025
1,706
2,566
2,407
1,777
2,138
0.0
0.0
0.0
0.5
1.3
2.2
3.2
5.0
8.1
11.4
10.9
9.2
4.4
0
0
5
91
285
458
621
886
1,438
2,255
2,362
1,857
2,291
0.0
0.0
0.0
0.4
1.2
2.1
2.9
4.4
6.8
10.2
10.6
9.4
4.6
5,201
303
1,376
10,689
50,009
107,261
134,927
129,283
103,290
74,934
49,605
30,621
32,297
Race/ethnicity
American Indian/Alaska Native
Asianc
Black/African American
Hispanic/Latinod
Native Hawaiian/Other Pacific Islander
White
Multiple races
41
62
6,209
2,442
6
4,039
722
—
—
—
—
—
—
—
52
66
6,022
2,502
9
3,916
813
—
—
—
—
—
—
—
43
49
5,984
2,604
5
3,996
807
—
—
—
—
—
—
—
51
63
5,770
2,417
5
4,025
842
—
—
—
—
—
—
—
37
78
5,415
2,323
10
3,896
790
—
—
—
—
—
—
—
2,018
3,661
290,675
134,144
391
283,272
15,589
5,202
2,204
1,123
—
—
—
5,268
2,084
1,154
—
—
—
5,334
2,119
1,161
—
—
—
5,374
2,006
1,194
—
—
—
5,132
1,829
1,107
—
—
—
333,758
146,679
56,775
1,392
38
65
10,024
—
—
—
7.8
1,368
34
58
9,966
—
—
—
7.6
1,339
28
55
10,037
—
—
—
7.6
1,311
27
66
9,976
—
—
—
7.5
1,322
35
47
9,473
—
—
—
7.1
42,909
521
8,956
589,598
Transmission categorye
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contactf
Perinatal
Otherg
Subtotal
Vol. 29
HIV Surveillance Report
Table 19b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by year of death and selected characteristics, 2012–2016 and
cumulative—United States and 6 dependent areas (cont)
2012
No.
Female adult or adolescent
Injection drug use
Heterosexual contactf
Perinatal
Otherg
Subtotal
89
Totali
Rateb
No.
2014
Rateb
No.
2015
Rateb
No.
Cumulativea
2016
Rateb
No.
Rateb
No.
1,263
2,160
43
30
3,496
—
—
—
—
2.6
1,288
2,071
33
22
3,414
—
—
—
—
2.5
1,230
2,164
32
25
3,451
—
—
—
—
2.5
1,120
2,006
46
23
3,195
—
—
—
—
2.3
1,096
1,911
46
22
3,076
—
—
—
—
2.2
62,539
68,014
666
3,777
134,997
1
0
1
—
—
0.0
1
0
1
—
—
0.0
0
0
0
—
—
0.0
0
2
2
—
—
0.0
0
0
0
—
—
0.0
4,727
474
5,201
3,200
1,500
6,417
2,064
340
5.7
2.2
5.5
2.8
8.4
3,209
1,424
6,308
2,109
331
5.7
2.1
5.3
2.8
8.3
3,041
1,441
6,499
2,151
356
5.4
2.1
5.4
2.9
9.0
2,922
1,428
6,372
2,145
306
5.2
2.1
5.3
2.8
7.9
2,872
1,338
5,962
2,115
262
5.1
2.0
4.9
2.8
6.9
215,127
75,420
277,909
134,957
26,383
13,521
4.3
13,381
4.2
13,488
4.2
13,173
4.1
12,549
3.8
729,796
Child (<13 yrs at death)
Perinatal
Otherg
Subtotal
Region of residenceh
Northeast
Midwest
South
West
U.S. dependent areas
2013
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a From the beginning of the epidemic through 2016.
b
Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category
because of the lack of denominator data.
c
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanics/Latinos can be of any race.
e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
g
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
h Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
i
Includes persons whose race/ethnicity is unknown.
Vol. 29
HIV Surveillance Report
Table 20a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States
American Indian/
Alaska Native
Black/African
American
Asiana
No.
Rated
No.
Rated
<13
0
0.0
0
0.0
1
0.0
13–14
1
1.4
0
0.0
0
15–19
0
0.0
0
0.0
6
20–24
0
0.0
2
0.2
25–29
0
0.0
3
30–34
4
2.4
35–39
2
1.3
40–44
6
45–49
White
90
No.
Rated
0
0.0
0
0.0
0
0.0
0
0.0
0.0
0
0.0
0
0.0
0
0.0
0
0.2
1
0.0
0
0.0
3
0.0
0
82
2.5
30
0.6
0
0.0
23
0.2
0.2
241
7.4
76
1.6
0
0.0
86
8
0.5
322
11.5
103
2.3
0
0.0
7
0.5
371
13.9
155
3.6
2
4.6
4.3
10
0.7
513
20.6
166
4.2
1
6
4.1
14
1.1
681
26.2
301
8.4
50–54
9
5.7
14
1.2
1,060
39.5
484
55–59
6
3.9
10
1.0
1,213
46.8
470
60–64
7
5.4
3
0.3
1,083
50.8
65
5
1.9
24
1.1
1,222
21
—
58
—
Injection drug use
5
—
9
Male-to-male sexual contact
and injection drug use
6
—
3
Heterosexual contactf
5
—
Perinatal
1
Otherg
No.
No.
Totalc
Multiple races
Rated
No.
Rated
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
Rated
No.
Rated
No.
Rated
Age at death (yr)
1
0.0
0.0
1
0.0
0.0
10
0.0
9
1.5
146
0.7
0.7
21
4.3
427
1.9
146
1.2
31
7.9
614
2.8
189
1.6
51
15.0
777
3.7
2.7
302
2.7
73
26.0
1,071
5.4
4
11.2
566
4.3
122
47.3
1,694
8.1
15.5
1
2.9
928
6.4
183
76.4
2,679
12.3
18.5
2
6.3
940
6.1
175
78.0
2,816
12.8
310
16.0
2
8.0
763
5.4
130
72.1
2,298
11.8
27.8
401
10.1
0
0.0
1,092
2.9
149
41.1
2,894
5.9
2,001
—
1,008
—
9
—
3,031
—
378
—
6,506
—
—
1,053
—
470
—
0
—
454
—
142
—
2,133
—
—
402
—
222
—
0
—
558
—
108
—
1,299
—
13
—
1,060
—
206
—
0
—
242
—
65
—
1,591
—
—
0
—
21
—
7
—
0
—
5
—
2
—
36
—
0
—
1
—
20
—
7
—
0
—
28
—
3
—
59
—
38
4.0
83
1.2
4,557
29.2
1,921
8.6
9
3.9
4,318
5.1
697
32.8
11,624
8.8
Transmission categorye
Male adult or adolescent
Male-to-male sexual contact
Subtotal
Vol. 29
HIV Surveillance Report
Table 20a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States (cont)
American Indian/
Alaska Native
Black/African
American
Asiana
Rated
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
No.
Rated
No.
Rated
No.
Rated
No.
Injection drug use
3
—
1
—
642
—
241
—
0
Heterosexual contactf
—
328
—
107
—
1,322
—
5
—
11
—
1,550
—
320
—
3
—
384
—
137
—
2,409
—
Perinatal
0
—
0
—
31
—
10
Otherg
—
0
—
2
—
2
—
45
—
0
—
0
—
14
—
Subtotal
8
0.8
12
0.1
2,237
12.8
5
—
0
—
6
—
1
—
26
—
576
2.6
3
1.3
720
0.8
247
10.9
3,803
2.7
Perinatal
0
—
0
—
0
—
Otherg
0
—
0
—
0
—
0
—
0
—
0
—
0
—
1
—
0
—
0
—
0
—
0
—
1
—
Subtotal
0
0.0
0
0.0
1
0.0
0
0.0
0
0.0
0
0.0
0
0.0
1
0.0
Northeast
0
0.0
20
0.5
1,422
22.3
1,017
12.6
0
0.0
834
2.2
337
36.3
3,630
6.4
Midwest
6
1.5
6
0.3
686
9.7
128
2.4
0
0.0
790
1.5
103
8.0
1,720
2.5
South
15
1.9
21
0.5
4,195
18.0
789
3.7
2
2.3
2,114
3.0
338
15.2
7,474
6.1
West
25
2.4
48
0.6
492
14.1
563
2.5
10
2.3
1,300
3.4
166
7.2
2,604
3.4
Total
46
1.9
95
0.5
6,795
16.9
2,497
4.3
12
2.1
5,038
2.5
944
14.0
15,428
4.8
No.
Rated
Totalc
Multiple races
No.
No.
Rated
White
Rated
No.
Rated
Female adult or adolescent
Child (<13 yrs at death)
91
Region of residenceh
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
g
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
h Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
Vol. 29
HIV Surveillance Report
Table 20b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas
American Indian/
Alaska Native
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Totalc
No.
No.
No.
No.
No.
92
Asiana
Black/African
American
No.
No.
No.
<13
0
0
1
0
0
0
0
1
13–14
1
0
0
0
0
0
0
1
15–19
0
0
7
1
0
3
0
11
20–24
0
2
83
33
0
23
9
150
25–29
0
3
241
82
0
86
21
433
30–34
4
8
322
112
0
146
31
623
35–39
2
7
371
179
2
189
51
801
40–44
6
10
513
194
2
303
73
1,101
45–49
6
14
681
349
4
566
122
1,742
50–54
9
14
1,060
541
1
928
184
2,737
55–59
6
10
1,216
536
3
940
175
2,886
60–64
7
3
1,085
359
2
763
130
2,349
65
5
24
1,224
477
0
1,092
149
2,972
21
58
2,004
1,077
9
3,031
378
6,578
Injection drug use
5
9
1,054
586
1
454
142
2,250
Male-to-male sexual contact and injection drug use
6
3
402
249
0
558
109
1,327
Heterosexual contacte
5
13
1,061
271
0
242
65
1,658
Perinatal
1
0
22
12
0
5
2
42
Otherf
0
1
20
7
0
28
3
59
38
83
4,564
2,201
10
4,318
698
11,913
Age at death (yr)
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Subtotal
Vol. 29
HIV Surveillance Report
Table 20b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas (cont)
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Totalc
No.
No.
No.
No.
No.
329
107
1,352
4
384
137
2,467
12
0
2
2
47
14
5
0
6
1
26
12
2,239
662
4
721
247
3,893
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
1
0
0
0
0
1
Northeast
0
20
1,422
1,017
0
834
337
3,630
Midwest
6
6
686
128
0
790
103
1,720
South
15
21
4,195
789
2
2,114
338
7,474
West
25
48
492
563
10
1,300
166
2,604
0
0
9
366
2
1
1
379
46
95
6,804
2,863
14
5,039
945
15,807
American Indian/
Alaska Native
Asiana
Black/African
American
No.
No.
No.
Injection drug use
3
1
643
270
0
Heterosexual contacte
5
11
1,551
375
Perinatal
0
0
31
Otherf
0
0
Subtotal
8
Perinatal
Otherf
Subtotal
Female adult or adolescent
Child (<13 yrs at end of year)
93
Region of residenceg
U.S. dependent areas
Total
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12 should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g
Vol. 29
Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
HIV Surveillance Report
Table 21a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States
American Indian/
Alaska Native
Black/African
American
Asiana
No.
Ratec
No.
Ratec
<13
0
0.0
0
0.0
0
0.0
13–14
0
0.0
0
0.0
0
15–19
0
0.0
0
0.0
20–24
0
0.0
1
25–29
0
0.0
30–34
2
35–39
White
94
Ratec
No.
Ratec
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0
4
0.1
0
0.0
0
0.1
56
1.7
15
0.3
3
0.2
170
5.2
54
1.2
8
0.5
244
8.7
2
1.3
6
0.4
294
40–44
5
3.6
8
0.6
45–49
4
2.7
12
50–54
9
5.7
55–59
6
60–64
65
Multiple races
Ratec
0.0
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0
0.0
0
0.0
0
0.0
4
0.0
0
0.0
8
0.1
7
1.1
87
0.4
1.2
0
0.0
41
0.3
14
2.8
282
1.2
85
1.9
0
0.0
87
0.7
26
6.6
452
2.1
11.0
138
3.2
0
0.0
129
1.1
38
11.2
607
2.9
435
17.4
134
3.4
1
2.7
221
1.9
60
21.4
864
4.4
0.9
564
21.7
254
7.1
3
8.4
464
3.6
106
41.1
1,407
6.7
13
1.1
867
32.3
420
13.5
1
2.9
743
5.1
158
65.9
2,211
10.1
3.9
6
0.6
983
38.0
403
15.9
2
6.3
767
5.0
147
65.5
2,314
10.5
7
5.4
2
0.2
850
39.9
250
12.9
1
4.0
597
4.2
115
63.8
1,822
9.3
2
0.8
19
0.9
939
21.3
321
8.1
0
0.0
838
2.2
118
32.5
2,237
4.5
17
—
46
—
1,548
—
822
—
7
—
2,345
—
299
—
5,085
—
Injection drug use
4
—
8
—
850
—
398
—
0
—
361
—
129
—
1,750
—
Male-to-male sexual contact and
injection drug use
5
—
3
—
334
—
191
—
0
—
453
—
97
—
1,083
—
Heterosexual contacte
5
—
11
—
842
—
175
—
0
—
186
—
58
—
1,277
—
Perinatal
0
—
0
—
18
—
6
—
0
—
5
—
2
—
31
—
0
—
0
—
16
—
6
—
0
—
23
—
2
—
47
—
31
3.3
68
0.9
3,608
23.1
1,598
7.2
7
3.0
3,373
4.0
587
27.6
9,272
7.0
No.
No.
Ratec
Total
No.
No.
Ratec
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
Ratec
No.
Age at death (yr)
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Other
f
Subtotal
Vol. 29
HIV Surveillance Report
Table 21a. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States (cont)
American Indian/
Alaska Native
Black/African
American
Asiana
No.
Ratec
No.
Ratec
No.
Ratec
Injection drug use
2
—
1
—
540
—
204
Heterosexual contacte
—
0
—
4
—
9
—
1,216
—
258
—
1
Perinatal
0
—
0
—
30
Otherf
—
10
—
0
—
0
—
12
—
4
Subtotal
6
0.6
10
0.1
1,798
10.3
Perinatal
0
—
Otherf
0
—
0
0
—
0
—
Subtotal
0
0.0
0
Northeast
0
0.0
Midwest
3
South
Multiple races
Total
No.
Ratec
243
—
84
—
1,074
—
—
272
—
115
—
1,874
—
0
—
2
—
2
—
44
—
—
0
—
5
—
1
—
22
—
476
2.2
1
0.4
522
0.6
202
8.9
3,015
2.2
—
0
—
0
—
0
—
0
—
0
—
0
—
0
—
0
—
0
—
0
—
0
—
0.0
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0
13
0.3
1,129
17.7
842
10.4
0
0.0
607
1.6
281
30.3
2,872
5.1
0.7
5
0.2
529
7.5
106
2.0
0
0.0
605
1.2
90
7.0
1,338
2.0
13
1.6
18
0.4
3,354
14.4
646
3.0
2
2.3
1,646
2.3
283
12.7
5,962
4.9
West
21
2.0
42
0.5
394
11.3
480
2.1
6
1.4
1,037
2.7
135
5.9
2,115
2.8
Total
37
1.6
78
0.4
5,406
13.4
2,074
3.6
8
1.4
3,895
2.0
789
11.7
12,287
3.8
No.
Ratec
White
Ratec
No.
Ratec
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
No.
Ratec
No.
Female adult or adolescent
Child (<13 yrs at death)
95
Region of residenceg
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g
Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
Vol. 29
HIV Surveillance Report
Table 21b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas
Black/
African American Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Total
No.
No.
No.
No.
96
American Indian/
Alaska Native
Asiana
No.
No.
<13
0
0
0
0
0
0
0
0
13–14
0
0
0
0
0
0
0
0
15–19
0
0
5
0
0
0
0
5
20–24
0
1
57
18
0
8
7
91
25–29
0
3
170
57
0
41
14
285
30–34
2
8
244
91
0
87
26
458
35–39
2
6
294
152
0
129
38
621
40–44
5
8
435
154
2
222
60
886
45–49
4
12
564
285
3
464
106
1,438
50–54
9
13
867
463
1
743
159
2,255
55–59
6
6
986
447
3
767
147
2,362
60–64
7
2
852
283
1
597
115
1,857
65
2
19
941
373
0
838
118
2,291
17
46
1,551
867
7
2,345
299
5,132
Injection drug use
4
8
851
476
1
361
129
1,829
Male-to-male sexual contact and injection drug use
5
3
334
214
0
453
98
1,107
Heterosexual contactd
5
11
843
218
0
186
58
1,322
Perinatal
0
0
19
9
0
5
2
35
Othere
0
0
16
6
0
23
2
47
31
68
3,615
1,790
8
3,373
588
9,473
No.
No.
Age at death (yr)
Transmission categoryc
Male adult or adolescent
Male-to-male sexual contact
Subtotal
Vol. 29
HIV Surveillance Report
Table 21b. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, 2016—United States and 6 dependent areas (cont)
American Indian/
Alaska Native
Asiana
No.
No.
Injection drug use
2
Heterosexual contactd
Black/
African American Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Total
No.
No.
No.
No.
No.
No.
1
541
225
0
243
84
1,096
4
9
1,217
291
2
273
115
1,911
Perinatal
0
0
30
12
0
2
2
46
Othere
0
0
12
4
0
5
1
22
Subtotal
6
10
1,800
533
2
523
202
3,076
Perinatal
0
0
0
0
0
0
0
0
Othere
0
0
0
0
0
0
0
0
Subtotal
0
0
0
0
0
0
0
0
Northeast
0
13
1,129
842
0
607
281
2,872
Midwest
3
5
529
106
0
605
90
1,338
South
13
18
3,354
646
2
1,646
283
5,962
West
21
42
394
480
6
1,037
135
2,115
0
0
9
249
2
1
1
262
37
78
5,415
2,323
10
3,896
790
12,549
Female adult or adolescent
Child (<13 yrs at end of year)
97
Region of residencef
U.S. dependent areas
Total
Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause.
Numbers less than 12 should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
d
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
e Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
f
Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
Vol. 29
HIV Surveillance Report
Table 22a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States
2012
2013
98
No.
Ratea
Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2,713
893
6,313
31,850
53,748
71,309
83,532
122,431
162,349
150,072
103,570
58,415
45,040
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/Other Pacific Islander
White
Multiple races
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
2014
No.
Ratea
5.1
10.8
29.5
141.0
251.2
340.9
428.2
581.9
748.0
664.4
498.4
327.8
104.4
2,594
780
5,712
32,013
57,226
72,584
83,778
115,986
157,037
158,700
112,263
65,295
52,299
2,441
10,050
371,422
185,780
680
280,244
40,706
105.6
64.0
957.9
350.3
130.5
141.8
678.0
462,027
76,756
54,099
70,613
4,248
2,989
670,732
2015
2016
No.
Ratea
Ratea
No.
4.9
9.3
27.0
140.3
265.1
341.0
426.8
555.7
739.6
703.1
529.7
360.3
117.1
2,476
739
5,301
31,733
61,377
74,426
85,031
109,812
150,024
165,923
120,732
73,108
60,255
4.7
8.8
25.2
138.7
279.4
345.8
427.2
533.9
719.2
736.0
561.9
394.1
130.4
2,340
720
4,975
30,858
65,419
76,386
87,741
102,760
144,966
169,315
130,020
80,600
69,816
4.4
8.7
23.6
136.0
291.7
352.8
431.3
509.2
696.5
759.4
597.2
423.2
146.3
2,225
675
4,629
29,800
68,563
79,729
90,455
98,768
138,717
169,919
138,543
89,322
80,102
4.2
8.2
21.9
133.1
299.0
365.0
434.5
500.5
661.6
777.6
630.1
458.3
162.6
2,524
10,809
381,498
192,375
717
286,019
41,417
108.3
66.7
974.6
355.3
134.6
144.7
669.6
2,645
11,707
391,895
199,515
754
291,615
41,902
112.5
69.9
991.6
360.8
138.8
147.4
657.6
2,773
12,648
402,561
206,995
822
297,019
42,200
117.0
73.1
1,008.7
366.3
148.2
150.1
643.2
2,959
13,621
413,587
214,839
851
302,283
42,410
124.0
76.3
1,026.6
372.1
150.4
152.8
628.4
—
—
—
481,321
75,767
54,145
—
—
—
501,533
74,658
54,158
—
—
—
521,787
73,737
54,116
—
—
—
542,000
72,956
54,137
—
—
—
—
—
—
526.2
72,358
4,362
2,960
690,913
—
—
—
536.9
74,065
4,489
2,951
711,854
—
—
—
547.9
75,790
4,591
2,945
732,966
—
—
—
559.0
77,510
4,679
2,936
754,218
—
—
—
570.1
No.
Ratea
Vol. 29
HIV Surveillance Report
Table 22a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States (cont)
2012
2013
2014
2015
No.
Rate
No.
51,763
160,638
4,637
1,752
218,790
—
—
—
—
163.7
51,259
164,917
4,808
1,776
222,760
—
—
—
—
165.2
50,781
169,066
4,958
1,802
226,607
—
—
—
—
166.6
50,461
173,243
5,067
1,839
230,610
—
—
—
—
168.1
50,154
177,783
5,180
1,886
235,004
—
—
—
—
169.9
2,306
407
2,713
—
—
5.1
2,141
453
2,594
—
—
4.9
2,005
471
2,476
—
—
4.7
1,894
446
2,340
—
—
4.4
1,801
424
2,225
—
—
4.2
Region of residenceg
Northeast
Midwest
South
West
222,448
105,960
392,077
171,750
398.2
157.4
334.3
233.6
225,465
109,229
405,257
176,316
402.3
161.7
342.2
237.5
229,582
112,165
417,593
181,597
408.5
165.6
348.9
242.1
231,781
114,831
431,307
187,997
411.7
169.3
356.2
247.9
236,042
118,611
442,353
194,441
418.8
174.5
361.3
253.7
Totalh
892,235
284.2
916,267
289.7
940,937
295.3
965,916
300.9
991,447
306.6
Child (<13 yrs at end of year)
Perinatal
Otherf
Subtotal
99
a
No.
Ratea
No.
2016
Ratea
Female adult or adolescent
Injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
a
Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c
Hispanics/Latinos can be of any race.
d
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f
g
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
Data are based on address of residence at the end of the specified year (i.e., most recent known address).
h Includes persons whose race/ethnicity is unknown.
Ratea
No.
Ratea
Vol. 29
HIV Surveillance Report
Table 22b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States and 6 dependent areas
2012
2013
100
No.
Ratea
Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
2,738
916
6,429
32,275
54,476
72,526
85,158
124,790
165,513
153,053
105,656
59,684
46,274
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/Other Pacific Islander
White
Multiple races
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
2014
No.
Ratea
5.1
10.9
29.7
141.0
251.7
342.4
430.9
585.7
753.2
669.8
502.5
330.7
105.7
2,613
801
5,801
32,451
57,931
73,765
85,344
118,129
160,092
161,813
114,561
66,640
53,687
2,442
10,097
371,728
202,580
702
280,301
40,723
—
—
—
—
—
—
—
466,026
81,035
54,975
73,073
4,381
3,028
682,518
2015
2016
No.
Ratea
No.
Ratea
4.9
9.4
27.0
140.4
265.3
342.5
429.3
559.0
744.7
708.6
534.3
363.1
118.5
2,493
747
5,393
32,169
62,126
75,504
86,540
111,841
152,873
169,125
123,147
74,601
61,785
4.7
8.8
25.3
138.8
279.7
346.9
429.4
537.1
723.9
741.6
566.6
397.3
131.8
2,352
726
5,043
31,260
66,202
77,362
89,252
104,609
147,685
172,506
132,567
82,227
71,563
4.4
8.7
23.6
136.1
291.9
353.5
433.5
512.1
701.1
764.8
602.1
426.7
147.9
2,238
678
4,677
30,160
69,339
80,711
91,902
100,516
141,250
173,058
141,227
91,127
82,046
4.2
8.2
21.8
133.1
299.1
365.8
436.4
503.3
665.8
782.8
635.2
462.1
164.2
2,525
10,856
381,811
209,272
738
286,084
41,431
—
—
—
—
—
—
—
2,646
11,753
392,213
216,443
776
291,690
41,916
—
—
—
—
—
—
—
2,774
12,699
402,872
223,950
848
297,094
42,216
—
—
—
—
—
—
—
2,960
13,673
413,891
231,838
881
302,359
42,427
—
—
—
—
—
—
—
—
—
—
485,522
79,946
55,009
—
—
—
505,944
78,731
54,992
—
—
—
526,343
77,725
54,946
—
—
—
546,730
76,854
54,951
—
—
—
—
—
—
528.8
74,842
4,495
3,001
702,816
—
—
—
539.5
76,576
4,618
2,991
723,852
—
—
—
550.5
78,328
4,719
2,984
745,045
—
—
—
561.6
80,072
4,803
2,976
766,385
—
—
—
572.7
No.
Ratea
Vol. 29
HIV Surveillance Report
Table 22b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2012–2016—United States and 6 dependent areas (cont)
2012
2013
2014
No.
Rate
No.
Rate
No.
Rate
52,993
164,704
4,763
1,771
224,232
—
—
—
—
165.5
52,466
169,008
4,931
1,794
228,199
—
—
—
—
167.0
51,953
173,149
5,078
1,819
231,999
—
—
—
—
168.4
51,608
177,301
5,190
1,858
235,957
—
—
—
—
169.9
51,274
181,828
5,298
1,906
240,306
—
—
—
—
171.6
2,331
407
2,738
—
—
5.1
2,160
453
2,613
—
—
4.9
2,022
471
2,493
—
—
4.7
1,906
446
2,352
—
—
4.4
1,814
424
2,238
—
—
4.2
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
222,448
105,960
392,077
171,750
17,253
398.2
157.4
334.3
233.6
427.4
225,465
109,229
405,257
176,316
17,361
402.3
161.7
342.2
237.5
434.6
229,582
112,165
417,593
181,597
17,407
408.5
165.6
348.9
242.1
442.2
231,781
114,831
431,307
187,997
17,438
411.7
169.3
356.2
247.9
450.1
236,042
118,611
442,353
194,441
17,482
418.8
174.5
361.3
253.7
459.2
Totalh
909,488
286.0
933,628
291.5
958,344
297.1
983,354
302.7
1,008,929
308.3
Child (<13 yrs at end of year)
Perinatal
Otherf
Subtotal
101
a
a
2016
No.
Female adult or adolescent
Injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
a
2015
Ratea
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
e
No.
Ratea
Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category
because of the lack of denominator data.
b
d
a
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g
Data are based on address of residence at the end of the specified year (i.e., most recent known address).
h
Includes persons whose race/ethnicity is unknown.
Vol. 29
HIV Surveillance Report
Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States
2012
Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
102
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/Other Pacific Islander
White
Multiple races
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
2013
a
2014
a
2015
a
2016
a
No.
Rate
No.
Rate
No.
Rate
No.
Rate
No.
Ratea
323
194
1,954
8,242
16,504
28,189
40,232
67,803
99,057
96,172
68,241
38,687
30,192
0.6
2.3
9.1
36.5
77.1
134.7
206.2
322.2
456.4
425.8
328.4
217.1
70.0
281
153
1,699
8,236
17,353
28,119
39,619
63,219
94,706
101,125
73,729
43,300
34,943
0.5
1.8
8.0
36.1
80.4
132.1
201.8
302.9
446.1
448.0
347.9
238.9
78.2
301
132
1,304
7,503
17,830
27,516
38,785
58,588
88,951
104,838
78,552
48,377
40,132
0.6
1.6
6.2
32.8
81.2
127.8
194.9
284.8
426.4
465.0
365.6
260.8
86.8
277
129
975
6,736
18,022
27,259
38,535
53,445
84,190
105,915
84,006
53,107
46,371
0.5
1.6
4.6
29.7
80.4
125.9
189.4
264.8
404.5
475.0
385.9
278.9
97.2
287
103
833
5,967
18,136
27,219
38,468
49,921
78,894
104,937
89,088
58,526
52,995
0.5
1.3
3.9
26.7
79.1
124.6
184.8
253.0
376.3
480.2
405.2
300.3
107.6
1,316
5,239
202,547
109,988
367
152,038
24,253
57.0
33.3
522.4
207.4
70.4
76.9
404.0
1,348
5,527
207,722
112,806
381
153,989
24,668
57.8
34.1
530.7
208.3
71.5
77.9
398.8
1,387
5,797
210,826
114,721
393
154,842
24,802
59.0
34.6
533.4
207.5
72.3
78.3
389.3
1,427
6,075
213,858
116,759
410
155,615
24,782
60.2
35.1
535.9
206.6
73.9
78.7
377.7
1,488
6,344
217,071
118,950
417
156,307
24,756
62.3
35.5
538.8
206.0
73.7
79.0
366.8
244,034
51,501
34,968
—
—
—
251,763
50,843
34,873
—
—
—
256,882
49,994
34,530
—
—
—
262,002
49,101
34,184
—
—
—
267,257
48,293
33,894
—
—
—
43,154
2,341
2,040
378,039
—
—
—
296.6
44,417
2,407
2,037
386,341
—
—
—
300.2
45,302
2,448
2,021
391,177
—
—
—
301.1
46,077
2,509
1,984
395,857
—
—
—
301.9
46,908
2,549
1,958
400,859
—
—
—
303.0
Vol. 29
HIV Surveillance Report
Table 23a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States (cont)
2012
2013
No.
—
—
—
—
87.8
31,367
84,761
2,631
1,101
119,860
300
23
323
—
—
0.6
Region of residenceg
Northeast
Midwest
South
West
131,321
55,395
210,210
98,864
Totalh
495,790
Child (<13 yrs at end of year)
Perinatal
Otherf
Subtotal
31,602
82,204
2,522
1,100
117,428
2014
Ratea
Female adult or adolescent
Injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
No.
Ratea
2015
103
No.
Ratea
—
—
—
—
88.9
31,012
86,518
2,692
1,109
121,331
258
23
281
—
—
0.5
235.1
82.3
179.2
134.5
132,224
56,725
217,024
100,509
157.9
506,482
No.
No.
Ratea
—
—
—
—
89.2
30,700
88,284
2,743
1,106
122,833
—
—
—
—
89.5
30,379
89,938
2,804
1,107
124,228
—
—
—
—
89.8
268
33
301
—
—
0.6
242
35
277
—
—
0.5
248
39
287
—
—
0.5
235.9
84.0
183.3
135.4
132,938
57,632
220,719
101,520
236.5
85.1
184.4
135.4
132,609
58,221
224,861
103,276
235.6
85.8
185.7
136.2
133,552
59,409
227,331
105,082
237.0
87.4
185.7
137.1
160.2
512,809
160.9
518,967
161.7
525,374
162.5
a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c
Hispanics/Latinos can be of any race.
d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g Data are based on address of residence at the end of the specified year (i.e., most recent known address).
h
Includes persons whose race/ethnicity is unknown.
2016
Ratea
Vol. 29
HIV Surveillance Report
Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States and
6 dependent areas
2012
2013
2014
a
2015
a
2016
104
No.
Rate
No.
Rate
No.
Rate
No.
Rate
No.
Ratea
Age at end of year (yr)
<13
13–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65
328
198
1,998
8,351
16,696
28,551
40,903
68,991
100,977
98,051
69,645
39,558
31,027
0.6
2.4
9.2
36.5
77.1
134.8
207.0
323.8
459.5
429.1
331.2
219.2
70.9
284
158
1,735
8,343
17,545
28,468
40,238
64,292
96,507
103,123
75,267
44,215
35,889
0.5
1.9
8.1
36.1
80.4
132.2
202.4
304.3
448.9
451.6
351.0
240.9
79.2
304
133
1,334
7,602
18,028
27,834
39,362
59,581
90,571
106,886
80,144
49,403
41,164
0.6
1.6
6.3
32.8
81.2
127.9
195.3
286.1
428.9
468.7
368.7
263.1
87.8
279
130
994
6,827
18,216
27,538
39,072
54,340
85,688
107,913
85,695
54,199
47,550
0.5
1.6
4.7
29.7
80.3
125.8
189.8
266.0
406.8
478.4
389.2
281.3
98.3
290
104
847
6,046
18,311
27,503
38,972
50,719
80,241
106,898
90,843
59,722
54,309
0.5
1.3
4.0
26.7
79.0
124.7
185.1
254.0
378.2
483.5
408.6
302.9
108.7
Race/ethnicity
American Indian/Alaska Native
Asianb
Black/African American
Hispanic/Latinoc
Native Hawaiian/Other Pacific Islander
White
Multiple races
1,317
5,256
202,715
119,236
380
152,068
24,260
—
—
—
—
—
—
—
1,349
5,544
207,891
122,150
392
154,023
24,674
—
—
—
—
—
—
—
1,388
5,814
210,994
124,018
404
154,879
24,808
—
—
—
—
—
—
—
1,428
6,093
214,027
125,988
424
155,651
24,789
—
—
—
—
—
—
—
1,489
6,363
217,236
128,134
433
156,344
24,765
—
—
—
—
—
—
—
246,086
54,018
35,528
—
—
—
253,890
53,327
35,425
—
—
—
259,045
52,420
35,067
—
—
—
264,176
51,485
34,718
—
—
—
269,461
50,640
34,424
—
—
—
44,544
2,419
2,061
384,656
—
—
—
298.0
45,830
2,487
2,059
393,018
—
—
—
301.7
46,733
2,526
2,041
397,833
—
—
—
302.6
47,518
2,585
2,004
402,487
—
—
—
303.4
48,354
2,623
1,980
407,482
—
—
—
304.5
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Injection drug use
Male-to-male sexual contact and
injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
a
a
Vol. 29
HIV Surveillance Report
Table 23b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by year and selected characteristics, 2012–2016—United States and
6 dependent areas (cont)
2012
2013
No.
—
—
—
—
88.8
32,087
86,861
2,705
1,109
122,762
305
23
328
—
—
0.6
Region of residenceg
Northeast
Midwest
South
West
U.S. dependent areas
131,321
55,395
210,210
98,864
9,484
Totalh
505,274
Child (<13 yrs at end of year)
Perinatal
Otherf
Subtotal
105
a
32,326
84,259
2,598
1,107
120,290
2014
Ratea
Female adult or adolescent
Injection drug use
Heterosexual contacte
Perinatal
Otherf
Subtotal
No.
Ratea
2015
No.
Ratea
—
—
—
—
89.9
31,722
88,603
2,767
1,117
124,209
261
23
284
—
—
0.5
235.1
82.3
179.2
134.5
235.0
132,224
56,725
217,024
100,509
9,582
158.9
516,064
No.
No.
Ratea
—
—
—
—
90.1
31,398
90,341
2,820
1,115
125,675
—
—
—
—
90.5
31,058
91,980
2,877
1,118
127,033
—
—
—
—
90.7
271
33
304
—
—
0.6
244
35
279
—
—
0.5
251
39
290
—
—
0.5
235.9
84.0
183.3
135.4
239.9
132,938
57,632
220,719
101,520
9,537
236.5
85.1
184.4
135.4
242.3
132,609
58,221
224,861
103,276
9,474
235.6
85.8
185.7
136.2
244.5
133,552
59,409
227,331
105,082
9,431
237.0
87.4
185.7
137.1
247.7
161.2
522,346
161.9
528,441
162.6
534,805
163.4
Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited. Rates are not calculated by transmission category
because of the lack of denominator data.
b
Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanics/Latinos can be of any race.
d
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e
Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g Data are based on address of residence at the end of the specified year (i.e., most recent known address).
h
2016
Ratea
Includes persons whose race/ethnicity is unknown.
Vol. 29
HIV Surveillance Report
Table 24a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States
American Indian/
Alaska Native
No.
Rated
Black/
African American
Asiana
No.
Rated
No.
Rated
Hispanic/Latinob
No.
Native Hawaiian/
Other Pacific
Islander
Rated
No.
Rated
White
No.
Totalc
Multiple races
Rated
No.
Rated
No.
Rated
Age at end of year (yr)
106
<13
6
1.3
113
4.3
1,391
19.2
286
2.1
3
2.8
287
1.1
139
5.9
2,225
4.2
13–14
3
4.3
24
5.9
432
38.6
97
4.9
1
6.3
86
2.0
32
10.7
675
8.2
15–19
7
3.9
59
5.6
2,898
97.0
963
20.0
0
0.0
492
4.3
204
29.0
4,629
21.9
20–24
123
63.5
418
33.0
17,111
518.3
6,543
135.7
24
53.7
4,212
34.7
1,362
220.2
29,800
133.1
25–29
250
131.4
1,084
70.7
36,394
1,115.3
15,293
328.3
71
136.9
12,239
96.0
3,226
654.6
68,563
299.0
30–34
290
176.0
1,420
91.4
37,074
1,321.7
20,040
445.3
86
173.5
17,165
138.7
3,647
927.4
79,729
365.0
35–39
330
218.3
1,683
116.1
38,793
1,450.6
23,917
552.8
114
260.4
21,441
181.2
4,160
1,225.6
90,455
434.5
40–44
320
228.0
2,134
149.9
40,765
1,633.3
25,959
652.4
115
305.1
25,147
221.1
4,292
1,527.9
98,768
500.5
45–49
462
315.5
2,186
168.7
53,752
2,069.6
32,439
905.0
120
335.9
43,594
334.0
6,051
2,345.0
138,717
661.6
50–54
454
287.1
1,757
151.5
63,891
2,379.5
34,784
1,115.0
124
356.1
61,449
425.1
7,264
3,032.0
169,919
777.6
55–59
350
225.3
1,138
108.5
54,206
2,092.8
25,393
999.2
87
275.0
51,466
334.3
5,714
2,546.1
138,543
630.1
60–64
216
168.0
801
86.4
36,080
1,692.7
15,254
788.5
58
232.0
33,271
234.9
3,498
1,939.6
89,322
458.3
65
148
57.2
804
37.8
30,800
700.1
13,871
348.7
48
97.3
31,434
82.5
2,821
777.7
80,102
162.6
1,511
—
9,220
—
168,389
—
124,081
—
602
—
214,817
—
22,951
—
542,000
—
Injection drug use
218
—
432
—
35,514
—
20,254
—
23
—
13,762
—
2,660
—
72,956
—
Male-to-male sexual contact and
injection drug use
272
—
374
—
15,821
—
11,602
—
41
—
22,282
—
3,685
—
54,138
—
Heterosexual contactf
163
—
963
—
49,108
—
15,044
—
35
—
9,612
—
2,548
—
77,510
—
5
—
29
—
2,670
—
1,164
—
1
—
547
—
254
—
4,679
—
13
—
70
—
849
—
433
—
2
—
1,429
—
134
—
2,936
—
2,182
230.1
11,088
154.7
272,351
1,747.4
172,579
774.5
703
304.3
262,448
312.6
32,233
1,517.4
754,218
570.1
Transmission categorye
Male adult or adolescent
Male-to-male sexual contact
Perinatal
Otherg
Subtotal
Vol. 29
HIV Surveillance Report
Table 24a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States (cont)
American Indian/
Alaska Native
No.
Rated
Black/
African American
Asiana
No.
Rated
Rated
No.
Hispanic/Latinob
No.
Native Hawaiian/
Other Pacific
Islander
Rated
No.
Rated
White
No.
Totalc
Multiple races
Rated
No.
Rated
No.
Rated
Female adult or adolescent
Injection drug use
241
—
182
—
24,946
—
9,498
—
25
—
12,408
—
2,764
—
50,155
—
Heterosexual contactf
510
—
2,139
—
110,892
—
31,001
—
118
—
26,053
—
6,916
—
177,783
—
9
—
29
—
3,083
—
1,190
—
1
—
588
—
272
—
5,180
—
11
—
70
—
925
—
285
—
1
—
499
—
86
—
1,886
—
771
77.8
2,420
29.9
139,845
800.9
41,974
191.4
145
63.2
39,548
45.3
10,038
442.7
235,004
169.9
Perinatal
6
—
75
—
1,137
—
260
—
3
—
195
—
125
—
1,801
—
Otherg
0
—
38
—
254
—
26
—
0
—
92
—
14
—
424
—
Subtotal
6
1.3
113
4.3
1,391
19.2
286
2.1
3
2.8
287
1.1
139
5.9
2,225
4.2
Northeast
156
123.6
2,928
78.2
91,772
1,440.9
70,543
874.4
57
268.9
55,872
150.6
14,238
1,535.3
236,042
418.8
Midwest
346
84.7
1,360
62.3
51,422
726.1
13,671
258.9
40
125.6
46,709
90.3
4,936
383.6
118,611
174.5
South
730
92.2
2,743
65.8
239,648
1,026.3
69,034
320.4
146
167.7
113,558
161.6
16,322
732.3
442,353
361.3
West
1,727
162.9
6,590
85.0
30,745
882.7
61,591
269.6
608
142.8
86,144
222.2
6,914
299.8
194,441
253.7
Total
2,959
124.0
13,621
76.3
413,587
1,026.6
214,839
372.1
851
150.4
302,283
152.8
42,410
628.4
991,447
306.6
Perinatal
Otherg
Subtotal
Child (<13 yrs at end of year)
107
Region of residenceh
Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
g
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
h
Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Vol. 29
HIV Surveillance Report
Table 24b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas
American Indian/
Alaska Native
No.
Asiana
Black/
African American
No.
No.
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Totalc
No.
No.
No.
No.
No.
Age at end of year (yr)
108
<13
6
113
1,393
295
4
287
140
2,238
13–14
3
24
432
100
1
86
32
678
15–19
7
59
2,898
1,011
0
492
204
4,677
20–24
123
418
17,114
6,894
26
4,213
1,365
30,160
25–29
250
1,085
36,407
16,048
76
12,241
3,226
69,339
30–34
290
1,424
37,086
20,998
91
17,168
3,647
80,711
35–39
330
1,689
38,814
25,324
120
21,445
4,163
91,902
40–44
320
2,141
40,794
27,662
117
25,153
4,292
100,516
45–49
462
2,192
53,806
34,890
123
43,607
6,056
141,250
50–54
454
1,765
63,936
37,855
125
61,460
7,267
173,058
55–59
351
1,150
54,248
28,003
90
51,482
5,714
141,227
60–64
216
804
36,113
17,014
58
33,278
3,499
91,127
65
148
809
30,850
15,744
50
31,447
2,822
82,046
1,511
9,253
168,460
128,628
620
214,866
22,962
546,730
Injection drug use
218
439
35,551
24,104
24
13,766
2,660
76,854
Male-to-male sexual contact
and injection drug use
272
375
15,828
12,401
42
22,287
3,686
54,951
Heterosexual contacte
164
965
49,169
17,536
38
9,616
2,548
80,072
5
29
2,671
1,287
1
547
254
4,803
13
70
849
473
2
1,429
134
2,976
2,183
11,130
272,527
184,428
726
262,510
32,245
766,385
Transmission categoryd
Male adult or adolescent
Male-to-male sexual contact
Perinatal
Other
f
Subtotal
Vol. 29
HIV Surveillance Report
Table 24b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas (cont)
American Indian/
Alaska Native
No.
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Totalc
No.
No.
No.
No.
No.
No.
Asiana
Black/
African American
No.
Female adult or adolescent
Injection drug use
241
184
24,961
10,596
25
12,411
2,764
51,274
Heterosexual contacte
510
2,147
110,997
34,913
124
26,064
6,919
181,828
9
29
3,086
1,304
1
588
273
5,298
11
71
927
302
1
499
86
1,906
771
2,430
139,971
47,115
151
39,562
10,042
240,306
Perinatal
6
75
1,139
269
4
195
126
1,814
Otherf
0
38
254
26
0
92
14
424
Subtotal
6
113
1,393
295
4
287
140
2,238
Northeast
156
2,928
91,772
70,543
57
55,872
14,238
236,042
Midwest
346
1,360
51,422
13,671
40
46,709
4,936
118,611
South
730
2,743
239,648
69,034
146
113,558
16,322
442,353
West
1,727
6,590
30,745
61,591
608
86,144
6,914
194,441
1
52
304
16,999
30
76
17
17,482
2,960
13,673
413,891
231,838
881
302,359
42,427
1,008,929
Perinatal
Otherf
Subtotal
Child (<13 yrs at end of year)
109
Region of residenceg
U.S. dependent areas
Total
Note. Numbers less than 12 should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f
Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Vol. 29
HIV Surveillance Report
Table 25a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States
American Indian/
Alaska Native
No.
Rated
Asian
No.
Black/
African American
a
Rated
No.
Rated
Hispanic/Latino
No.
b
Native Hawaiian/
Other Pacific
Islander
Rated
No.
Rated
White
No.
Totalc
Multiple races
Rated
Rated
No.
No.
Rated
Age at end of year (yr)
110
<13
1
0.2
6
0.2
188
2.6
42
0.3
1
0.9
28
0.1
21
0.9
287
0.5
13–14
2
2.9
2
0.5
65
5.8
13
0.7
1
6.3
12
0.3
8
2.7
103
1.3
15–19
2
1.1
13
1.2
565
18.9
158
3.3
0
0.0
56
0.5
39
5.6
833
3.9
20–24
22
11.4
55
4.3
3,693
111.9
1,261
26.2
5
11.2
576
4.7
354
57.2
5,967
26.7
25–29
54
28.4
210
13.7
10,488
321.4
4,042
86.8
18
34.7
2,307
18.1
1,017
206.4
18,136
79.1
30–34
99
60.1
412
26.5
13,661
487.0
7,170
159.3
26
52.4
4,464
36.1
1,387
352.7
27,219
124.6
35–39
146
96.6
602
41.5
17,395
650.5
10,829
250.3
51
116.5
7,461
63.0
1,984
584.5
38,468
184.8
40–44
169
120.4
960
67.4
21,337
854.9
13,943
350.4
52
138.0
10,974
96.5
2,484
884.3
49,921
253.0
45–49
260
177.5
1,178
90.9
31,397
1,208.8
19,579
546.3
68
190.4
22,578
173.0
3,829
1,483.9
78,894
376.3
50–54
263
166.3
1,054
90.9
39,834
1,483.5
23,129
741.4
80
229.7
35,510
245.7
5,062
2,112.9
104,937
480.2
55–59
237
152.6
753
71.8
34,744
1,341.4
17,775
699.4
51
161.2
31,492
204.6
4,026
1,793.9
89,088
405.2
60–64
135
105.0
545
58.8
23,547
1,104.7
10,884
562.6
32
128.0
20,854
147.2
2,521
1,397.9
58,526
300.3
98
37.9
554
26.0
20,157
458.2
10,125
254.5
32
64.9
19,995
52.5
2,024
558.0
52,995
107.6
Male-to-male sexual contact
694
—
4,124
—
78,847
—
62,521
—
295
—
108,526
—
12,226
—
267,257
—
Injection drug use
126
—
247
—
23,281
—
14,095
—
10
—
8,572
—
1,958
—
48,293
—
Male-to-male sexual contact and
injection drug use
170
—
217
—
10,413
—
7,538
—
24
—
13,028
—
2,502
—
33,894
—
94
—
580
—
28,968
—
9,991
—
20
—
5,550
—
1,699
—
46,908
—
2
—
12
—
1,465
—
653
—
1
—
270
—
146
—
2,549
—
11
—
50
—
462
—
306
—
1
—
1,032
—
97
—
1,958
—
1,097
115.7
5,230
73.0
143,436
920.3
95,104
426.8
351
151.9
136,979
163.2
18,628
876.9
400,859
303.0
65
Transmission categorye
Male adult or adolescent
Heterosexual contactf
Perinatal
Other
g
Subtotal
Vol. 29
HIV Surveillance Report
Table 25a. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States (cont)
American Indian/
Alaska Native
No.
Rated
Black/
African American
Asiana
No.
Rated
No.
Rated
Hispanic/Latinob
No.
Native Hawaiian/
Other Pacific
Islander
Rated
No.
Rated
White
Rated
No.
Totalc
Multiple races
Rated
No.
No.
Rated
Female adult or adolescent
Injection drug use
119
—
94
—
15,453
—
6,186
—
13
—
6,594
—
1,917
—
30,379
—
Heterosexual contactf
258
—
961
—
55,807
—
16,756
—
50
—
12,120
—
3,982
—
89,938
—
Perinatal
5
—
10
—
1,685
—
669
—
1
—
275
—
158
—
2,804
—
Otherg
8
—
43
—
502
—
193
—
1
—
311
—
49
—
1,107
—
390
39.4
1,108
13.7
73,447
420.6
23,804
108.5
65
28.3
19,300
22.1
6,107
269.3
124,228
89.8
Perinatal
1
—
5
—
164
—
36
—
1
—
22
—
19
—
248
—
Otherg
0
—
1
—
24
—
6
—
0
—
6
—
2
—
39
—
Subtotal
1
0.2
6
0.2
188
2.6
42
0.3
1
0.9
28
0.1
21
0.9
287
0.5
Northeast
81
64.2
1,368
36.5
52,002
816.5
41,498
514.4
23
108.5
29,710
80.1
8,846
953.9
133,552
237.0
Midwest
172
42.1
581
26.6
25,453
359.4
7,345
139.1
16
50.2
23,070
44.6
2,771
215.3
59,409
87.4
South
331
41.8
1,125
27.0
123,337
528.2
35,931
166.8
48
55.1
57,252
81.5
9,302
417.4
227,331
185.7
West
904
85.3
3,270
42.2
16,279
467.4
34,176
149.6
330
77.5
46,275
119.3
3,837
166.4
105,082
137.1
Total
1,488
62.3
6,344
35.5
217,071
538.8
118,950
206.0
417
73.7
156,307
79.0
24,756
366.8
525,374
162.5
Subtotal
Child (<13 yrs at end of year)
111
Region of residenceh
Note. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
e Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
g Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
h
Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Vol. 29
HIV Surveillance Report
Table 25b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas
American Indian/
Alaska Native
No.
Asiana
Black/
African American
No.
No.
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Totalc
No.
No.
No.
No.
No.
Age at end of year
112
<13
1
6
189
43
2
28
21
290
13–14
2
2
65
14
1
12
8
104
15–19
2
13
565
172
0
56
39
847
20–24
22
55
3,694
1,337
6
576
355
6,046
25–29
54
210
10,493
4,211
19
2,307
1,017
18,311
30–34
99
413
13,667
7,445
27
4,465
1,387
27,503
35–39
146
604
17,404
11,317
55
7,462
1,984
38,972
40–44
169
963
21,351
14,721
53
10,976
2,484
50,719
45–49
260
1,179
31,426
20,887
70
22,581
3,833
80,241
50–54
263
1,060
39,864
25,042
81
35,519
5,064
106,898
55–59
238
756
34,764
19,495
53
31,501
4,026
90,843
60–64
135
546
23,567
12,055
32
20,857
2,522
59,722
98
556
20,187
11,395
34
20,004
2,025
54,309
Male-to-male sexual contact
694
4,138
78,889
64,627
304
108,552
12,233
269,461
Injection drug use
126
249
23,297
16,421
11
8,574
1,958
50,640
Male-to-male sexual contact
and injection drug use
170
217
10,418
8,060
24
13,032
2,502
34,424
95
580
29,007
11,395
21
5,552
1,699
48,354
2
12
1,466
726
1
270
146
2,623
11
50
462
328
1
1,032
97
1,981
1,098
5,246
143,539
101,557
362
137,011
18,635
407,482
65
Transmission categoryd
Male adult or adolescent
Heterosexual contacte
Perinatal
Otherf
Subtotal
Vol. 29
HIV Surveillance Report
Table 25b. Persons living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and selected characteristics, year-end 2016—United States and 6 dependent areas (cont)
American Indian/
Alaska Native
No.
Asiana
Black/
African American
No.
No.
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Multiple races
Totalc
No.
No.
No.
No.
No.
Female adult or adolescent
Injection drug use
119
94
15,462
6,853
13
6,597
1,917
31,058
Heterosexual contacte
258
963
55,855
18,740
54
12,122
3,983
91,980
Perinatal
5
10
1,688
738
1
275
159
2,877
Otherf
8
44
503
203
1
311
49
1,118
390
1,111
73,508
26,534
69
19,305
6,109
127,033
Perinatal
1
5
165
37
2
22
19
251
Otherf
0
1
24
6
0
6
2
39
Subtotal
1
6
189
43
2
28
21
290
Northeast
81
1,368
52,002
41,498
23
29,710
8,846
133,552
Midwest
172
581
25,453
7,345
16
23,070
2,771
59,409
South
331
1,125
123,337
35,931
48
57,252
9,302
227,331
West
904
3,270
16,279
34,176
330
46,275
3,837
105,082
1
19
165
9,184
16
37
9
9,431
1,489
6,363
217,236
128,134
433
156,344
24,765
534,805
Subtotal
Child (<13 yrs at end of
year)
113
Region of residenceg
U.S. dependent areas
Total
Note. Numbers less than 12 should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Heterosexual contact with a person known to have, or to be at high risk for, HIV infection.
f Includes hemophilia, blood transfusion, and risk factor not reported or not identified.
g
Vol. 29
Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Table 26. Diagnoses of HIV infection, by area of residence, 2016 and 2017—United States and 6 dependent areas
2016
Area of residence
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Subtotal
U.S. dependent areas
American Samoa
Guam
Northern Mariana Islands
Puerto Rico
Republic of Palau
U.S. Virgin Islands
Subtotal
Total
2017
Adults and
adolescents
No.
Ratea
665
16.3
37
6.1
722
12.6
310
12.5
5,116
15.6
424
9.2
261
8.5
112
13.9
343
58.2
4,708
26.6
2,480
29.1
78
6.5
47
3.4
1,472
13.7
481
8.7
133
5.1
146
6.1
334
9.0
1,122
28.9
53
4.6
1,104
21.8
633
10.8
745
8.9
292
6.4
429
17.4
509
10.0
21
2.4
76
4.9
512
20.9
40
3.5
1,161
15.3
138
8.0
2,832
16.8
1,392
16.3
45
7.2
976
10.0
293
9.1
223
6.4
1,138
10.4
69
7.6
744
17.8
40
5.7
708
12.7
4,508
19.9
137
5.8
5
0.9
902
12.8
428
7.0
67
4.3
227
4.7
21
4.3
39,459
14.6
Children
No.
Ratea
0
0.0
0
0.0
2
0.2
0
0.0
13
0.2
0
0.0
2
0.4
0
0.0
1
1.1
18
0.6
8
0.4
0
0.0
0
0.0
8
0.4
1
0.1
4
0.8
1
0.2
2
0.3
2
0.2
0
0.0
4
0.4
1
0.1
1
0.1
4
0.4
0
0.0
7
0.7
1
0.6
0
0.0
0
0.0
0
0.0
5
0.4
0
0.0
2
0.1
9
0.6
0
0.0
4
0.2
1
0.1
1
0.2
3
0.2
0
0.0
2
0.3
1
0.6
8
0.7
8
0.2
0
0.0
0
0.0
3
0.2
3
0.3
0
0.0
0
0.0
0
0.0
130
0.2
No.
665
37
724
310
5,129
424
263
112
344
4,726
2,488
78
47
1,480
482
137
147
336
1,124
53
1,108
634
746
296
429
516
22
76
512
40
1,166
138
2,834
1,401
45
980
294
224
1,141
69
746
41
716
4,516
137
5
905
431
67
227
21
39,589
0
4
0
534
2
13
553
40,012
0
0
0
0
0
0
0
130
0
4
0
534
2
13
553
40,142
0.0
3.2
0.0
18.2
11.2
14.7
17.0
14.6
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.2
Total
Ratea
13.7
5.0
10.5
10.4
13.1
7.7
7.3
11.8
50.3
22.9
24.1
5.5
2.8
11.5
7.3
4.4
5.1
7.6
24.0
4.0
18.4
9.3
7.5
5.4
14.4
8.5
2.1
4.0
17.4
3.0
13.0
6.6
14.3
13.8
6.0
8.4
7.5
5.5
8.9
6.5
15.0
4.8
10.8
16.2
4.5
0.8
10.8
5.9
3.7
3.9
3.6
12.2
0.0
2.4
0.0
15.7
9.4
12.1
14.5
12.3
Adults and
adolescents
No.
Ratea
653
15.9
29
4.8
764
13.1
290
11.6
4,495
13.6
440
9.4
262
8.5
124
15.2
319
53.6
4,783
26.6
2,588
30.0
79
6.6
46
3.3
1,255
11.7
517
9.3
126
4.8
118
4.9
349
9.4
1,031
26.6
29
2.5
1,026
20.2
605
10.3
777
9.2
278
6.0
428
17.3
504
9.8
32
3.6
88
5.6
494
19.7
34
2.9
1,108
14.6
114
6.6
2,768
16.4
1,311
15.2
36
5.8
1,020
10.4
302
9.3
198
5.6
1,093
10.0
83
9.1
714
16.9
37
5.2
688
12.2
4,358
19.0
116
4.8
19
3.5
868
12.2
439
7.1
78
5.0
259
5.3
10
2.1
38,182
14.0
Children
No.
Ratea
3
0.4
0
0.0
3
0.3
1
0.2
5
0.1
1
0.1
2
0.4
1
0.7
2
2.0
17
0.6
7
0.4
2
0.9
0
0.0
10
0.5
2
0.2
0
0.0
0
0.0
2
0.3
2
0.2
0
0.0
3
0.3
2
0.2
1
0.1
1
0.1
0
0.0
2
0.2
0
0.0
0
0.0
1
0.2
0
0.0
1
0.1
0
0.0
4
0.1
4
0.2
0
0.0
1
0.1
0
0.0
0
0.0
1
0.1
0
0.0
4
0.5
0
0.0
1
0.1
6
0.1
0
0.0
0
0.0
5
0.4
2
0.2
0
0.0
0
0.0
0
0.0
99
0.2
No.
656
29
767
291
4,500
441
264
125
321
4,800
2,595
81
46
1,265
519
126
118
351
1,033
29
1,029
607
778
279
428
506
32
88
495
34
1,109
114
2,772
1,315
36
1,021
302
198
1,094
83
718
37
689
4,364
116
19
873
441
78
259
10
38,281
0
6
0
445
0
7
458
38,640
0
0
0
0
0
0
0
99
0
6
0
445
0
7
458
38,739
0.0
4.7
0.0
15.4
0.0
7.9
14.3
14.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.2
Total
Ratea
13.5
3.9
10.9
9.7
11.4
7.9
7.4
13.0
46.3
22.9
24.9
5.7
2.7
9.9
7.8
4.0
4.1
7.9
22.1
2.2
17.0
8.8
7.8
5.0
14.3
8.3
3.0
4.6
16.5
2.5
12.3
5.5
14.0
12.8
4.8
8.8
7.7
4.8
8.5
7.8
14.3
4.3
10.3
15.4
3.7
3.0
10.3
6.0
4.3
4.5
1.7
11.8
0.0
3.6
0.0
13.3
0.0
6.5
12.3
11.8
Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address). Data for the year 2017 are considered preliminary because they are based on
only a 6-month reporting delay.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a Rates are per 100,000 population.
HIV Surveillance Report
114
Vol. 29
HIV Surveillance Report
Table 27. Stage 3 (AIDS), by area of residence, 2016, 2017, and cumulative—United States and 6 dependent areas
2016
Adults and
adolescents
2017
Children
Adults and
adolescents
Total
Children
Cumulativea
Total
115
Vol. 29
Area of residence
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
298
22
293
110
2,201
178
140
71
187
2,239
1,104
33
24
682
231
61
59
181
559
16
583
271
378
133
275
228
15
35
241
22
527
63
1,605
598
15
7.3
3.6
5.1
4.4
6.7
3.8
4.6
8.8
31.7
12.7
13.0
2.7
1.8
6.3
4.2
2.3
2.5
4.9
14.4
1.4
11.5
4.6
4.5
2.9
11.1
4.5
1.7
2.2
9.8
1.9
7.0
3.6
9.5
7.0
2.4
1
0
0
0
5
0
0
0
0
3
4
0
0
3
0
1
0
0
1
0
1
0
1
0
0
2
0
0
0
0
2
1
3
1
0
0.1
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.1
0.2
0.0
0.0
0.1
0.0
0.2
0.0
0.0
0.1
0.0
0.1
0.0
0.1
0.0
0.0
0.2
0.0
0.0
0.0
0.0
0.1
0.3
0.1
0.1
0.0
299
22
293
110
2,206
178
140
71
187
2,242
1,108
33
24
685
231
62
59
181
560
16
584
271
379
133
275
230
15
35
241
22
529
64
1,608
599
15
6.2
3.0
4.2
3.7
5.6
3.2
3.9
7.5
27.3
10.9
10.7
2.3
1.4
5.3
3.5
2.0
2.0
4.1
12.0
1.2
9.7
4.0
3.8
2.4
9.2
3.8
1.4
1.8
8.2
1.6
5.9
3.1
8.1
5.9
2.0
294
13
306
141
1,879
171
121
58
147
2,179
1,295
31
19
604
251
60
61
157
503
22
581
269
334
145
246
176
11
33
192
12
488
45
1,451
592
14
7.2
2.2
5.2
5.6
5.7
3.6
3.9
7.1
24.7
12.1
15.0
2.6
1.4
5.6
4.5
2.3
2.5
4.2
13.0
1.9
11.4
4.6
4.0
3.1
9.9
3.4
1.2
2.1
7.7
1.0
6.4
2.6
8.6
6.9
2.2
0
0
2
0
0
0
0
0
0
8
6
2
0
3
1
0
0
0
3
1
0
1
0
0
0
1
0
0
0
0
1
0
1
0
0
0.0
0.0
0.2
0.0
0.0
0.0
0.0
0.0
0.0
0.3
0.3
0.9
0.0
0.1
0.1
0.0
0.0
0.0
0.4
0.6
0.0
0.1
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
294
13
308
141
1,879
171
121
58
147
2,187
1,301
33
19
607
252
60
61
157
506
23
581
270
334
145
246
177
11
33
192
12
489
45
1,452
592
14
6.0
1.8
4.4
4.7
4.8
3.0
3.4
6.0
21.2
10.4
12.5
2.3
1.1
4.7
3.8
1.9
2.1
3.5
10.8
1.7
9.6
3.9
3.4
2.6
8.2
2.9
1.0
1.7
6.4
0.9
5.4
2.2
7.3
5.8
1.9
Adults and
adolescents Children
12,571
861
14,512
5,412
177,127
11,320
16,943
4,548
20,928
136,876
51,268
3,566
888
44,109
11,513
2,509
3,673
6,770
25,355
1,427
40,162
24,736
20,099
6,952
10,050
14,352
560
2,100
8,245
1,353
58,875
3,520
201,308
24,925
249
80
6
51
38
714
34
184
29
191
1,571
264
20
4
288
63
15
17
39
150
10
339
233
121
33
58
68
3
12
28
10
812
10
2,420
145
2
Total
12,651
867
14,563
5,450
177,841
11,354
17,127
4,577
21,119
138,447
51,532
3,586
892
44,397
11,576
2,524
3,690
6,809
25,505
1,437
40,501
24,969
20,220
6,985
10,108
14,420
563
2,112
8,273
1,363
59,687
3,530
203,728
25,070
251
HIV Surveillance Report
Table 27. Stage 3 (AIDS), by area of residence, 2016, 2017, and cumulative—United States and 6 dependent areas (cont)
2016
Adults and
adolescents
Area of residence
116
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Subtotal
U.S. dependent areas
American Samoa
Guam
Northern Mariana Islands
Puerto Rico
Republic of Palau
U.S. Virgin Islands
Subtotal
Total
2017
Children
Adults and
adolescents
Total
Cumulativea
Total
Adults and
adolescents Children
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
No.
Rateb
475
152
100
541
29
366
21
307
2,078
47
7
387
170
43
103
11
18,515
4.9
4.7
2.9
5.0
3.2
8.8
3.0
5.5
9.2
2.0
1.3
5.5
2.8
2.8
2.1
2.3
6.8
0
1
0
1
0
1
0
0
5
0
0
1
1
0
0
0
39
0.0
0.1
0.0
0.1
0.0
0.1
0.0
0.0
0.1
0.0
0.0
0.1
0.1
0.0
0.0
0.0
0.1
475
153
100
542
29
367
21
307
2,083
47
7
388
171
43
103
11
18,554
4.1
3.9
2.4
4.2
2.7
7.4
2.4
4.6
7.5
1.5
1.1
4.6
2.3
2.4
1.8
1.9
5.7
421
145
95
559
37
429
9
308
1,903
41
13
370
191
39
104
6
17,571
4.3
4.5
2.7
5.1
4.0
10.1
1.3
5.5
8.3
1.7
2.4
5.2
3.1
2.5
2.1
1.3
6.4
0
0
0
1
0
1
0
1
0
0
0
0
0
0
0
0
33
0.0
0.0
0.0
0.1
0.0
0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
421
145
95
560
37
430
9
309
1,903
41
13
370
191
39
104
6
17,604
3.6
3.7
2.3
4.4
3.5
8.6
1.0
4.6
6.7
1.3
2.1
4.4
2.6
2.1
1.8
1.0
5.4
21,293
6,671
7,735
42,919
3,193
19,201
415
17,770
97,391
2,954
572
22,631
14,898
2,040
6,083
348
1,235,776
151
27
18
372
29
122
7
71
411
21
6
191
33
11
39
2
9,573
21,444
6,698
7,753
43,291
3,222
19,323
422
17,841
97,802
2,975
578
22,822
14,931
2,051
6,122
350
1,245,349
0
5
0
263
1
8
277
0.0
4.0
0.0
9.0
5.6
9.1
8.5
0
0
0
0
0
1
1
0.0
0.0
0.0
0.0
0.0
5.2
0.2
0
5
0
263
1
9
278
0.0
3.0
0.0
7.7
4.7
8.4
7.3
0
4
0
190
0
5
199
0.0
3.2
0.0
6.6
0.0
5.7
6.2
0
0
0
0
0
0
0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0
4
0
190
0
5
199
0.0
2.4
0.0
5.7
0.0
4.7
5.3
1
109
7
35,080
6
806
36,009
0
2
0
406
0
21
429
1
111
7
35,486
6
827
36,438
18,792
6.9
40
0.1
18,832
5.8
17,770
6.4
33
0.1
17,803
5.4
1,271,785
10,002
1,281,787
Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.
a From the beginning of the epidemic through 2017.
b
Children
Rates are per 100,000 population.
Total
Vol. 29
HIV Surveillance Report
Table 28. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas
American Indian/
Alaska Native
Area of residence
117
Vol. 29
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
No.
5
171
599
5
316
66
10
3
11
61
23
9
13
32
7
5
9
5
30
7
18
28
27
105
10
11
24
25
52
0
11
260
56
170
13
Asiana
Black/African
American
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
21.0
207.4
274.7
26.8
224.7
220.5
163.5
116.0
854.0
131.9
114.2
337.3
85.6
192.8
53.6
68.0
46.2
61.3
120.5
98.3
144.3
271.3
57.1
233.5
86.6
49.8
50.7
208.1
244.6
0.0
103.2
176.6
115.2
178.4
46.0
33
22
195
17
4,894
128
91
7
72
515
233
392
8
455
185
54
35
49
66
7
205
395
131
150
18
76
3
39
278
10
322
12
1,774
168
4
58.8
56.7
103.5
45.0
100.2
87.8
65.7
22.0
283.2
104.6
67.5
83.1
40.3
76.7
152.4
84.7
49.3
92.6
93.6
51.2
62.2
103.1
51.4
70.1
69.4
75.3
42.3
104.2
129.5
33.4
44.1
44.6
119.6
71.1
41.7
8,037
100
1,991
2,401
21,235
1,796
3,415
1,857
10,459
49,547
35,166
158
96
16,703
3,956
509
732
2,245
13,742
240
23,913
5,836
8,613
2,854
6,898
5,319
21
587
2,257
141
15,941
186
48,049
18,768
133
758.8
492.9
841.0
647.5
1,127.1
992.6
1,134.2
1,097.4
3,939.5
1,896.2
1,343.6
680.7
1,078.9
1,116.5
800.0
610.6
540.3
771.1
1,137.0
1,710.1
1,607.6
1,470.7
765.7
1,142.1
767.4
930.1
497.7
840.2
1,087.3
1,035.3
1,645.6
581.9
1,973.1
1,041.6
815.6
405
69
4,686
364
46,251
2,686
3,487
263
1,138
25,134
3,559
297
171
6,826
1,027
249
502
467
935
101
2,179
5,380
906
827
307
689
39
328
2,337
158
10,053
1,568
44,524
2,390
25
285.0
183.6
287.3
232.6
389.7
299.4
799.7
415.3
1,943.3
588.3
505.3
284.9
114.9
410.0
315.3
192.3
206.1
423.8
517.7
629.7
495.4
888.2
250.0
399.8
457.5
377.9
141.3
230.1
367.2
443.3
712.0
196.4
1,477.7
360.3
133.9
3
3
19
5
232
12
5
1
8
42
15
236
2
21
1
0
1
1
6
0
3
5
3
4
1
5
2
1
28
0
7
0
19
10
0
153.5
42.6
182.3
86.6
192.1
202.7
481.2
373.1
2,787.5
385.4
300.5
214.4
88.0
720.9
53.9
0.0
51.9
50.3
383.9
0.0
118.7
219.5
135.9
201.0
116.8
91.1
320.0
108.8
187.9
0.0
279.6
0.0
260.1
194.9
0.0
3,435
285
7,710
2,437
48,831
7,209
3,047
935
2,303
30,189
9,776
1,262
775
9,790
5,415
1,602
1,493
3,810
4,936
1,146
4,225
8,069
5,236
3,838
1,804
5,634
476
1,057
3,952
812
6,813
1,165
23,588
7,581
184
124.9
73.7
229.1
131.2
372.2
219.6
141.9
177.7
1,013.6
301.0
207.1
446.2
67.4
142.8
120.7
70.0
79.6
119.0
209.9
105.4
156.7
184.2
81.0
100.9
124.8
136.1
61.8
82.6
305.7
76.6
156.2
165.3
244.9
135.3
34.0
Totalc
Multiple races
No.
679
41
431
283
4,361
265
230
125
499
2,512
2,565
269
37
1,899
406
136
151
257
367
41
1,963
345
501
282
386
368
27
48
288
51
2,251
91
9,511
1,216
17
Rated
1,493.5
129.9
479.8
820.8
594.5
323.6
578.4
956.8
4,544.6
1,158.8
2,285.5
130.6
170.5
1,520.4
579.0
471.2
334.9
568.7
909.1
286.5
2,203.6
440.5
367.2
393.3
1,968.8
477.0
157.8
239.6
458.9
381.7
2,602.3
421.0
4,279.5
1,059.7
194.6
No.
Rated
12,643
309.9
691
114.3
15,676
273.1
5,516
222.3
126,129
385.1
12,215
264.2
10,286
335.1
3,191
395.7
14,495 2,459.9
108,003
610.8
51,350
602.4
2,623
218.4
1,102
80.7
35,728
332.3
10,997
199.5
2,555
98.1
2,926
122.4
6,836
184.3
20,085
517.8
1,543
133.9
32,506
642.8
20,060
342.5
15,422
183.7
8,065
175.6
9,458
383.0
12,104
237.4
592
67.7
2,086
133.5
9,194
375.2
1,173
101.5
35,452
468.2
3,283
189.5
127,934
759.7
30,310
355.7
376
60.3
HIV Surveillance Report
Table 28. Adults and adolescents living with diagnosed HIV infection, by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas (cont)
American Indian/
Alaska Native
Area of residence
118
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Subtotal
U.S. dependent arease
American Samoa
Guam
Northern Mariana Islands
Puerto Rico
Republic of Palau
U.S. Virgin Islands
Subtotal
Total
Black/African
American
Asiana
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Totalc
Multiple races
No.
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
11
303
52
37
7
13
74
11
46
21
0
13
127
3
26
12
2,953
56.7
117.0
136.0
238.1
188.8
82.8
141.9
68.1
58.9
91.8
0.0
67.0
165.0
88.3
63.7
128.7
152.3
103
76
132
275
33
37
5
68
870
60
11
277
427
6
83
2
13,508
48.6
105.7
85.0
75.1
104.9
55.3
50.6
69.9
79.8
97.8
118.6
60.1
80.7
46.8
65.3
43.1
88.6
9,330
1,382
468
17,303
556
11,484
116
9,033
31,261
252
66
12,422
1,978
363
2,255
26
412,196
798.4
587.6
754.5
1,533.5
1,091.6
1,043.4
974.1
994.5
1,160.7
1,022.6
1,097.8
928.0
882.6
675.5
795.0
490.8
1,247.3
1,393
603
940
6,050
657
789
34
825
27,494
605
47
1,997
1,826
83
828
55
214,553
450.0
212.0
244.4
900.1
542.5
396.5
164.2
338.6
331.6
200.7
506.6
343.0
279.7
388.5
298.0
128.5
485.2
2
8
18
19
1
4
1
4
26
6
1
7
49
0
1
0
848
60.6
187.0
139.4
619.1
179.2
163.1
277.8
146.3
139.9
27.2
625.0
137.1
123.8
0.0
63.3
0.0
184.2
9,426
3,227
4,938
10,772
1,078
3,976
280
5,719
21,848
1,730
513
6,011
7,538
1,221
2,688
211
301,996
119.1
145.2
181.6
125.5
156.5
145.1
46.8
134.9
214.2
90.9
101.2
132.7
171.9
84.1
66.0
50.9
176.3
885
327
201
1,699
64
405
15
527
3,249
60
27
808
815
94
188
8
42,271
622.0
224.2
223.8
1,357.0
448.2
841.6
143.2
777.5
1,291.4
163.5
355.5
598.7
425.0
521.4
339.0
123.6
962.5
21,258
5,926
6,749
36,159
2,396
16,718
525
16,190
84,802
2,737
665
21,565
12,769
1,774
6,070
314
989,222
217.6
183.8
195.0
331.9
263.0
400.7
74.6
290.4
374.8
115.3
122.9
305.0
209.4
113.6
124.9
65.0
365.5
0
0
0
1
0
0
1
—
—
—
—
—
—
—
0
45
1
2
2
2
52
—
—
—
—
—
—
—
0
3
0
2
0
297
302
—
—
—
—
—
—
—
0
7
1
16,782
1
199
16,990
—
—
—
—
—
—
—
1
19
2
1
6
0
29
—
—
—
—
—
—
—
0
10
2
19
0
45
76
—
—
—
—
—
—
—
0
8
1
2
0
5
16
—
—
—
—
—
—
—
1
92
7
16,809
9
551
17,469
2.6
72.8
17.4
572.6
50.5
625
538.1
2,954
—
13,560
—
412,498
—
231,543
—
877
—
302,072
—
42,287
—
1,006,691
367.6
Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Numbers less than 12, and rates based on these numbers, should be interpreted with caution
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population.
e Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.
No.
Rated
Vol. 29
HIV Surveillance Report
Table 29. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas
American Indian/
Alaska Native
Area of residence
119
Vol. 29
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
No.
0
95
304
2
163
32
7
2
6
25
9
3
5
9
3
3
2
3
13
3
4
16
11
57
2
9
18
10
26
0
6
133
32
75
10
Asiana
Black/African
American
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
White
Totalc
Multiple races
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
No.
Rated
0.0
115.2
139.4
10.7
115.9
106.9
114.5
77.3
465.8
54.1
44.7
112.4
32.9
54.2
23.0
40.8
10.3
36.8
52.2
42.1
32.1
155.1
23.2
126.8
17.3
40.7
38.0
83.3
122.3
0.0
56.3
90.4
65.8
78.7
35.4
12
14
73
4
2,467
52
44
4
30
228
90
226
2
204
84
21
14
16
25
5
82
199
51
75
9
35
1
20
128
7
146
4
817
52
3
21.4
36.1
38.7
10.6
50.5
35.7
31.8
12.6
118.0
46.3
26.1
47.9
10.1
34.4
69.2
32.9
19.7
30.2
35.5
36.6
24.9
51.9
20.0
35.1
34.7
34.7
14.1
53.4
59.6
23.4
20.0
14.9
55.1
22.0
31.3
3,587
43
861
1,025
11,765
820
2,107
1,184
5,873
28,171
17,874
83
41
8,477
1,880
265
356
1,091
7,097
86
12,806
3,407
4,480
1,353
3,330
2,774
12
303
1,112
71
8,215
88
28,098
8,435
62
338.6
211.9
363.7
276.4
624.4
453.2
699.8
699.7
2,212.1
1,078.1
682.9
357.6
460.8
566.7
380.2
317.9
262.8
374.7
587.2
612.8
860.9
858.6
398.3
541.4
370.5
485.0
284.4
433.7
535.7
521.3
848.0
275.3
1,153.8
468.1
380.2
217
41
2,264
180
26,273
1,357
2,231
156
559
12,662
1,892
171
95
3,698
556
153
282
272
495
55
1,218
3,109
478
456
167
370
21
172
1,154
95
5,241
855
26,942
1,129
13
152.7
109.1
138.8
115.0
221.4
151.3
511.7
246.3
954.6
296.4
268.6
164.0
63.8
222.1
170.7
118.2
115.8
246.8
274.1
342.9
276.9
513.3
131.9
220.5
248.9
202.9
76.1
120.7
181.3
266.5
371.2
107.1
894.2
170.2
69.6
1
2
10
3
112
5
5
1
2
13
4
144
0
9
0
0
0
0
2
0
1
2
2
0
0
3
1
1
13
0
1
0
5
2
0
51.2
28.4
96.0
52.0
92.7
84.5
481.2
373.1
696.9
119.3
80.1
130.8
0.0
309.0
0.0
0.0
0.0
0.0
128.0
0.0
39.6
87.8
90.6
0.0
0.0
54.7
160.0
108.8
87.2
0.0
39.9
0.0
68.5
39.0
0.0
1,442
164
3,834
1,144
27,387
2,987
1,848
543
972
16,120
4,857
709
385
4,723
2,748
922
791
1,924
2,546
615
2,070
4,354
2,715
1,680
877
2,896
271
524
1,908
406
3,382
711
12,342
3,245
84
52.4
42.4
113.9
61.6
208.7
91.0
86.1
103.2
427.8
160.7
102.9
250.7
33.5
68.9
61.3
40.3
42.2
60.1
108.2
56.6
76.8
99.4
42.0
44.2
60.7
70.0
35.2
41.0
147.6
38.3
77.5
100.9
128.2
57.9
15.5
341
23
228
161
2,375
153
154
73
274
1,540
1,482
160
25
1,074
236
73
80
145
207
20
1,162
199
285
160
228
229
18
31
160
32
1,387
56
5,946
625
11
750.0
72.8
253.8
467.0
323.8
186.9
387.3
558.7
2,495.4
710.4
1,320.5
77.7
115.2
859.9
336.6
252.9
177.4
320.9
512.8
139.8
1,304.4
254.1
208.9
223.1
1,162.9
296.8
105.2
154.8
254.9
239.5
1,603.4
259.1
2,675.4
544.7
125.9
No.
5,600
382
7,575
2,519
70,547
5,406
6,396
1,963
7,717
58,760
26,209
1,496
553
18,194
5,507
1,437
1,525
3,451
10,386
784
17,343
11,287
8,022
3,781
4,613
6,316
342
1,061
4,501
611
18,380
1,847
74,203
13,563
183
Rated
137.3
63.2
132.0
101.5
215.4
116.9
208.4
243.5
1,309.7
332.3
307.5
124.6
40.5
169.2
99.9
55.2
63.8
93.0
267.8
68.0
342.9
192.7
95.6
82.3
186.8
123.9
39.1
67.9
183.7
52.9
242.8
106.6
440.7
159.2
29.3
HIV Surveillance Report
Table 29. Adults and adolescents living with diagnosed HIV infection ever classified as stage 3 (AIDS), by race/ethnicity and area of residence, year-end 2016—United States and 6 dependent areas (cont)
American Indian/
Alaska Native
Area of residence
120
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Subtotal
U.S. dependent arease
American Samoa
Guam
Northern Mariana Islands
Puerto Rico
Republic of Palau
U.S. Virgin Islands
Subtotal
Total
No.
Rated
5
150
31
14
3
6
42
6
21
10
0
6
75
1
11
8
1,487
Hispanic/Latinob
Native Hawaiian/
Other Pacific
Islander
No.
Rated
No.
Rated
372.5
275.1
420.8
853.9
628.3
572.9
411.5
480.5
577.0
499.1
565.5
427.3
465.8
342.4
373.7
207.7
656.3
681
305
537
3,396
390
432
19
450
14,729
337
29
1,007
1,021
50
460
36
118,908
220.0
107.2
139.6
505.3
322.1
217.1
91.8
184.7
177.6
111.8
312.6
173.0
156.4
234.0
165.6
84.1
268.9
0
3
9
8
1
3
1
2
7
3
1
4
30
0
0
0
416
0
1
0
1
0
162
164
—
—
—
—
—
—
—
0
1
0
9,070
0
112
9,183
—
—
—
—
—
—
—
217,047
—
128,091
—
Black/African
American
Asiana
No.
Rated
No.
Rated
25.8
57.9
81.1
90.1
80.9
38.2
80.6
37.1
26.9
43.7
0.0
30.9
97.4
29.4
26.9
85.8
76.7
37
31
59
128
17
20
1
33
360
24
5
128
217
1
32
1
6,338
17.5
43.1
38.0
34.9
54.0
29.9
10.1
33.9
33.0
39.1
53.9
27.8
41.0
7.8
25.2
21.6
41.6
4,353
647
261
9,635
320
6,305
49
4,364
15,541
123
34
5,720
1,044
184
1,060
11
216,883
0
0
0
1
0
0
1
—
—
—
—
—
—
—
0
16
1
0
1
1
19
—
—
—
—
—
—
—
1,488
—
6,357
—
Note. Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanics/Latinos can be of any race.
c Includes persons whose race/ethnicity is unknown.
d
Rates are per 100,000 population.
Vol. 29
e Rates by race/ethnicity are not provided because U.S. census information for U.S. dependent areas is limited.
White
Totalc
Multiple races
No.
Rated
No.
Rated
No.
0.0
70.1
69.7
260.7
179.2
122.3
277.8
73.2
37.7
13.6
625.0
78.4
75.8
0.0
0.0
0.0
90.4
4,525
1,590
2,858
5,897
598
2,001
113
2,956
11,437
905
265
2,816
4,038
697
1,344
113
156,279
1
8
2
0
4
0
15
—
—
—
—
—
—
—
431
—
Rated
57.2
71.5
105.1
68.7
86.8
73.0
18.9
69.7
112.1
47.5
52.3
62.2
92.1
48.0
33.0
27.3
91.2
474
170
104
1,061
28
253
9
319
1,810
30
15
451
495
56
101
6
24,735
333.1
116.6
115.8
847.4
196.1
525.7
85.9
470.7
719.4
81.7
197.5
334.2
258.1
310.6
182.1
92.7
563.2
10,076
2,896
3,859
20,139
1,357
9,020
234
8,130
43,906
1,432
349
10,132
6,925
989
3,008
175
525,087
103.1
89.8
111.5
184.9
149.0
216.2
33.2
145.8
194.1
60.3
64.5
143.3
113.5
63.3
61.9
36.2
194.0
0
4
0
6
0
27
37
—
—
—
—
—
—
—
0
5
0
1
0
3
9
—
—
—
—
—
—
—
1
35
3
9,079
5
305
9,428
2.6
27.7
7.5
309.3
28.1
346.0
290.4
156,316
—
24,744
—
534,515
195.2
Table 30. Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), yearend 2016, by metropolitan statistical area of residence—United States and Puerto Rico
Prevalence of diagnosed HIV
infection, year-end 2016b
Diagnosis, 2017a
MSA of residence
No.
Ratec
Rankd
Akron, OH
Albany–Schenectady–Troy, NY
Albuquerque, NM
Allentown–Bethlehem–Easton, PA–NJ
Atlanta–Sandy Springs–Roswell, GA
Augusta–Richmond County, GA–SC
Austin–Round Rock, TX
Bakersfield, CA
Baltimore–Columbia–Towson, MD
Baton Rouge, LA
Birmingham–Hoover, AL
Boise City, ID
Boston–Cambridge–Newton, MA–NHe
Boston Division
Cambridge Division
Bridgeport–Stamford–Norwalk, CT
Buffalo–Cheektowaga–Niagara Falls, NY
Cape Coral–Fort Myers, FL
Charleston–North Charleston, SC
Charlotte–Concord–Gastonia, NC–SC
Chattanooga, TN–GA
Chicago–Naperville–Elgin, IL–IN–WI
Chicago Division
Elgin Division
Gary Division
Lake County Division
Cincinnati, OH–KY–IN
Cleveland–Elyria, OH
Colorado Springs, CO
Columbia, SC
Columbus, OH
Dallas–Fort Worth–Arlington, TX
Dallas Division
Fort Worth Division
Dayton, OH
Deltona–Daytona Beach–Ormond Beach, FL
Denver–Aurora–Lakewood, CO
Des Moines–West Des Moines, IA
Detroit–Warren–Dearborn, MI
Detroit Division
Warren Division
Durham–Chapel Hill, NC
El Paso, TX
Fayetteville–Springdale–Rogers, AR–MO
Fresno, CA
Grand Rapids–Wyoming, MI
Greensboro–High Point, NC
Greenville–Anderson–Mauldin, SC
Harrisburg–Carlisle, PA
Hartford–West Hartford–East Hartford, CT
Honolulu (Urban), HI
50
61
37
48
1,607
89
290
149
443
224
182
22
456
240
209
51
99
81
117
394
51
1,104
984
36
46
38
271
209
35
170
276
1,300
995
305
80
94
316
39
520
322
198
80
150
28
158
59
143
94
48
98
60
7.1
6.9
4.1
5.7
27.3
14.8
13.7
16.7
15.8
26.9
15.8
3.1
9.4
11.9
8.8
5.4
8.7
11.0
15.1
15.6
9.2
11.6
13.4
5.6
6.6
4.4
12.4
10.2
4.8
20.6
13.3
17.6
20.3
12.3
10.0
14.5
10.9
6.0
12.1
18.4
7.7
14.1
17.8
5.2
16.0
5.6
18.8
10.5
8.4
8.1
6.1
79
83
103
89
3
28
35
18
23
5
22
105
61
—
—
94
65
49
26
25
63
45
—
—
—
—
41
58
96
9
38
16
—
—
59
29
50
88
43
—
—
31
15
95
21
91
12
54
68
70
87
HIV Surveillance Report
121
No.
Ratec
937
2,107
1,653
596
32,043
2,305
5,848
1,485
17,013
5,097
4,004
260
13,830
7,965
5,571
2,602
2,509
2,103
2,550
8,014
1,154
29,822
27,256
417
1,177
972
4,028
5,222
902
3,923
5,528
26,092
20,394
5,698
1,583
1,804
9,301
820
9,818
6,675
3,143
2,215
2,064
616
1,811
1,196
2,627
1,970
383
3,267
1,583
133.4
238.7
182.3
71.4
552.9
387.5
283.8
167.8
607.4
610.0
349.1
37.6
287.8
398.3
234.6
274.1
221.1
291.1
334.7
323.7
209.1
312.4
371.6
65.5
167.8
111.4
186.0
253.5
126.9
479.9
270.1
359.7
424.0
233.2
197.7
283.3
326.1
129.2
228.0
380.0
123.3
396.3
245.4
117.3
184.9
114.0
347.2
222.7
67.4
270.0
159.5
Vol. 29
Table 30. Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), yearend 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)
Prevalence of diagnosed HIV
infection, year-end 2016b
Diagnosis, 2017a
MSA of residence
No.
Ratec
Rankd
No.
Ratec
Houston–The Woodlands–Sugar Land, TX
Indianapolis–Carmel–Anderson, IN
Jackson, MS
Jacksonville, FL
Kansas City, MO–KS
Knoxville, TN
Lakeland–Winter Haven, FL
Lancaster, PA
Las Vegas–Henderson–Paradise, NV
Lexington–Fayette, KY
Little Rock–North Little Rock–Conway, AR
Los Angeles–Long Beach–Anaheim, CA
Anaheim Division
Los Angeles Division
Louisville/Jefferson County, KY–IN
Madison, WI
McAllen–Edinburg–Mission, TX
Memphis, TN–MS–AR
Miami–Fort Lauderdale–West Palm Beach, FL
Fort Lauderdale Division
Miami Division
West Palm Beach Division
Milwaukee–Waukesha–West Allis, WI
Minneapolis–St. Paul–Bloomington, MN–WI
Modesto, CA
Nashville–Davidson–Murfreesboro–Franklin, TN
New Haven–Milford, CT
New Orleans–Metairie, LA
New York–Newark–Jersey City, NY–NJ–PAe
Nassau County Division
New York Division
Newark Division
North Port–Sarasota–Bradenton, FL
Ogden–Clearfield, UT
Oklahoma City, OK
Omaha–Council Bluffs, NE–IA
Orlando–Kissimmee–Sanford, FL
Oxnard–Thousand Oaks–Ventura, CA
Palm Bay–Melbourne–Titusville, FL
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD
Camden Division
Montgomery County Division
Philadelphia Division
Wilmington Division
Phoenix–Mesa–Scottsdale, AZ
Pittsburgh, PA
Portland–South Portland, ME
Portland–Vancouver–Hillsboro, OR–WA
Providence–Warwick, RI–MA
Provo–Orem, UT
Raleigh, NC
1,340
282
137
353
183
66
94
23
446
50
137
1,832
304
1,528
171
27
94
288
2,177
683
1,181
313
144
234
43
197
89
344
3,266
194
2,597
458
83
11
159
53
718
68
55
842
125
77
540
100
562
126
14
158
118
9
145
19.4
13.9
23.7
23.5
8.6
7.5
13.7
4.2
20.2
9.8
18.6
13.7
9.5
15.0
13.2
4.1
10.9
21.4
35.3
35.3
42.9
21.3
9.1
6.5
7.8
10.4
10.3
27.0
16.1
6.8
17.9
18.1
10.3
1.7
11.5
5.7
28.6
8.0
9.3
13.8
10.0
3.9
25.2
13.8
11.9
5.4
2.6
6.4
7.3
1.5
10.9
11
32
6
7
66
75
36
101
10
60
13
34
—
—
39
102
51
8
1
—
—
—
64
85
73
55
56
4
20
—
—
—
57
107
46
90
2
72
62
33
—
—
—
—
44
93
106
86
78
108
52
28,581
5,414
2,911
6,759
4,545
1,252
2,247
174
7,703
1,076
2,157
54,845
6,596
48,249
3,502
717
1,278
6,926
53,269
19,135
26,243
7,891
3,100
6,882
673
5,003
3,229
7,679
138,830
6,003
118,072
13,683
1,901
359
2,697
482
11,316
974
1,497
23,920
2,874
667
18,066
2,313
11,685
846
816
5,321
3,423
183
3,742
420.4
269.9
502.3
457.8
215.8
144.3
336.9
32.3
357.2
212.3
294.1
411.5
207.6
475.3
272.6
110.7
150.3
514.9
872.2
998.1
959.0
542.8
196.7
193.5
124.3
267.7
375.5
604.1
684.7
209.9
814.3
542.8
241.1
55.0
196.5
52.2
461.3
114.4
259.0
393.6
229.8
34.0
844.7
319.6
251.4
36.1
154.5
219.6
211.8
30.4
286.8
HIV Surveillance Report
122
Vol. 29
Table 30. Diagnoses of HIV infection, 2017, and persons living with diagnosed HIV infection (prevalence), yearend 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)
Prevalence of diagnosed HIV
infection, year-end 2016b
Diagnosis, 2017a
MSA of residence
No.
Ratec
Rankd
Richmond, VA
Riverside–San Bernardino–Ontario, CA
Rochester, NY
Sacramento–Roseville–Arden-Arcade, CA
St. Louis, MO–IL
Salt Lake City, UT
San Antonio–New Braunfels, TX
San Diego–Carlsbad, CA
San Francisco–Oakland–Hayward, CAe
Oakland Division
San Francisco Division
San Jose–Sunnyvale–Santa Clara, CA
San Juan–Carolina–Caguas, PR
Santa Rosa, CA
Scranton–Wilkes-Barre–Hazelton, PA
Seattle–Tacoma–Bellevue, WA
Seattle Division
Tacoma Division
Spokane–Spokane Valley, WA
Springfield, MA
Stockton–Lodi, CA
Syracuse, NY
Tampa–St. Petersburg–Clearwater, FL
Toledo, OH
Tucson, AZ
Tulsa, OK
Virginia Beach–Norfolk–Newport News, VA–NC
Washington–Arlington–Alexandria, DC–VA–MD–WV
Silver Spring Division
Washington Division
Wichita, KS
Winston-Salem, NC
Worcester, MA–CT
Youngstown–Warren–Boardman, OH–PA
187
490
75
163
311
83
389
405
635
312
307
162
317
28
24
303
254
49
24
47
63
22
561
45
116
80
285
1,087
202
885
29
88
62
23
14.4
10.7
7.0
7.0
11.1
6.9
15.7
12.1
13.4
11.1
18.5
8.1
15.0
5.6
4.3
7.8
8.5
5.6
4.3
7.4
8.5
3.4
18.1
7.5
11.3
8.1
16.5
17.5
15.4
18.0
4.5
13.2
6.6
4.2
31,025
Metropolitan areas (population of 50,000–499,999)
Nonmetropolitan areas
Subtotal for MSAs (population of 500,000)
Totalf
No.
Ratec
30
53
81
80
48
82
24
42
37
—
—
69
27
92
98
74
—
—
99
77
67
104
14
76
47
71
19
17
—
—
97
40
84
100
3,212
11,412
2,929
4,880
6,868
1,928
6,425
12,677
23,031
8,168
14,065
3,032
9,375
1,431
297
9,204
7,809
1,395
590
2,127
1,268
1,284
12,308
987
2,422
1,862
4,818
20,038
3,869
16,169
886
1,841
2,015
720
250.5
252.3
271.6
212.6
244.7
162.6
264.8
382.2
490.1
292.6
854.7
152.3
435.1
284.0
53.5
242.0
265.3
162.3
106.3
337.3
172.7
195.5
405.3
163.3
239.2
188.6
279.7
325.8
298.5
333.1
137.4
278.2
215.1
132.2
13.8
—
790,466
355.5
4,907
8.4
—
100,328
172.0
2,314
5.0
—
55,032
119.3
38,726
11.8
—
1,008,264
308.5
Abbreviation: MSA, metropolitan statistical area.
Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico.
Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
MSA definitions for this report can be found at http://www.census.gov/programs-surveys/metro-micro.html.
a Data are based on residence at time of diagnosis of HIV infection.
b
Data are based on address of residence at the end of the specified year (i.e., most recent known address).
c
Rates are per 100,000 population.
d Based on rate.
e
Counts of diagnoses of HIV infection for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division
with population of <500,000.
f
Includes persons whose county of residence is unknown.
HIV Surveillance Report
123
Vol. 29
HIV Surveillance Report
Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence),
year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico
Diagnosis, cumulativea,b
MSA of residence
124
Vol. 29
Akron, OH
Albany–Schenectady–Troy, NY
Albuquerque, NM
Allentown–Bethlehem–Easton, PA–NJ
Atlanta–Sandy Springs–Roswell, GA
Augusta–Richmond County, GA–SC
Austin–Round Rock, TX
Bakersfield, CA
Baltimore–Columbia–Towson, MD
Baton Rouge, LA
Birmingham–Hoover, AL
Boise City, ID
Boston–Cambridge–Newton, MA–NHf
Boston Division
Cambridge Division
Bridgeport–Stamford–Norwalk, CT
Buffalo–Cheektowaga–Niagara Falls, NY
Cape Coral–Fort Myers, FL
Charleston–North Charleston, SC
Charlotte–Concord–Gastonia, NC–SC
Chattanooga, TN–GA
Chicago–Naperville–Elgin, IL–IN–WI
Chicago Division
Elgin Division
Gary Division
Lake County Division
Cincinnati, OH–KY–IN
Cleveland–Elyria, OH
Colorado Springs, CO
Columbia, SC
Columbus, OH
Diagnosis, 2017b
Adults or
adolescents
Children
Total
Rated
Ranke
No.
No.
No.
2.4
3.6
1.3
4.2
11.9
24.7
4.8
4.9
10.6
15.3
6.5
1.7
4.0
5.6
3.3
3.6
4.2
6.6
6.6
6.3
4.0
5.5
6.1
2.2
5.7
2.2
4.6
4.7
1.1
12.7
5.6
90
68
104
59
10
1
48
46
11
2
29
103
62
—
—
70
57
26
27
31
63
41
—
—
—
—
54
52
105
5
39
No.
17
32
12
35
698
148
102
44
298
128
75
12
192
112
78
34
48
49
51
159
22
521
448
14
40
19
101
97
8
105
117
985
2,674
1,856
1,797
34,876
2,823
6,488
2,183
26,219
5,918
3,665
458
17,331
10,708
6,234
4,335
3,097
2,340
2,841
6,293
1,371
39,463
36,107
826
1,465
1,065
4,032
5,515
760
4,729
4,993
1
27
4
18
146
26
26
9
229
26
25
0
163
97
65
57
20
25
25
30
3
265
242
9
9
5
21
47
5
26
24
986
2,701
1,860
1,815
35,022
2,849
6,514
2,192
26,448
5,944
3,690
458
17,494
10,805
6,299
4,392
3,117
2,365
2,866
6,323
1,374
39,728
36,349
835
1,474
1,070
4,053
5,562
765
4,755
5,017
Prevalence of stage 3
(AIDS), year-end 2016c
No.
410
1,207
943
305
16,356
1,145
3,058
842
9,214
2,679
1,689
88
7,632
4,464
3,023
1,541
1,287
1,211
1,326
3,492
615
14,987
13,675
226
565
521
1,971
2,472
405
2,163
2,492
Rated
58.4
136.7
104.0
36.5
282.2
192.5
148.4
95.1
329.0
320.6
147.3
12.7
158.8
223.2
127.3
162.3
113.4
167.6
174.0
141.1
111.4
157.0
186.4
35.5
80.5
59.7
91.0
120.0
57.0
264.6
121.7
HIV Surveillance Report
Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence),
year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)
Diagnosis, cumulativea,b
MSA of residence
125
Vol. 29
Dallas–Fort Worth–Arlington, TX
Dallas Division
Fort Worth Division
Dayton, OH
Deltona–Daytona Beach–Ormond Beach, FL
Denver–Aurora–Lakewood, CO
Des Moines–West Des Moines, IA
Detroit–Warren–Dearborn, MI
Detroit Division
Warren Division
Durham–Chapel Hill, NC
El Paso, TX
Fayetteville–Springdale–Rogers, AR–MO
Fresno, CA
Grand Rapids–Wyoming, MI
Greensboro–High Point, NC
Greenville–Anderson–Mauldin, SC
Harrisburg–Carlisle, PA
Hartford–West Hartford–East Hartford, CT
Honolulu (Urban), HI
Houston–The Woodlands–Sugar Land, TX
Indianapolis–Carmel–Anderson, IN
Jackson, MS
Jacksonville, FL
Kansas City, MO–KS
Knoxville, TN
Lakeland–Winter Haven, FL
Lancaster, PA
Las Vegas–Henderson–Paradise, NV
Lexington–Fayette, KY
Little Rock–North Little Rock–Conway, AR
Diagnosis, 2017b
Adults or
adolescents
Children
Total
Rated
Ranke
No.
No.
No.
7.8
9.0
5.3
3.6
7.5
4.3
3.1
5.0
8.0
2.9
7.0
5.8
1.9
6.8
2.5
4.7
7.4
4.4
3.8
2.7
9.0
5.9
14.5
12.0
3.4
2.5
6.3
2.4
7.6
3.5
9.6
19
—
—
69
21
56
78
45
—
—
23
37
100
24
88
51
22
55
65
84
14
35
4
8
73
89
32
91
20
71
12
No.
574
441
133
29
49
125
20
216
141
75
40
49
10
67
27
36
66
25
46
27
620
119
84
180
73
22
43
13
168
18
71
28,328
22,357
5,971
1,672
2,152
8,817
796
13,917
10,841
3,076
1,710
2,210
538
2,254
1,251
1,854
2,152
1,679
5,959
2,437
35,656
5,580
3,726
8,553
6,087
1,369
2,621
922
6,835
1,054
2,003
66
39
27
14
18
24
4
79
62
17
10
10
6
11
6
19
7
9
46
14
182
27
31
80
18
8
22
23
27
1
15
28,394
22,396
5,998
1,686
2,170
8,841
800
13,996
10,903
3,093
1,720
2,220
544
2,265
1,257
1,873
2,159
1,688
6,005
2,451
35,838
5,607
3,757
8,633
6,105
1,377
2,643
945
6,862
1,055
2,018
Prevalence of stage 3
(AIDS), year-end 2016c
No.
13,313
10,408
2,905
817
1,060
3,997
451
5,158
3,585
1,573
914
1,137
311
1,010
601
952
1,069
165
2,030
882
14,939
2,690
1,371
3,796
2,489
632
1,319
76
3,732
544
932
Rated
183.5
216.4
118.9
102.0
166.4
140.2
71.1
119.8
204.1
61.7
163.5
135.2
59.2
103.1
57.3
125.8
120.9
29.0
167.8
88.8
219.8
134.1
236.6
257.1
118.2
72.8
197.7
14.1
173.0
107.3
127.1
HIV Surveillance Report
Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence),
year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)
Diagnosis, cumulativea,b
Diagnosis, 2017b
Adults or
adolescents
Children
Total
No.
No.
No.
126
MSA of residence
No.
Rated
Ranke
Los Angeles–Long Beach–Anaheim, CA
Anaheim Division
Los Angeles Division
Louisville/Jefferson County, KY–IN
Madison, WI
McAllen–Edinburg–Mission, TX
Memphis, TN–MS–AR
Miami–Fort Lauderdale–West Palm Beach, FL
Fort Lauderdale Division
Miami Division
West Palm Beach Division
Milwaukee–Waukesha–West Allis, WI
Minneapolis–St. Paul–Bloomington, MN–WI
Modesto, CA
Nashville–Davidson–Murfreesboro–Franklin, TN
New Haven–Milford, CT
New Orleans–Metairie, LA
New York–Newark–Jersey City, NY–NJ–PAf
Nassau County Division
New York Division
Newark Division
North Port–Sarasota–Bradenton, FL
Ogden–Clearfield, UT
Oklahoma City, OK
Omaha–Council Bluffs, NE–IA
Orlando–Kissimmee–Sanford, FL
Oxnard–Thousand Oaks–Ventura, CA
Palm Bay–Melbourne–Titusville, FL
810
108
702
67
13
32
160
917
301
449
167
45
120
21
70
27
160
1,649
112
1,323
202
44
4
81
16
302
18
30
6.1
3.4
6.9
5.2
2.0
3.7
11.9
14.9
15.5
16.3
11.4
2.9
3.3
3.8
3.7
3.1
12.5
8.1
3.9
9.1
8.0
5.5
0.6
5.9
1.7
12.0
2.1
5.1
34
—
—
43
99
66
9
3
—
—
—
83
74
64
67
77
6
15
—
—
—
40
107
36
102
7
98
44
73,428
8,813
64,615
3,398
702
1,162
7,630
70,504
21,593
36,869
12,042
3,363
6,093
926
5,304
5,196
11,565
229,235
9,531
193,040
24,705
2,524
340
3,153
1,449
12,288
1,295
1,887
309
46
263
30
5
13
23
1,009
265
513
231
20
24
6
26
74
80
3,012
117
2,512
370
29
4
4
5
94
5
12
73,737
8,859
64,878
3,428
707
1,175
7,653
71,513
21,858
37,382
12,273
3,383
6,117
932
5,330
5,270
11,645
232,247
9,648
195,552
25,075
2,553
344
3,157
1,454
12,382
1,300
1,899
Prevalence of stage 3
(AIDS), year-end 2016c
No.
29,368
3,652
25,716
1,642
338
705
3,296
27,960
10,112
13,159
4,689
1,534
3,133
441
2,484
2,085
4,014
79,260
3,450
68,202
6,961
1,076
189
1,292
217
5,937
533
886
Rated
220.3
114.9
253.3
127.8
52.2
82.9
245.0
457.8
527.5
480.9
322.5
97.3
88.1
81.5
132.9
242.4
315.8
390.9
120.6
470.3
276.1
136.5
28.9
94.1
23.5
242.0
62.6
153.3
Vol. 29
HIV Surveillance Report
Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence),
year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)
Diagnosis, cumulativea,b
MSA of residence
127
Vol. 29
Philadelphia–Camden–Wilmington, PA–NJ–DE–MD
Camden Division
Montgomery County Division
Philadelphia Division
Wilmington Division
Phoenix–Mesa–Scottsdale, AZ
Pittsburgh, PA
Portland–South Portland, ME
Portland–Vancouver–Hillsboro, OR–WA
Providence–Warwick, RI–MA
Provo–Orem, UT
Raleigh, NC
Richmond, VA
Riverside–San Bernardino–Ontario, CA
Rochester, NY
Sacramento–Roseville–Arden-Arcade, CA
St. Louis, MO–IL
Salt Lake City, UT
San Antonio–New Braunfels, TX
San Diego–Carlsbad, CA
San Francisco–Oakland–Hayward, CAf
Oakland Division
San Francisco Division
San Jose–Sunnyvale–Santa Clara, CA
San Juan–Carolina–Caguas, PR
Santa Rosa, CA
Scranton–Wilkes-Barre–Hazelton, PA
Seattle–Tacoma–Bellevue, WA
Seattle Division
Tacoma Division
Spokane–Spokane Valley, WA
Diagnosis, 2017b
Adults or
adolescents
Children
Total
Rated
Ranke
No.
No.
No.
6.5
2.6
2.2
12.7
6.8
4.8
2.2
2.3
2.6
3.1
0.8
5.8
6.6
4.7
4.2
3.4
4.0
1.8
6.5
4.8
5.5
3.8
8.8
2.6
6.2
2.2
0.5
2.9
3.2
2.1
2.3
28
—
—
—
—
49
95
94
87
76
106
38
25
53
58
72
61
101
30
47
42
—
—
86
33
97
108
80
—
—
92
No.
398
33
44
272
49
227
52
12
63
51
5
77
86
215
45
80
113
22
160
161
258
107
146
52
132
11
3
114
96
18
13
35,739
3,988
2,954
25,029
3,768
10,579
4,149
749
6,142
4,853
165
3,191
4,613
11,608
3,737
5,198
7,955
2,085
7,190
15,985
46,469
12,184
32,563
4,912
25,125
2,166
740
11,366
10,015
1,351
691
317
43
12
238
24
32
22
2
9
45
3
20
36
63
17
31
45
9
32
72
102
53
44
17
279
8
7
27
18
9
1
36,056
4,031
2,966
25,267
3,792
10,611
4,171
751
6,151
4,898
168
3,211
4,649
11,671
3,754
5,229
8,000
2,094
7,222
16,057
46,571
12,237
32,607
4,929
25,404
2,174
747
11,393
10,033
1,360
692
Prevalence of stage 3
(AIDS), year-end 2016c
No.
13,252
1,378
312
10,166
1,396
5,483
421
404
2,961
1,948
85
1,746
1,386
6,893
1,652
2,589
3,412
994
3,353
6,912
13,376
4,838
8,063
1,856
4,718
943
148
4,843
4,101
742
337
Rated
218.1
110.2
15.9
475.3
192.9
118.0
18.0
76.5
122.2
120.6
14.1
133.8
108.1
152.4
153.2
112.8
121.6
83.8
138.2
208.4
284.7
173.3
490.0
93.2
219.0
187.2
26.7
127.4
139.4
86.3
60.7
HIV Surveillance Report
Table 31. Stage 3 (AIDS), 2017 and cumulative, and persons living with diagnosed HIV infection ever classified as stage 3 (AIDS) (prevalence),
year-end 2016, by metropolitan statistical area of residence—United States and Puerto Rico (cont)
Diagnosis, cumulativea,b
128
Diagnosis, 2017b
Adults or
adolescents
Children
Total
Rated
Ranke
No.
No.
No.
No.
Rated
30
23
15
288
16
42
33
137
490
84
406
19
53
27
12
4.7
3.1
2.3
9.3
2.7
4.1
3.3
7.9
7.9
6.4
8.3
2.9
7.9
2.9
2.2
50
79
93
13
85
60
75
16
18
—
—
81
17
82
96
2,611
1,524
1,635
15,104
1,070
2,577
2,064
6,458
39,866
4,067
35,799
1,073
1,463
2,588
773
28
15
10
117
15
12
11
66
330
27
303
2
11
22
0
2,639
1,539
1,645
15,221
1,085
2,589
2,075
6,524
40,196
4,094
36,102
1,075
1,474
2,610
773
1,202
707
732
6,888
457
1,245
960
2,008
9,788
1,927
7,861
456
750
1,220
332
190.6
96.3
111.4
226.8
75.6
123.0
97.2
116.6
159.1
148.7
161.9
70.7
113.3
130.2
61.0
14,043
6.3
—
1,074,829
8,644
1,083,473
418,764
188.3
Metropolitan areas (population of 50,000–499,999)
2,348
4.0
—
123,600
851
124,451
52,405
89.8
Nonmetropolitan areas
1,239
2.7
—
67,006
440
67,446
29,381
63.7
17,794
5.4
—
1,270,856
9,979
1,280,835
534,454
163.5
MSA of residence
Springfield, MA
Stockton–Lodi, CA
Syracuse, NY
Tampa–St. Petersburg–Clearwater, FL
Toledo, OH
Tucson, AZ
Tulsa, OK
Virginia Beach–Norfolk–Newport News, VA–NC
Washington–Arlington–Alexandria, DC–VA–MD–WV
Silver Spring Division
Washington Division
Wichita, KS
Winston-Salem, NC
Worcester, MA–CT
Youngstown–Warren–Boardman, OH–PA
Subtotal for MSAs (population of 500,000)
Totalg
No.
Prevalence of stage 3
(AIDS), year-end 2016c
Abbreviation: MSA, metropolitan statistical area.
Note. Because of the lack of U.S. census information for all U.S. dependent areas, table includes data for only the United States and Puerto Rico.
Data for the year 2017 are considered preliminary because they are based on only a 6-month reporting delay.
Numbers less than 12, and rates based on these numbers, should be interpreted with caution.
MSA definitions for this report can be found at http://www.census.gov/programs-surveys/metro-micro.html.
a
From the beginning of the epidemic through 2017.
b Data are based on residence at time of diagnosis of HIV infection.
c
d
Data are based on address of residence at the end of the specified year (i.e., most recent known address).
Vol. 29
Rates are per 100,000 population.
e Based on rate.
f
g
Counts of stage 3 (AIDS) classifications for the metropolitan divisions do not sum to the MSA total. MSA total includes data from 1 metropolitan division with population of <500,000.
Includes persons whose county of residence is unknown.
Web Addresses for Reports of State and Local HIV Surveillance
Alabama
Alaska
Arizona
Arkansas
California
Chicago
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Guam
Hawaii
Houston
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Los Angeles
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
New York City
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Philadelphia
Puerto Rico
Rhode Island
San Francisco
South Carolina
South Dakota
Tennessee
Texas
U.S. Virgin Islands
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
http://www.alabamapublichealth.gov/hiv/publications.html
http://epibulletins.dhss.alaska.gov/Bulletin/DisplayClassificationBulletins/46
http://www.azdhs.gov/phs/edc/odis/hiv-epidemiology/reports/index.php?pg=annual
https://www.healthy.arkansas.gov/programs-services/topics/hiv-aids-sti-surveillance
https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OAsre.aspx
https://www.cityofchicago.org/city/en/depts/cdph/provdrs/health_data_and_reports/svcs/get_sti_hiv_datainchicago.html
https://www.colorado.gov/pacific/cdphe/stihiv-data-and-trends
https://portal.ct.gov/DPH/AIDS--Chronic-Diseases/Surveillance/Connecticut-HIV-Statistics
http://www.dhss.delaware.gov/dhss/dph/epi/disstatshiv.html
https://dchealth.dc.gov/service/hiv-reports-and-publications
http://www.floridahealth.gov/diseases-and-conditions/aids/surveillance/index.html
https://dph.georgia.gov/data-fact-sheet-summaries#SurveillanceSummaries
http://dphss.guam.gov/content/hiv-surveillance-program
http://health.hawaii.gov/harmreduction/hiv-aids/data-and-statistics/
http://www.houstontx.gov/health/HIV-STD/
http://healthandwelfare.idaho.gov/Health/FamilyPlanningSTDHIV/STDStatistics/tabid/393/Default.aspx
http://dph.illinois.gov/topics-services/diseases-and-conditions/hiv-aids/hiv-surveillance/update-reports
http://www.in.gov/isdh/23266.htm
http://idph.iowa.gov/hivstdhep/hiv/data
http://www.kdheks.gov/sti_hiv/hiv_std_update.html
https://chfs.ky.gov/agencies/dph/dehp/hab/Pages/reports-stats.aspx
http://publichealth.lacounty.gov/dhsp/Reports.htm
http://new.dhh.louisiana.gov/index.cfm/newsroom/category/63
http://www.maine.gov/dhhs/mecdc/infectious-disease/hiv-std/data/index.shtml
http://phpa.dhmh.maryland.gov/OIDEOR/CHSE/Pages/statistics.aspx
https://www.mass.gov/lists/hivaids-epidemiologic-profiles
http://www.michigan.gov/mdch/0,4612,7-132-2940_2955_2982_46000_46003---,00.html
http://www.health.state.mn.us/divs/idepc/diseases/hiv/stats/index.html
http://www.msdh.state.ms.us/msdhsite/index.cfm/14,0,150,134,html
http://health.mo.gov/data/hivstdaids/data.php
https://dphhs.mt.gov/publichealth/cdepi/diseases/HIV_HCV
http://dhhs.ne.gov/publichealth/Pages/dpc_hiv.aspx
http://dpbh.nv.gov/Programs/HIV-OPHIE/dta/Publications/HIV/AIDS_Surveillance_Program_(HIV-OPHIE)_-_Publications/
http://www.dhhs.nh.gov/data/index.htm
http://www.nj.gov/health/hivstdtb/hiv-aids/statmap.shtml
http://nmhealth.org/data/infectious/20/
http://www.health.state.ny.us/diseases/aids/statistics/index.htm
http://www1.nyc.gov/site/doh/data/data-sets/hiv-aids-surveillance-and-epidemiology-reports.page
http://epi.publichealth.nc.gov/cd/stds/figures.html
https://www.ndhealth.gov/hiv/Data/
http://www.odh.ohio.gov/healthstats/disease/hivdata/hivcov.aspx
https://www.ok.gov/health/Disease,_Prevention,_Preparedness/HIV_STD_Service/Fact_Sheets_-_OK_Data/index.html
https://www.oregon.gov/oha/ph/DiseasesConditions/CommunicableDisease/DiseaseSurveillanceData/HIVData/Pages/index.aspx
https://www.health.pa.gov/topics/programs/HIV/Pages/Annual-Summary.aspx
http://www.phila.gov/health/AACO/AACODataResearch.html
http://www.salud.gov.pr/Estadisticas-Registros-y-Publicaciones/Pages/Publicaciones-sobre-la-salud.aspx
http://health.ri.gov/publications/bytopic.php?parm=HIV
http://www.sfdph.org/dph/files/reports/default.asp
http://www.dhec.sc.gov/Health/DiseasesandConditions/InfectiousDiseases/HIVandSTDs/DataandReports/
http://doh.sd.gov/diseases/infectious/HIV-AIDS/Prevention.aspx
https://www.tn.gov/health/health-program-areas/statistics/health-data/hiv-data.html
http://www.dshs.state.tx.us/hivstd/reports/default.shtm
https://doh.vi.gov/programs/communicable-diseases
http://health.utah.gov/epi/diseases/hivaids/surveillance/index.html
http://www.healthvermont.gov/immunizations-infectious-disease/hiv/surveillance
http://www.vdh.virginia.gov/disease-prevention/disease-prevention/hiv-aids-sexually-transmitted-disease-std-hepatitis-reports/
http://www.doh.wa.gov/DataandStatisticalReports/DiseasesandChronicConditions/HIVAIDSData.aspx
http://www.dhhr.wv.gov/oeps/std-hiv-hep/HIV_AIDS/Pages/HIVSurveillance.aspx
http://dhs.wisconsin.gov/aids-hiv/Stats/index.htm
https://health.wyo.gov/publichealth/communicable-disease-unit/hivaids-surveillance-program/
Note. Electronic reports are not available for the following areas: American Samoa and the Northern Mariana Islands.
HIV Surveillance Report
129
Vol. 29
| File Type | application/pdf |
| File Title | HIV Surveillance Report 2017 |
| Subject | HIV; AIDS; HIV infection; surveillance report; surveillance data on HIV infection; diagnosed HIV infection; HIV prevention; HIV |
| Author | CDC/OID/NCHHSTP/DHAP/HICSB |
| File Modified | 2019-03-14 |
| File Created | 2009-01-27 |